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Parkinson’s disease (PD) is a neurodegenerative disorder affecting ~1% of the population 
above 60 years. It is primarily characterized by severe motor deficits following the progressive 
and selective loss of dopaminergic neurons (DaNs) in the substantia nigra pars compacta 
(SNc). Non-motor symptoms, such as hyposmia and depression, further arise in a prodromal 
manner. Mitochondrial dysfunction plays an essential role for the loss of SNc DaNs, as 
evidenced by mitochondrial complex I impairing toxins, an especially high accumulation rate 
of mitochondrial DNA (mtDNA) deletions as well as the wide variety of mitochondrial-related 
gene mutations in familial forms of PD. Given that neighboring DaNs in the ventral tegmental 
area (VTA) are relatively spared from neurodegeneration, however, cell-type specific factors 
must additionally contribute to the selective vulnerability in PD. In this work, data of three 
manuscripts are presented, confirming that distinct DaN populations respond differently to 
mitochondrial dysfunction following inactivation of mitochondrial transcription factor A (TFAM) 
in mice. In the olfactory bulb (OB), only small anaxonic DaNs (SCs) are mildly reduced in 
numbers, which is however associated with severe olfactory dysfunction and suggests a 
putative role for OB DaNs in the development of PD-related hyposmia. The midbrain reveals 
progressive and exclusive loss of SNc DaNs, which is accompanied by a severe decline of 
motor function. In contrast to the VTA, DaNs in the SNc die through a detrimental imbalance 
in the mitochondrial redox system, triggered by enhanced intracellular Ca2+ loads. Whereas 
SNc DaNs perish due to the rapid and continuous loss of mtDNA upon TFAM inactivation, they 
can adapt to impaired mtDNA replication, demonstrated after the expression of a mutated 
variant of the mitochondrial helicase TWINKLE (K320E). Despite similar severe 
neurodegeneration of both SNc and VTA DaNs, aged SNc DaNs preserve striatal innervation 
and thereby normal motor performance. Conversely, VTA DaN projections are lost, causing 
depressive-like behavior in these animals. Thus, identification and stimulation of ongoing 
compensatory mechanisms in aged SNc DaNs of K320E-TwinkleDaN mice host the potential to 
help the small number of remaining SNc DaNs in PD patients to escape from cell death and 








Die Parkinson-Krankheit (PD) ist eine neurodegenerative Erkrankung und betrifft rund 1% der 
Bevölkerung über 60 Jahre. Sie äußert sich vor allem durch die motorischen Ausfälle infolge 
des progressiven und selektiven Verlusts von dopaminergen Neuronen (DaNs) in der 
substantia nigra pars compacta (SNc). Nichtmotorische Symptome, wie Geruchsverlust und 
Depression, treten dabei zusätzlich prodromal auf. Die mitochondriale Dysfunktion spielt beim 
Verlust von SNc DaNs eine entscheidende Rolle, wie durch Toxine, die den mitochondrialen 
Komplex I beeinträchtigen, einer sehr hohen Akkumulationsrate von mitochondrialen DNA 
(mtDNA) Deletionen sowie einem breiten Spektrum an mitochondrial-bezogenen 
Genmutationen bei familiären PD-Fällen gezeigt wird. Die Tatsache, dass benachbarte DaNs 
im ventralen tegmentalen Areal (VTA) vom Zelltod nahezu verschont bleiben, legt jedoch nahe, 
dass zusätzliche, zelltypspezifische Faktoren zu der selektiven Vulnerabilität bei PD beitragen. 
In dieser Arbeit werden die Daten dreier Manuskripte dargestellt, welche zeigen, dass DaNs 
verschiedener Populationen unterschiedlich auf mitochondriale Dysfunktion reagieren, die auf 
der Inaktivierung des mitochondrialen Transkriptionsfaktors A (TFAM) in Mäusen beruht. Im 
olfaktorischen Bulbus (OB) sind lediglich kleine, anaxonische DaNs (SCs) zahlenmäßig leicht 
reduziert, was jedoch mit einer schweren olfaktorischen Dysfunktion assoziiert ist und eine 
mutmaßliche Rolle von OB DaNs beim PD-bezogenen Geruchsverlust vermuten lässt. Das 
Mittelhirn zeigt hingegen einen progressiven und alleinigen Verlust von SNc DaNs, der mit 
einer starken Abnahme der motorischen Leistung einhergeht. Im Gegensatz zum VTA sterben 
DaNs der SNc durch ein verheerendes Ungleichgewicht im mitochondrialen Redox-System, 
das durch einen zu hohen Ca2+-Gehalt in ebendiesen Zellen ausgelöst wird. Während SNc 
DaNs somit infolge eines schnellen sowie kontinuierlichen Verlusts von mtDNA sterben, 
können sie sich an eine Störung der mtDNA Replikation, in Form einer mutierten Variante der 
mitochondrialen Helikase TWINKLE (K320E), anpassen. Trotz schwerer Neurodegeneration 
sowohl von SNc als auch VTA DaNs schaffen es die überlebenden SNc DaNs ferner die 
striatale Innervierung und somit die motorische Aktivität der Mäuse zu erhalten. Auf der 
anderen Seite hingegen, verlieren VTA DaNs ihre Projektionen, was schließlich einen 
depressiven Phänotyp hervorruft. Somit könnten die kompensatorischen Mechanismen, die in 
den SNc DaNs alter K320E-TwinkleDaN Mäuse vonstattengehen, dazu verwendet werden, die 
geringe Anzahl überlebender SNc DaNs in PD-Erkrankten vor dem Tod zu bewahren und 







1  Introduction 
1.1 Mitochondrial Dysfunction and Parkinson’s disease 
Since its first association with the neurodegenerative disease through the discovery of a toxic 
agent almost 40 years ago, mitochondrial dysfunction has been intensively studied in the 
context of Parkinson’s disease (PD). Reduced activity of mitochondrial complex I, which is the 
outcome of toxins related to PD, in the most affected brain area has for a long time been the 
crucial phenotype at the cellular level besides Lewy bodies. The huge number of mutated 
genes that are directly linked to mitochondrial function in familial cases, further highlights the 
essential role of mitochondria in the pathophysiology of PD. 
1.1.1 Complex I Deficiency 
The mitochondrial enzyme nicotinamide adenine dinucleotide (NADH) ubiquinone 
oxidoreductase, named complex I, is the first in the mitochondrial electron transport chain, and 
responsible for both the electron transfer from NADH to Q10 and proton pumping into the 
mitochondrial intermembrane space in order to ensure ATP production (Wirth et al. 2016). 
Reduced activity of mitochondrial complex I has been first described in the substantia nigra 
pars compacta (SNc) of post mortem brains from patients with idiopathic PD in 1989 (Schapira 
et al. 1989). The same observations have been made by analyzing isolated mitochondria from 
the striatum (Mizuno et al. 1989) as well as platelet mitochondria of those patients (Parker, 
Boyson, and Parks 1989). A reduced complex I activity in PD has been subsequently reported, 
by a variety of studies, to be a phenomenon that is restricted to the SNc (Hattori et al. 1991; 
Mann et al. 1992; Janetzky et al. 1994; Mann et al. 1994). Studies including other brain regions 
are limited and of contradictory results. Whereas some revealed decreased complex I activity 
in homogenates of frontal cortices from PD patients (Parker, Boyson, and Parks 1989; Keeney 
et al. 2006), others could not detect any differences compared to healthy individuals (Schapira, 
Mann, et al. 1990; Janetzky et al. 1994). A recent study presented unchanged complex I 
activity in the prefrontal cortex of PD patients, but a reduction in PD patients which additionally 
suffer from dementia, suggesting altered mitochondrial complex activity in this brain region to 
be rather linked to the combination of both conditions (Gatt et al. 2016). The analysis of enzyme 
activity or protein content in the cerebellum and striatum did not show any difference comparing 
PD patients and controls (Mizuno et al. 1989; Schapira, Mann, et al. 1990; Mann et al. 1992; 
Janetzky et al. 1994). 
It is out of question that intact complex I activity is of great importance for mitochondrial 
functionality, especially for highly energy consuming synaptic processes in the projection area 
of SNc dopaminergic neurons (DaNs) (Telford, Kilbride, and Davey 2009; Kilbride, Telford, and 
Davey 2020). However, the significance of complex I deficiency in the development of PD is 





secondary response to disease-related modifications. Flønes et al. recently showed that 
complex I deficiency is indeed found throughout the PD brain, including the prefrontal cortex, 
hippocampus and putamen as well as regions which are spared from neurodegeneration, such 
as the cerebellum (Flones et al. 2018), questioning the pathogenic role of complex I 
impairment in PD. 
1.1.2 Gene Mutations 
A genetic correlation in PD has been first described almost 100 years ago (Bell and Clark 
1926). Today we know that there is a wide range of genetic variants and modifications that is 
related to PD-like disorders or parkinsonism. In this chapter I will focus on the monogenic origin 
of PD. With only ~5 – 10% of all patients, only a minority of PD cases is caused by monogenic 
mutations (Lill 2016), many of them being directly linked to mitochondrial dysfunction (see 
Fig. 1-1). These mutations occur in an autosomal dominant and recessive manner. 
1.1.2.1 SNCA 
The first discovered autosomal dominant gene in PD is SNCA (synuclein alpha)  
(Polymeropoulos et al. 1997). Although rarely found among familial forms of PD (Scott et al. 
1999), the discovery of SNCA subsequently led to the identification of its encoded protein 
α-Synuclein (α-Syn) as the main component of the intracellular Lewy bodies arising also in 
many cases of idiopathic PD (Spillantini et al. 1997). The function of α-Syn is still not fully 
understood, but it might be involved in the maintenance, trafficking as well as exocytosis of 
synaptic vesicle and thereby modulates neurotransmitter release (Bendor, Logan, and 
Edwards 2013; Lautenschlager, Kaminski, and Kaminski Schierle 2017; Lautenschlager et al. 
2018). 
In order to unravel its neurotoxic effect in aggregated form, α-Syn and its interactions with 
mitochondria are intensively studied. Although α-Syn does not possess a canonical 
mitochondrial targeting sequence, it has been reported to be localized to mitochondria, leading 
to reduced complex I activity (Devi et al. 2008). Mitochondrial binding is achieved via 
translocase of outer membrane 20 (TOM20) and impairs mitochondrial protein import (Di Maio 
et al. 2016). A recent study just showed that α-Syn is involved in the reduction of mitochondrial 
respiratory activity and neurodegeneration by suppressing the mitochondrial matrix protease 
ClpP (Hu et al. 2019). When localized to mitochondria-endoplasmic reticulum contact sites, 
α-Syn is reported to influence mitochondrial morphology (Guardia-Laguarta et al. 2014) as well 
as calcium (Ca2+) signaling and thereby reduces energy production (Paillusson et al. 2017). 
Aggregates of α-Syn show an increased tendency to bind to mitochondria (Wang, Becker, et 
al. 2019) and induce cell death via the oxidation of the ATP synthase and the following 
increased opening probability of the mitochondrial permeability transition pore (mPTP) 





bodies than solely α-Syn aggregation that causes neurodegeneration through mitochondrial 
damage (Mahul-Mellier et al. 2020). 
1.1.2.2 LRRK2 
Another autosomal dominant form is referred to the LRRK2 (leucine-rich repeat kinase 2) 
gene, in which mutations are most frequently detected in PD (Paisan-Ruiz et al. 2004; Zimprich 
et al. 2004). Mutations in the LRRK2 gene lead to increased kinase activity and have hence 
been classified as gain-of-function mutations (West et al. 2005; Greggio et al. 2006; Lu and 
Tan 2008; Sheng et al. 2012). Although the significance in PD is undisputed, the physiological 
role as well as the pathological mechanism of LRRK2 is still not fully understood. LRRK2 has 
been associated with a wide range of cellular processes, with many of them directly impacting 
mitochondrial functionality. LRRK2 interacts with microtubules and cytoskeleton proteins 
(Caesar et al. 2013; Beilina et al. 2014; Law et al. 2014) and is important for microtubule 
assembly (Parisiadou et al. 2009; Lin et al. 2010). In PD patients with LRRK2 mutation, a 
decrease in tubulin acetylation was detected (Esteves et al. 2015), which is important for 
organellar trafficking and axonal function (Reed et al. 2006; Esteves, Gozes, and Cardoso 
2014). Together with the localization of LRRK2 on the mitochondrial outer membrane (West et 
al. 2005; Biskup et al. 2006), this raises the question whether in PD, mitochondrial transport 
might be affected by LRRK2 as well. Indeed, cells expressing a mutant LRRK2 revealed 
impaired mitochondrial trafficking (Thomas et al. 2016), which could mechanistically be 
explained by the direct interaction of LRRK2 with Miro, an outer mitochondrial membrane 
protein anchoring the microtubule motors kinesin and dynein to mitochondria (Hsieh et al. 
2016). 
Furthermore, mitochondrial morphology is found to be altered in LRRK2 mutants (Yue et al. 
2015), including elongated mitochondria (Mortiboys et al. 2010). However, most studies rather 
reported mitochondrial fragmentation which has been linked to reduced levels of the short form 
of OPA1 (Stafa et al. 2014) as well as direct interaction of LRRK2 with DRP1 (dynamin-related 
protein 1), thereupon promoting mitochondrial fission (Wang et al. 2012; Su and Qi 2013; 
Smith et al. 2016; Perez Carrion et al. 2018). Eventually, there is evidence that LRRK2 is 
involved in mitochondrial clearance via autophagy (Ramonet et al. 2011; Cherra et al. 2013; 
Hindle et al. 2013; Orenstein et al. 2013; Cookson 2016): While LRRK2 physiologically 
promotes the removal of Miro, mutated LRRK2 disrupts this function and delays the 
degradation of damaged mitochondria (Hsieh et al. 2016). 
1.1.2.3 VPS35 
VPS35 (vacuolar protein sorting 35) encodes the vacuolar protein sorting-associated protein 
35 and mutations in this gene were first observed in European PD cases appearing in an 





part of the retromer complex, which is involved in intracellular protein trafficking. VPS35 by 
itself is responsible for binding and sorting of protein cargo (Hierro et al. 2007; Seaman 2012) 
and contributes to the formation of mitochondrial derived vesicles (MDVs), which shuttle 
mitochondrial cargo to peroxisomes or lysosomes (Soubannier et al. 2012; Sugiura et al. 2014) 
in order to degrade a selection of mitochondrial proteins instead of the entire organelle 
(McLelland et al. 2014). Regarding mitochondrial function, VSP35 has been primarily linked to 
fusion and fission. A mutant VSP35 caused mitochondrial fragmentation, which is explained 
by either decreased Mitofusin 2 (MFN2) levels in response to mitochondrial E3 ubiquitin ligase 
1 (MUL1) degradation (Tang et al. 2015), or increased turnover of DRP1 complexes by MDVs 
and lysosomal degradation (Wang et al. 2016). 
 
Fig. 1-1 Mitochondrial dysfunction upon PD-related gene mutations is linked to a variety of pathways. 
Monogenic mutations associated with PD can affect mitochondrial function, among others, via impaired 
mitochondrial biogenesis, enhanced ROS production, defective mitophagy, disrupted mitochondrial trafficking, 
deficient respiratory chain, modification of mitochondrial dynamics, imbalanced Ca2+ homeostasis and the 







CHCHD2 (coiled-coil-helix-coiled-coil-helix domain containing 2) mutations have been recently 
identified to be responsible for autosomal dominant, late-onset PD in three Japanese families 
(Funayama et al. 2015). However, other studies, including screening of Caucasians, south 
Italians (Jansen et al. 2015; Gagliardi et al. 2017) and Brazilians (Voigt et al. 2019), could not 
confirm this finding. It is believed that the localization of CHCHD2 to the mitochondrial 
intermembrane space maintains cristae structure and respiratory chain integrity, whereas 
impaired CHCHD2 function caused a reduced activity of complex III and IV and oxidative 
damage (Bannwarth et al. 2014; Meng et al. 2017), which could additionally be shown in 
fibroblasts from CHCHD2 mutant PD patients (Lee et al. 2018). 
1.1.2.4 Parkin 
With over 120 identified mutations so far (Lill 2016), Parkin (PARK2) mutations are the most 
common cause of autosomal recessive PD (Kitada et al. 1998) with predominantly early 
disease onset (Klein et al. 2003; Hedrich et al. 2004; Kilarski et al. 2012). Parkin is a cytosolic 
E3 ubiquitin ligase that regulates the degradation of mitochondria via mitophagy. It 
ubiquitinates a wide range of cytosolic as well as outer mitochondrial membrane (OMM) 
proteins upon mitochondrial damage, such as mitochondrial depolarization (Chan et al. 2011; 
Sarraf et al. 2013). The accumulation of polyubiquitin chains on mitochondria subsequently 
leads to the recruitment of autophagosomes and lysosomes (Geisler et al. 2010; Matsuda et 
al. 2010; Narendra et al. 2010). Under basal condition, the activity of Parkin is repressed 
(Chaugule et al. 2011; Riley et al. 2013; Trempe et al. 2013; Wauer and Komander 2013), 
probably via K6-linked ubiquitination-mediated degradation (Durcan et al. 2014). 
Despite its conserved role in mediating mitophagy in diverse mammalian cell lines, the 
relevance of Parkin in neurons and especially in PD pathology has been questioned. Some 
studies showed an only moderate Parkin contribution to the degradation of damaged 
mitochondria in primary neurons (Cai et al. 2012; Grenier, McLelland, and Fon 2013), whereas 
others confirmed the importance of Parkin in mitophagy in these cells (Grenier, Kontogiannea, 
and Fon 2014) and especially axons (Ashrafi et al. 2014). Intriguingly, Parkin-deficient mice 
(Perez and Palmiter 2005) as well as rats (Dave et al. 2014) revealed no PD-related 
phenotype. However, in the context of mitochondrial dysfunction upon impaired replication of 
mitochondrial DNA (mtDNA), loss of Parkin caused DaN degeneration and L-3,4-
dihydroxyphenylalanine (L-DOPA) reversible motor symptoms (Pickrell et al. 2015), 
highlighting the importance of Parkin-mediated mitochondrial quality control in DaNs. 
Besides mitophagy, Parkin is suggested to play a role in the regulation of mitochondrial 
biogenesis (Scarffe et al. 2014) via the degradation of the parkin interacting substrate (PARIS), 





proliferator-activated receptor gamma coactivator 1α (PGC-1α), the main transcriptional 
activator of mitochondrial genes (Shin et al. 2011). Local knockout (KO) of Parkin in the 
midbrain of mice via virus injection consequently led to reduced mitochondrial number and size 
as well as morphological abnormalities (Stevens et al. 2015). Other studies have linked Parkin 
to the turnover of synaptic vesicles, showing Parkin-mediated ubiquitination of synaptic vesicle 
proteins (Zhang et al. 2000; Huynh et al. 2003; Trempe et al. 2013; Cao et al. 2014) as well as 
proteins responsible for vesicle recycling (Fallon et al. 2002; Fallon et al. 2006; Joch et al. 
2007). Hence, it is assumed that Parkin plays a role in synaptic transmission control. Moreover, 
studies including the in vitro investigation of DaNs that are directly derived from Parkin mutant 
patients via induced pluripotent stem cell (iPSC) technology confirm this assumption. Thus, 
iPSC-derived DaNs revealed excessive DA release as well as reduced DA uptake (Jiang et al. 
2012) and large DA-induced bursting of spontaneous excitatory postsynaptic currents in 
contrast to iPSCs from normal subjects (Zhong et al. 2017). These results underscore an 
altered sensitivity of patient-derived DaNs towards DA. In order to understand the exact 
processes that are responsible for PD in Parkin mutant patients, further investigations are 
needed. The absence of α-Syn aggregations in most of the PD cases including a disrupted 
function of Parkin (Pramstaller et al. 2005; Doherty et al. 2013) points to a different mechanism 
compared to idiopathic cases of PD. 
1.1.2.5 PINK1 
The second most common cause of autosomal recessive PD are mutations in the PINK1 
(PTEN-induced putative kinase 1) gene (Valente et al. 2004) with loss-of-function mutations 
being associated with early-onset PD (Truban et al. 2017). PINK1 is a mitochondrial 
serine/threonine kinase and, besides Parkin, another key protein responsible for mitochondrial 
quality control via mitophagy. With intact mitochondrial function, PINK1 is imported into 
mitochondria via the TOM complex (Lazarou et al. 2012) and cleaved by mitochondrial 
proteases, such as PARL (Jin et al. 2010; Deas et al. 2011; Greene et al. 2012). In contrast, 
upon mitochondrial damage, the import of PINK1 is inhibited and the protein accumulates on 
the OMM (Lin and Kang 2008; Zhou et al. 2008). As a consequence, PINK1 activates Parkin 
and thus mediates mitochondrial clearance via autophagy (Vives-Bauza et al. 2010). The 
activation of Parkin is regulated by PINK1 via direct phosphorylation at Serine 65 (Kondapalli 
et al. 2012) and trans-activation by phosphorylation of ubiquitin at Serine 65, which is followed 
by binding to Parkin (Kane et al. 2014; Kazlauskaite et al. 2014; Koyano et al. 2014). 
Interestingly, PINK1 can initiate mitophagy even without Parkin while using alternative 
receptors, such as nuclear dot protein 52 (NDP52) and optineurin (OPTN) (Lazarou et al. 
2015). 
The loss of PINK1 activity has been primarily related to mitochondrial dysfunction, including 





the regulation of mitophagy. However, mitochondrial Ca2+ overload-induced death of PINK1-
deficient DaNs (Kostic et al. 2015) further suggests an involvement of PINK1 in Ca2+ handling. 
In addition, mitochondrial biogenesis via Parkin-mediated PARIS regulation (Lee et al. 2017) 
and fission (Pryde et al. 2016) were reported to be positively regulated by PINK1. 
1.1.2.6 ATP13A2 
A novel gene that has been identified to lead to a rare form of autosomal recessive juvenile-
onset PD, the so called Kufor-Rakeb syndrome, is ATP13A2 (ATPase cation transporting 
13A2) (Park, Blair, and Sue 2015; Suleiman, Hamwi, and El-Hattab 2018). ATP13A2 encodes 
the P5B ATPase, which mediates the transport of cations across endo/lyosomal membranes 
and is believed to be involved in vesicular transport (Park et al. 2014), endolysosomal activity 
(Sato et al. 2016; Rayaprolu et al. 2018) and indirectly glycolysis (Park et al. 2016). So far, 
studies using ATP13A2-deficient cells have presented lysosomal defects with corresponding 
disturbances in cation, especially Zn2+, homeostasis. Moreover, these cells revealed impaired 
mitochondrial functionality in the form of reduced ATP conversion, mitochondrial fragmentation 
and reactive oxygen species (ROS) production (Ramonet et al. 2012; Park et al. 2014). 
However, further research needs to be conducted to decipher the exact consequences of 
ATP13A2 mutations in patients. 
1.1.2.7 DJ-1 
Mutations in the DJ-1 encoding gene PARK7 (parkinsonism associated deglycase) cause 
autosomal recessive early-onset PD (van Duijn et al. 2001; Bonifati et al. 2003) with a 
prevalence of only up to 1% of these cases (Maraganore et al. 2004; Alcalay et al. 2010; Sironi 
et al. 2013). DJ-1 is a ubiquitously expressed protein and implicated in a variety of cellular 
processes. Whereas the molecular mechanisms of DJ-1 functions remain elusive, there is a 
wide acceptance for its control of ROS and its neuroprotective effect upon oxidative damage 
(Taira et al. 2004; Surmeier et al. 2010; Cookson 2012). While mainly localized in the 
cytoplasm, DJ-1 can be translocated to mitochondria in response to oxidative stress (Irrcher 
et al. 2010; Kim et al. 2012). The loss of DJ-1 has been connected to reduced autophagic 
activity and mitochondrial dysfunction in fibroblasts (Krebiehl et al. 2010), to mitochondrial 
fragmentation and reduced mitochondrial membrane potential in human dopaminergic cells 
(Thomas et al. 2016), and more importantly, to the loss of SNc DaNs in mice (Rousseaux et 
al. 2012). There is recent evidence, that DJ-1 is additionally involved in the regulation of 
mitochondrial Ca2+ handling by direct interaction with the mitochondria-ER coupling complex 
(Basso, Marchesan, and Ziviani 2020). 
1.1.3 Toxins 
The discovery of PD-related toxins led to the first connection of the neurodegenerative disease 





deciphered the pathological mechanisms during the course of PD. Today, these toxins are 
mainly used in animal models to assess the potential neuroprotective effects of newly identified 
drugs on the survival of DaNs and related motor symptoms. 
1.1.3.1 MPTP 
The very first association of PD with mitochondrial dysfunction was enabled by the discovery 
of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Nearly 40 years ago, MPTP was 
found to induce parkinsonian-like symptoms in drug users consuming self-produced heroine-
like substances (Langston et al. 1983; Langston and Ballard 1983). Through its lipophilic 
property, MPTP crosses the blood-brain-barrier and is subsequently converted into its toxic 
form 1-methyl-4-phenylpyridinium (MPP+) via the astrocytic monoamine oxidase (MAO) (Levitt, 
Pintar, and Breakefield 1982). Once its released via the organic transporter-3 from astrocytes 
(Cui et al. 2009), MPP+ is preferentially taken up by DaNs due to its high affinity to the DA 
transporter (DAT) (Javitch et al. 1985; Gainetdinov et al. 1997), accumulates inside 
mitochondria due to its lipophilic charge and has been shown to inhibit complex I, finally 
causing selective degeneration of SNc DaNs in both mice and humans (Langston and Ballard 
1983; Heikkila et al. 1985; Nicklas, Vyas, and Heikkila 1985). 
Besides affecting complex I activity, MPP+ is believed to compete with DA for being stored in 
vesicles, thus provoking DA extrusion and subsequent conversion into compounds with 
oxidative damage potential, such as 3,4-dihydroxyphenylacetaldehyde (DOPAL) (Panneton et 
al. 2010). In support of this, oxidative stress together with neuroinflammation have been found 
to occur in post mortem PD brains (Langston et al. 1999). However, many symptoms that are 
typical for idiopathic PD were absent upon MPTP consumption, including the Lewy pathology 
and the impairment of other brain regions as well as non-dopaminergic cells. 
1.1.3.2 Rotenone 
In 1987, an epidemiological study reported for the first time about an increased prevalence of 
PD in rural areas where certain pesticides were used (Barbeau et al. 1987). However, 
subsequent contradictory studies did not allow a conclusive confirmation of this observed 
phenomenon, probably caused by its limitations on the investigation of entire classes of 
pesticides instead of specific agents (Nandipati and Litvan 2016). One of these naturally 
occurring pesticides is rotenone, which can be extracted from roots of Lonchocarpus and 
Derris plants (Soloway 1976). It mechanistically acts like MPTP and inhibits complex I causing 
progressive loss of midbrain DaNs (Betarbet et al. 2000). Its highly lipophilic features and 
independence of transporters allow a direct and fast cell penetrance of rotenone, even through 
the blood-brain-barrier (Martinez and Greenamyre 2012). Therefore, it can be administered via 
different routes, including intraperitoneally, intravenously, subcutaneously and stereotactically, 





and Bobrovskaya 2015). However, whereas rotenone exposure is known to be one of the 
greatest risks to develop PD in humans, inhalation did not cause an impairment in the 
nigrostriatal system in rodents (Rojo et al. 2007). 
Mitochondrial dysfunction upon impaired complex I activity through rotenone treatment is 
referred to cause ROS production and reduced glutathione levels (Duty and Jenner 2011; 
Martinez and Greenamyre 2012) and sensitizes DaNs to further oxidative damage (Milusheva 
et al. 2005). Correspondingly, reduced DJ-1 levels have been detected in homogenates of 
different brain regions, including the SNc, from rats treated with rotenone (Sonia Angeline et 
al. 2012). The same study presented a decreased Parkin expression, which could either simply 
be accompanied with the severe loss of DaNs or point to impaired mitochondrial quality control 
in the SNc upon rotenone exposure. Moreover, rotenone-induced dopaminergic cell death is 
believed to be initiated by the activation of mitochondrial-dependent caspases, which in turn 
induce apoptosis (Chung, Miranda, and Maier 2007). 
Like MPTP, rotenone treatment reproduces many features of PD, including selective loss of 
SNc DaNs, striatal DA depletion and motor impairment. Furthermore, rotenone induces α-Syn 
pathology (Betarbet et al. 2000; Biskup et al. 2006; Marella et al. 2008; Cannon et al. 2009; 
Ferris et al. 2013), which is not observed when using MPTP. However, it must be noted that 
the rotenone model is limited in the number of animals that develop the loss of the nigrostriatal 
system, in the location of the lesion, the degree of lesion severity, and the mortality rate 
(Cicchetti, Drouin-Ouellet, and Gross 2009; Greenamyre et al. 2010). It is further not clear, 
whether the motor decline is solely due to the impaired DA system or to diffuse mitochondrial 
dysfunction in other cell types and brain regions, respectively, as shown when using different 
doses of rotenone (Fleming et al. 2004; Richter, Hamann, and Richter 2007). 
1.1.3.3 6-OHDA 
6-Hydroxydopamine (6-OHDA) is an established neurotoxin structurally similar to DA and used 
to induce the degeneration of the nigrostriatal system in rodents. Due to its low penetrance of 
the blood-brain-barrier, the necessity of a direct injection into the brain where it is taken up by 
catecholaminergic neurons (Luthman et al. 1989), has been reported already over 50 years 
ago (Ungerstedt 1968). In order to provoke DaN damage only, noradrenaline reuptake 
inhibitors are additionally applied (Waddington 1980). 6-OHDA is either injected unilaterally 
into the medial forebrain bundle and the SNc, respectively, where anterograde (nigrostriatal) 
DaN degeneration is starting within 24 h (Faull and Laverty 1969; Jeon, Jackson-Lewis, and 
Burke 1995), or into the dorsal striatum with retrograde (striatonigral) loss of DaNs occurring 
within one to three weeks (Sauer and Oertel 1994; Przedborski et al. 1995). This way by, usage 





well as concurrently generating an intrinsic control by the uninjured hemisphere (Thiele, Warre, 
and Nash 2012). 
6-OHDA-mediated neuron death is thought to be mainly caused by oxidative damage through 
auto-oxidation of 6-OHDA and subsequent generation of various ROS (Soto-Otero et al. 2000). 
However, the role of mitochondrial dysfunction in this toxin-induced loss of DaNs is debated 
as well. Whereas the impact of 6-OHDA on mitochondrial function in vivo is not clear, there is 
strong evidence in cultured cells. Thus, 6-OHDA treatment has been shown to induce 
mitochondrial fragmentation via upregulation of Drp1 expression (Gomez-Lazaro et al. 2008) 
as well as reduced expression of Mfn1, Mfn2 and OPA1 (Xi et al. 2018). It further leads to 
decreased mitochondrial membrane potential (Ren et al. 2019) and increased mitophagy upon 
extracellular-signal-regulated protein kinase 2 (ERK2) accumulation (Dagda et al. 2008; Zhu 
et al. 2007) via the externalization of cardiolipin (Chu et al. 2013). Moreover, axonal transport 
of vesicles as well as mitochondria is impaired after 6-OHDA treatment, which is probably due 
to ROS damage (Lu et al. 2014). These findings suggest, that it is the oxidative damage in the 
first place, that causes 6-OHDA-mediated degeneration of DaNs, with mitochondrial 
malfunction being of secondary importance. 
1.1.4 mtDNA Deletions 
After being first described in neuromuscular disorders in the late 1980s (Holt, Harding, and 
Morgan-Hughes 1988; Wallace et al. 1988; Shoffner et al. 1990), mutations of the mtDNA 
attracted more and more attention to be a potential cause of complex I deficiency and 
mitochondrial dysfunction in PD patients (Schapira 1994). Sequence analysis of mtDNA did 
not reveal specific mutations associated with PD, and parkinsonism-like symptoms were only 
sporadically found in mitochondrial disease patients (Rana et al. 2000; Thyagarajan et al. 
2000). However, based on the recognition that heteroplasmic mtDNA deletions are able to 
cause myopathy (Holt, Harding, and Morgan-Hughes 1988) as well as Kearn-Sayres syndrome 
(Zeviani et al. 1988), the presence of mtDNA deletions in brains of PD patients was 
investigated as well. Whereas the amount of deleted molecules was too low to be detected via 
southern blot (Lestienne et al. 1990; Schapira, Holt, et al. 1990), mtDNA deletions could be 
indeed presented in the striatum of post mortem PD brains by using the at this time newly 
developed polymerase chain reaction (PCR) (Ikebe et al. 1990; Ozawa et al. 1990). 
Interestingly, striatal mtDNA deletions were also verified in age-matched controls in contrast 
to other brain regions, although to a lesser extent than in PD (Ozawa et al. 1990). Subsequent 
studies confirmed this observation in the dorsal striatum and extended it to the SNc (Soong et 
al. 1992), suggesting DaN-enriched regions to be hotspots for mtDNA deletions during normal 
aging and especially in PD (Melov et al. 1999; Gu et al. 2002). Later on, laser microdissection 
of single cells from post mortem brains revealed elevated levels of mtDNA deletions (~50% of 





2006) and even more abundant in PD patients (Bender et al. 2006). These studies further 
showed that respiratory chain deficiency of SNc DaNs correlated with increased mtDNA 
deletions, providing a direct link between accumulating deletions and mitochondrial 
dysfunction (see Fig. 1-2). 
MtDNA deletions in SNc DaNs vary widely in size (~2000 – 9500bp) and are thought to be 
somatically acquired via clonal expansion (Reeve et al. 2008). Their accumulation is driven by 
the catecholamine metabolism (Neuhaus et al. 2014; Neuhaus et al. 2017), explaining why 
especially DaNs are hotspots for such alterations in the mtDNA. A possible mechanistic 
explanation for the differential outcome during normal ageing and PD was provided by the 
groups of Tzoulis and Bindoff: Whereas in SNc DaNs of healthy individuals, the population of 
wild-type mtDNA is maintained by increased total mtDNA copy number upon deletion 
accumulation, this compensatory upregulation fails and results in depletion of the wild-type 
mtDNA population in PD patients (Dolle et al. 2016). These findings could be confirmed by two 
established mouse models with impaired mtDNA maintenance and mtDNA replication, 
Fig. 1-2 Accumulation of mtDNA deletions in SNc DaNs of PD patients. With increasing age, SNc DaNs 
accumulate deletions of mtDNA, a process which is accelerated in PD. Deletion accumulation is associated with 
mitochondrial dysfunction, presented by COX deficiency (blue stained neuron). Defective replication as well as 
misrepaired double strand breaks of mtDNA are proposed to result in deletion formation. Deleted molecules are 
thought to accumulate via clonal expansion over time, whereas underlying mechanisms remain unclear (Figure was 
generated according to Picard et al. 2016 by using BioRender tools. Image illustrating COX-deficient SNc neuron 





respectively. Depletion of mtDNA in DaNs via cell type-specific KO of the mitochondrial 
transcription factor A (TFAM) has been shown to mimic the key features of PD pathology in 
mice. These so called MitoPark mice revealed selective neurodegeneration and progressive 
motor impairment (Ekstrand et al. 2007). Furthermore, DaNs were able to compensate multiple 
mtDNA deletions upon mutation of mitochondrial DNA polymerase γ (POLγ) by the 
upregulation of mtDNA copy number (Trifunovic et al. 2004; Perier et al. 2013). However, 
crossing these Mutator mice with Parkin KO mice, which do not show any impairment of DaNs 
(Perez and Palmiter 2005), caused selective loss of DaNs and an accompanied motor 
dysfunction (Pickrell et al. 2015). This highlights that the success of the compensatory increase 
in mtDNA copy number upon deletion accumulation further depends on functional 
mitochondrial quality control. SNc DaNs of idiopathic PD patients have been further shown to 
reveal low TFAM levels, accompanied with reduced mtDNA copy number and complex I 
deficiency (Grunewald et al. 2016). It is thereby likely that in PD, the significant pathological 
event is the depletion of wild-type mtDNA as a result of accumulating deletions, rather than 
solely the presence of mtDNA deletions. If balancing the amount of wild-type mtDNA and 
mtDNA deletions, by increasing mtDNA copy number and holding the amount of deleted 
mtDNA molecules at tolerable levels, fails in SNc DaNs, this will inevitably cause mitochondrial 
dysfunction and subsequently provoke neuron death. 
The mechanism for the formation of mtDNA deletions is still not fully understood. For a long 
period of time, incorrect mtDNA replication in the form of strand displacement has been thought 
to be primarily responsible (Clayton 1982). The contribution of the replication machinery on 
deletion formation in general is evidenced by a variety of studies reporting multiple mtDNA 
deletions in patients with mutations in genes that are responsible for mtDNA replication, such 
as Twinkle (Suomalainen et al. 1992; Hudson et al. 2005; Hanisch et al. 2015) and POLγ (Di 
Fonzo et al. 2003; Ferreira et al. 2011; Nissanka et al. 2018). However, this scenario was 
challenged to also occur in SNc DaNs (Reeve et al. 2008). Simultaneously, mtDNA deletions 
were suggested to rather arise as a consequence of misrepaired double strand breaks upon 
mtDNA damage (Krishnan et al. 2008). The connection between deletion formation and 
mtDNA double strand breaks has been subsequently confirmed in neurons in vitro (Fukui and 
Moraes 2009) as well as in vivo (Fukui and Moraes 2009), including DaNs (Pickrell et al. 2011). 
The fact that mtDNA double strand breaks are promoted by ROS (Pinto et al. 2017), could 
further explain the accumulation of mtDNA deletions in healthy individuals, with regard to 
increasing ROS-induced mtDNA damage with normal ageing. Thereby, mtDNA deletions 
underscore the significance of ageing in the development of PD (Liu 2014; Rizzo et al. 2016; 
Collier, Kanaan, and Kordower 2017). 
The potential of measuring mtDNA levels as a putative biomarker for PD has been intensively 





cell-free mtDNA in the cerebrospinal fluid (CSF) in Alzheimer’s disease patients (Podlesniy et 
al. 2013), those results could be shown in PD patients as well (Pyle et al. 2015) and seem to 
be further influenced upon treatment (Lowes et al. 2020). This indicates that alterations in the 
amount of CSF mtDNA could rather be used for the diagnosis of ongoing neurodegeneration 
in general than specifically for PD. Reduced mtDNA copy number has been further detected 
in peripheral blood cells and SNc DaNs of PD patients, in contrast to healthy individuals (Pyle, 
Anugrha, et al. 2016), however, these findings could not be repeated in PD patients with 
depression (Pyle, Lowes, et al. 2016). A recent study confirmed that blood mtDNA copy 
number is unchanged in PD patients and controls, indicating that it is not an adequate 
biomarker for PD (Davis et al. 2020). Correspondingly, fibroblasts from idiopathic PD patients 
as well as patients with a LRRK2 mutation background did not show any changes in mtDNA 
copy number (Podlesniy et al. 2019). In face of the unsolved mechanistic relation between 
neurodegeneration and reduced circulating cell-free mtDNA as well as the majority of data 
reporting no alterations of the mtDNA copy number in diverse biopsies of PD patients, mtDNA 
levels are currently no promising candidate for reliable PD diagnosis. 
1.1.5 Oxidative Stress 
Oxidative stress is a widespread term characterizing a pathophysiological cellular state with 
increased presence of ROS not balanced by the cellular anti-oxidative systems. The three 
main ROS are superoxide (O2-), hydrogen peroxide (H2O2) and hydroxyl radical (OH-), all being 
produced from molecular oxygen (O2) (Collin 2019). Mitochondria are the primary intracellular 
source of ROS through the interaction of unpaired electrons with molecular O2 at the 
respiratory chain (Cadenas and Davies 2000; Andreyev, Kushnareva, and Starkov 2005). In 
particular, complex I and III have been shown to be the major ROS producers in isolated 
mitochondria (Kudin et al. 2004; Kudin, Debska-Vielhaber, and Kunz 2005; Kussmaul and Hirst 
2006). Increased O2- production at complex I is observed upon high matrix NADH 
concentrations and high mitochondrial membrane potential, respectively, whereas at 
complex III, high O2- levels are induced by selective inhibition. Thus, ROS contribution by 
complex III is rather thought to be of secondary importance (Murphy 2009). 
Mitochondria possess their own antioxidant system in order to counteract increased ROS 
levels. Reduced glutathione (GSH) can scavenge ROS and thereby protects biomolecules 
from oxidative damage (Ruszkiewicz and Albrecht 2015). Moreover, mitochondrial matrix 
enzymes with antioxidant activity, such as manganese-dependent superoxide dismutase 
(MnSOD), are able to convert O2- into H2O2 (Miriyala, Holley, and St Clair 2011). Glutathione 
peroxidase (GPx) subsequently transforms H2O2 into H2O while oxidizing GSH. The oxidized 
form, GSSG, is in turn reduced back to GSH by glutathione reductase (GR) and the usage of 
NADPH (Ruszkiewicz and Albrecht 2015). In addition, peroxiredoxins can directly eliminate 





mitochondria-located isoform peroxiredoxin 5 has been reported to protect cells from 
neurodegeneration upon treatment with MPTP (De Simoni et al. 2013) and rotenone (Wang, 
Huang, et al. 2019), respectively. 
Constantly keeping mitochondrially-derived ROS at low levels, DaNs additionally have to face 
another source, since the metabolism of DA is associated with the production of a variety of 
ROS and hence impede antioxidant processes in this cell type (Delcambre, Nonnenmacher, 
and Hiller 2016). Consequently, signs of oxidative damage (Dexter et al. 1989; Alam et al. 
1997; Floor and Wetzel 1998; Bosco et al. 2006) as well as low GSH concentrations (Sofic et 
al. 1992; Sian et al. 1994; Jenner and Olanow 1996) have been detected early in the SNc of 
PD patients. In addition, the deficiency of complex I, the primary ROS producer (Murphy 2009), 
in SNc DaNs leads to elevated ROS levels, thereby causing a vicious circle that might greatly 
contribute to cell death in PD (Dias, Junn, and Mouradian 2013). The importance of oxidative 
stress in PD pathology is further confirmed by the fact that mutations in CHCHD2 or DJ-1 
encoded by PARK7 as well as treatment with MPTP, Rotenone and 6-OHDA (see above) are 
associated with oxidative damage and degeneration of DaNs. 
1.2 Dopaminergic Neurons in Parkinson’s disease 
Cardinal symptoms in PD only occur with the loss of DaNs in the SNc to a certain degree. The 
‘shaking palsy’, as it was initially termed by James Parkinson in 1817 (Parkinson 2002), 
considerably improved our understanding of voluntary movement control. Besides the SNc, 
other DA-enriched brain regions are affected in PD and linked to prodromal non-motor 
symptoms, such as hyposmia and depression (Postuma, Aarsland, et al. 2012). However, 
though multiple and promising insights have been gained up to now, the especially severe 
vulnerability of nigral DaNs is not fully understood and treatments to slow down 
neurodegeneration are still lacking. 
1.2.1 Selective Vulnerability 
PD is a complex neurological disorder that occurs in a heterogeneous manner and includes 
the loss of differential neuronal subtypes in a variety of areas in the brain. In addition to the 
SNc mentioned above, among others, neurons in the locus coeruleus, nucleus basalis of 
Meynert, pedunculopontine nucleus, raphe nucleus, dorsal motor nucleus of the vagus, 
olfactory bulb (OB), amygdala and hypothalamus are also affected (Dickson 2012). Thus, 
neurodegeneration in PD is not only restricted to DaNs but also involves serotonergic, 
noradrenergic, cholinergic, GABAergic and glutamatergic neurons (Brichta, Greengard, and 
Flajolet 2013). This heterogeneous damage of diverse neurological systems is primarily linked 
to non-motor symptoms which can precede motor impairment by up to ten years (Martinez-





However, motor symptoms remain the key pathology and the pivotal event for diagnosis of PD. 
Motor dysfunction is primarily caused by the loss of DaNs in the SNc and the accompanying 
depletion of DA in the dorsal striatum (Michel, Hirsch, and Hunot 2016; Obeso et al. 2017). It 
is the DaNs that are therefore in the focus of potential cell replacement therapies (Sonntag et 
al. 2018). Interestingly, a neighboring DaN-enriched midbrain region, the ventral tegmental 
area (VTA), is much less affected (Alberico, Cassell, and Narayanan 2015) although both SNc 
and VTA DaNs are closely related with only <1% (Grimm et al. 2004) and <3% (Greene, 
Dingledine, and Greenamyre 2005), respectively, of genes being differentially expressed. This 
selectivity in the death of DaNs is occupying scientists since decades. Whereas the favored 
loss of SNc DaNs upon treatment with MPTP and 6-OHDA, which rely on cell penetrance via 
DAT, could be explained by the lower expression of the transporter in VTA DaNs (Lammel et 
al. 2008), the explanation for rotenone, which should be able to access any cell but still causes 
selective DaN death via diverse routes of administration, is more complex. Monogenic 
mutations causing familial forms of PD are widespread in the brain and complex I deficiency 
has been shown to occur throughout the whole brain of idiopathic PD patients (Flones et al. 
2018). Furthermore, both SNc and VTA DaNs of wildtype mice have been shown to equally 
accumulate mtDNA deletions with increasing age (Neuhaus et al. 2014). Consequently, there 
must be further cell-type specific factors rendering SNc DaNs highly vulnerable to 
mitochondrial dysfunction (see Fig. 1-3). 
Investigation of electrophysiological patterns of both midbrain DaN populations has greatly 
contributed to a better understanding of the selective vulnerability. SNc as well as VTA DaNs 
demonstrate autonomous pacemaking (Grace and Bunney 1984; Puopolo, Raviola, and Bean 
2007; Khaliq and Bean 2010). In juvenile SNc DaNs and generally in VTA DaNs, voltage-
dependent Na+ channels are mainly responsible for pacemaker activity, while in adult SNc 
DaNs, L-type voltage-gated Ca2+ channels [Cav1 (Catterall et al. 2005)] contribute to the 
autonomous firing (Chan et al. 2007). Whereas Cav1 activity is not essential for pacemaking 
(Guzman et al. 2009; Poetschke et al. 2015), it is associated with somatodendritic Ca2+ 
oscillations (Chan et al. 2007) and on the one hand thought to assist pacemaker activity and 
directly boost oxidative phosphorylation (Surmeier, Guzman, and Sanchez-Padilla 2010). On 
the other hand, however, Ca2+ oscillations are a disservice to SNc DaNs, as they cause 
oxidative stress by unknown mechanisms (Guzman et al. 2010). Ca2+ entry via Cav1 channels 
might be further promoted in PD via the inhibition of the hyperpolarization-activated current 
(Ih). MPTP treatment blocked Ih in SNc DaNs (Masi et al. 2013) and thereby increased neuronal 
activity (Masi et al. 2015) as well as elevated intracellular Ca2+ levels (Carbone et al. 2017). 
The metabolic challenge upon increased Ca2+ concentrations in SNc DaNs, in contrast to VTA 
DaNs (Philippart et al. 2016), is thought to render these neurons more vulnerable to 





epidemiological studies revealed a 20-30% lower risk for the development of PD in patients 
treated for high blood pressure with Cav1 inhibitors (Lang, Gong, and Fan 2015), so called 
dihydropyridines (DHP) which block both Cav1.2 and Cav1.3 channels (Koschak et al. 2001; 
Xu and Lipscombe 2001). Despite controversial in vivo results regarding dose efficiency as 
well as specificity, the DHP isradipine, has been tested in a phase III clinical trial on PD patients 
(Biglan et al. 2017). This clinical trial failed ('Isradipine Versus Placebo in Early Parkinson 
Disease: A Randomized Trial'  2020), supporting recent concerns about the dosage’s efficiency 
(Ortner et al. 2017). 
Other voltage-gated Ca2+ channels have been linked to increased cytosolic Ca2+ levels and the 
accompanying vulnerability of SNc DaNs. T-type voltage-gated Ca2+ channels have been 
shown to contribute to Ca2+ oscillations (Guzman et al. 2018) and to drive degeneration of SNc 
DaNs in a familial form of PD (Tabata et al. 2018). In addition, a recent study identified the R-
type channel Cav2.3 to be most strongly expressed among all voltage-gated Ca2+ channels in 
Fig. 1-3 Cell-autonomous factors contributing to the vulnerability of SNc DaNs to mitochondrial 
dysfunction. Schematic summary of selected cellular key features that contribute to the selective vulnerability of 
SNc DaNs in PD upon mitochondrial dysfunction. Autonomous pacemaking is associated with Ca2+ oscillations 
mediated by distinct voltage-gated Ca2+ channels (Cav). Low Ca2+ buffering capacity further contributes to enhanced 
intracellular Ca2+ load, which in turn causes oxidative stress by unknown mechanisms. SNc DaNs have a long, 
unmyelinated axon which is extremely branched, leading to high energetic demands and a strong dependence on 
functional mitochondria. ATP-sensitive potassium (K-ATP) channels open in metabolic demand situations, and 
thereby connect neuronal activity with the energetic state of the cell. When mitochondrial function is impaired, 
however, hyperactivity of K-ATP channels can result in the complete loss of neuronal excitability and contributes to 






mouse SNc DaNs. The KO of this channel revealed neuroprotective effects upon MPTP 
treatment through the reduction of activity-associated Ca2+ signals and upregulation of the 
neuronal Ca2+ sensor (NCS-1) (Benkert et al. 2019). NCS-1 in turn promotes DA-induced auto-
inhibition (Boeckel and Ehrlich 2018) via binding to DA D2-autoreceptors (Dragicevic et al. 
2014; Ford 2014; Philippart and Khaliq 2018) and is thereby believed to protect SNc DaNs 
from activity-dependent Ca2+ overload (Catoni, Cali, and Brini 2019). 
The importance of the prevention of increased cytosolic Ca2+ levels is underscored by the 
severe loss of those ventrolateral DaNs in the SNc of PD patients (Halliday et al. 1996; Braak 
et al. 2003), which do not express the intracellular Ca2+-buffering protein calbindin (Damier et 
al. 1999). However, the neuroprotective potential of calbindin is still inconclusive. Whereas, 
besides in PD patients, calbindin-positive SNc DaNs were spared in MPTP-treated monkeys 
as well (German et al. 1992; Dopeso-Reyes et al. 2014), the lack of calbindin did not modify 
its sensitivity to MPTP toxicity (Airaksinen, Thoenen, and Meyer 1997). Calbindin 
overexpression (Yuan et al. 2013), however, as well as viral vector-mediated gene delivery of 
calbindin (Inoue et al. 2019) attenuated MPTP-induced selective neurodegeneration and 
further reduced the number of α-Syn expressing DaNs. It is therefore likely that the presence 
of α-Syn aggregates and Lewy bodies in PD is linked to increased intracellular Ca2+ levels in 
SNc DaNs in the first place (Post, Lieberman, and Mosharov 2018). This regulatory role of 
Ca2+ is mediated by the Ca2+-activated protease calpain, of which a higher activity was found 
in post mortem PD brains (Crocker et al. 2003). In addition, calpain levels were increased in 
cells and mouse striatum upon MPTP treatment (Singh et al. 2019). Interestingly, calpain 
activity is attenuated by calbindin and reduction of calpain activity prevents DaNs from 
increased α-Syn aggregation and synaptic impairment (Diepenbroek et al. 2014) as well as 
from MPTP-induced cell death (Choi et al. 2008). These findings support the potential 
neuroprotective effect of the presence of calbindin, and once more, the significance of 
maintaining intracellular Ca2+ homeostasis in SNc DaNs. 
Apart from voltage-gated Ca2+ channels, other ion channels have been implicated in the 
vulnerability of SNc DaNs. ATP-sensitive potassium (K-ATP) channels are metabolic sensors, 
as their open probability is higher in metabolic demand situations, followed by membrane 
hyperpolarization and inhibition of neuronal activity in order to reduce energetic costs (Liss and 
Roeper 2001). Under physiological conditions, these channels hence protect the cell from 
overexcitability and excitotoxicity. Conversely, K-ATP channels have been shown to activate 
SNc DaNs by controlling burst activity to maintain goal-directed behavior for food seeking, 
among others (Schiemann et al. 2012). Upon MPTP treatment, however, K-ATP channels of 
SNc DaNs open and cause a complete loss of electrophysiological activity, in contrast to VTA 





This suggests a breakdown of the SNc DaN neuronal activity following complex I deficiency in 
face of enhanced energy demands. 
The high as well as consistent energetic demands of SNc DaNs become apparent when 
considering the unique axonal architecture. In contrast to the VTA, DaNs located in the SNc 
possess unusually large and extremely branched axons that are connected to a large number 
of nerve cells. The axon of a single SNc DaN is estimated to give rise to up to 245,000 
synapses in rats and 2.4 million synapses in humans, respectively (Bolam and Pissadaki 
2012). The architecture of these concurrently unmyelinated axons (Braak et al. 2004) is 
accompanied by an extremely high energetic demand in order to maintain ion homeostasis for 
continuous action potential propagation and synaptic processes (Pacelli et al. 2015). 
Consequently, SNc DaNs are vulnerable to additional stressors influencing the energetic 
balance of the cell, and especially the impairment of mitochondrial function. 
1.2.2 Motor Symptoms 
Since the initial description by James Parkinson 200 years ago (Parkinson 2002), motor 
symptoms are still the cardinal, clinical component of PD. Bradykinesia is the essential feature 
in PD and occurs in combination with either resting tremor, rigidity, or both (Postuma et al. 
2015). It is the ‘palsy’ part of the ‘shaking palsy’ as originally termed, and defined as the 
slowness of movement and decrement in amplitude or speed as movements are continued 
(Postuma et al. 2015; Berg et al. 2018; Bologna et al. 2020). Tremor, the rhythmic oscillation 
of a body part (Bhatia et al. 2018), is also present in the essential tremor disease, however, 
the unilateral onset and appearance at rest is considered to be specific for PD (Reich 2020). 
The third motor component, rigidity, is defined as the resistance to passive movements 
independent of velocity. In order to distinguish rigidity from spasticity, this resistance should 
not be restricted to failure in relaxing with regard to diagnosis (Postuma et al. 2015). 
Voluntary movement control is explained by the basal ganglia model. Regarding the classical 
model, the main input component of the basal ganglia is the dorsal striatum (Albin, Young, and 
Penney 1989; DeLong 1990), where most of SNc DaNs are projecting to (Liss and Roeper 
2008; Watabe-Uchida et al. 2012). In humans, the dorsal striatum is composed of the caudate 
nucleus and the putamen (Ghandili and Munakomi 2020), whereas it is seen as one structure, 
called the caudate putamen (CPu), in mice (Allen Institute 2020). The major output regions of 
the basal ganglia are the globus pallidus pars interna (GPi) and the substantia nigra pars 
reticulata (SNr). These brain areas project to the thalamus and thereby regulate the activity of 
the motor cortices (Obeso et al. 2000). In the ‘direct pathway’, the GPi and the SNr are 
inhibited. Thus, they allow the thalamus to activate the motor cortices (see Fig. 1-4). In 
contrast, the ‘indirect pathway’ further includes inhibitory projections of the globus pallidus pars 





target the main output components of the basal ganglia (GPi/SNr). This results in GPi and SNr 
activation and subsequent thalamus inhibition. Thus, the net outcome of the indirect pathway 
is the inactivation of the motor centers (Albin, Young, and Penney 1989; DeLong 1990; 
Benarroch 2016). Notably, these two pathways seem to be simultaneously rather than 
consecutively activated during movement initiation (Cui et al. 2013). A third pathway, the so 
called ‘hyperdirect pathway’, is characterized by a projection from the cortex to the STN and 
considered to be responsible for outcome optimization (Nambu, Tokuno, and Takada 2002; 
Aron et al. 2016). 
In PD, the lack of DA in the dorsal striatum upon the loss of SNc DaNs reduces the activity of 
the direct pathway, which is initiated by striatal activation via D1 receptors. Concurrently, the 
indirect pathway is promoted (Wichmann and DeLong 1996). As a consequence, the activity 
of the main output components of the basal ganglia (GPi/SNr) is enhanced by both the lack of 
inhibition from the direct pathway, as well as increased activation from the indirect pathway 
due to the reduced firing of GPe neurons and subsequent STN disinhibition (Pan and Walters 
1988; Bergman et al. 1994; Hutchison et al. 1994; Sterio et al. 1994; Wichmann et al. 1999; 
Kita and Kita 2011). Thalamo-cortical and brainstem motor systems are consequently inhibited 
via both pathways, impairing preparation and execution of voluntary movement (Wichmann 
Fig. 1-4 Voluntary movement control under physiological conditions and during Parkinson’s disease. A) 
According to the basal ganglia model, SNc DaNs innervate the dorsal striatum (putamen) and activate 
D1-expressing striatal medium spiny neurons of the direct pathway (red lines) and inhibit D2--expressing striatal 
neurons of the indirect pathway (blue lines), respectively. The major output regions, GPi and SNr, project to the 
thalamus, which in turn stimulates the motor cortices. B) In PD, the progressive loss of SNc DaNs results in 
insufficient striatal DA supply and leads to an imbalance between the direct and indirect pathway. As a result, 
thalamo-cortical motor systems are inhibited via both pathways, which affects movement preparation as well as 





and DeLong 1996). Thus, motor symptoms in PD are related to the depletion of DA in the main 
input component of the basal ganglia upon DaN loss in the SNc. However, it is believed that 
the cerebellum also plays a role in bradykinesia formation (Bostan and Strick 2018) and that 
compensatory hyperactivity of pyramidal neurons in the premotor cortex might further 
contribute to rigidity (Yu et al. 2007). 
When ~30-50% of SNc DaNs are perished, motor symptoms of PD patients become apparent 
(Obeso et al. 2017). At this time point, DA release in the dorsal striatum is already reduced by 
~50-60% (Fearnley and Lees 1990; Ehringer and Hornykiewicz 1998). Since striatal nerve 
terminals have been shown to degenerate before their cell bodies (Chu et al. 2012; Kordower 
et al. 2013), loss of SNc DaNs in PD is thought to occur in a striatonigral (retrograde) manner. 
PD-related mouse models reveal motor impairment at dopaminergic loss rates comparable to 
humans, while the spontaneous motor activity is classically assessed by the open field test 
(Seibenhener and Wooten 2015). When ~40-60% of SNc DaNs are perished, genetically as 
well as pharmacologically induced, mice show impaired motor behavior (Crocker et al. 2003; 
Ekstrand et al. 2007; Wakamatsu et al. 2007; Lu et al. 2009; Chen et al. 2012; Rousseaux et 
al. 2012; Becker et al. 2018; Zeng, Geng, and Jia 2018). 
Motor symptoms of PD patients can nowadays be treated with a range of drugs, including the 
well-known blood-brain barrier permeable L-DOPA, DA agonists and MAO type B (MAOB) 
inhibitors. The overall aim is to increase or maintain striatal DA levels, either by the DA 
precursor, DA agonists and inhibition of DA breakdown, respectively (Kalia and Lang 2015). 
In the early phase of PD, L-DOPA is currently the first choice of treatment with low doses at 
the beginning and subsequent titration to therapeutic threshold, while DA agonists and MAOB 
blockers are reserved for intervention at later stages of the disease (de Bie et al. 2020). Though 
the mechanism of L-DOPA is still not fully understood and the traditional idea of a DA precursor 
has been challenged since it does not explain the fading pharmacological efficiency (Obeso et 
al. 2017), L-DOPA has been demonstrated to improve, and more importantly, not to worsen 
the progression of PD in the long run (Fahn et al. 2004). However, motor dyskinesias present 
a serious problem (Aquino and Fox 2015; Vijayakumar and Jankovic 2016) as  occurring in 
~30% of PD patients after the first year of L-DOPA treatment ('Impact of deprenyl and 
tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. 
Parkinson Study Group'  1996) and additional ~10% with each following year (Ahlskog and 
Muenter 2001). Thus, the development of new formulations of L-DOPA and novel delivery 
techniques is still ongoing (Obeso et al. 2017). When L-DOPA and DA agonists have 
eventually failed and dyskinesia becomes disabling, surgical intervention by deep brain 
stimulation (DBS) of the STN and GPi is the next candidate for the treatment of motor 
impairment. DBS improves motor symptoms by modifying the dynamics of basal ganglia 





2008; Vitek et al. 2012; Cleary et al. 2013; Muller and Robinson 2018). Whereas due to the 
prior pharmacological treatments the average age of PD patients treated with DBS is about 
10-13 years after disease diagnosis, DBS could be performed earlier in future interventions, 
regarding the positive results after application in the early disease phase (Schuepbach et al. 
2013). 
1.2.3 Hyposmia 
In contrast to many other neurodegenerative diseases, the advantage hallmark of PD is the 
occurrence of non-motor prodromal symptoms (Postuma, Lang, et al. 2012). One of these 
prodromes is hyposmia, which is found in ~95% of PD patients and can precede motor 
impairment by up to ten years (Haehner, Hummel, and Reichmann 2009; Lang 2011; Doty 
2012). Though the vast majority of people with hyposmia will never develop PD (Abbott et al. 
2005), olfactory dysfunction probably possesses the best potential of all non-motor symptoms 
for PD prediction (Beach et al. 2010; Obeso et al. 2017). The mechanisms causing PD-related 
hyposmia are still not understood. However, first pathological changes in PD, including the 
presence of Lewy bodies, are observed in olfactory systems, such as the anterior olfactory 
nucleus and the OB (Braak et al. 2003). Recently, impaired olfactory behavior has been 
presented upon α-Syn inclusions in the OB of transgenic mice (Taguchi et al. 2020). This might 
explain the early appearance of dysfunctional olfaction and further supports a long standing 
hypothesis of an infectious agent (Braak et al. 2004), affecting olfactory nerve terminals first 
followed by spreading throughout the central nervous system (CNS), to be the initial cause of 
PD (Breen, Halliday, and Lang 2019).  
Besides their prominent roles in the striatonigral and mesolimbic system, DaNs are additionally 
present in the OB. They make up about 5% of the neuronal OB population and are primarily 
located in the glomerular layer (GL) (Cave and Baker 2009). As interneurons, DaNs are 
involved in the discrimination of odors rather than the detection (Tillerson et al. 2006; Escanilla 
et al. 2009). In particular, they modulate the activity of both olfactory sensory fibers (Berkowicz 
and Trombley 2000; Wachowiak et al. 2005) and mitral cells by D2 receptor-mediated inhibition 
(Nagayama, Homma, and Imamura 2014; Banerjee et al. 2015) as well as via contacts with 
external tufted cells (Liu et al. 2013). In spite of a variety of literature reporting about different 
categorizations, DaNs in the OB can be clearly divided into small (5-10 µm) anaxonic (SCs) 
and large (10-15 µm) axonic cells (LACs) (Pignatelli and Belluzzi 2017). Notably, SCs can be 
generated throughout life in both humans and mice (Kosaka et al. 1987; Vergano-Vera et al. 
2006; Bovetti et al. 2009; Kosaka and Kosaka 2009; Galliano et al. 2018). This neurogenic 
process is initiated by the presence of progenitor cells in the dorsolateral region of the 
subventricular zone (SVZ) (Fiorelli et al. 2015). These cells are characterized by the 
transcription factor paired box 6 (PAX6), which is required for DaN phenotype development 





the ~20,000-30,000 daily generated new-born progenitor cells migrate to the GL, whereas the 
vast majority differentiates into interneurons in the granule cell layer (Codega et al. 2014; 
Bonaguidi et al. 2016). 
Regarding the general vulnerability of DaNs in PD as well as early pathological changes in the 
DaN-enriched OB, it would be obvious that hyposmia is linked to a reduced number or an 
altered functionality of DaNs. However, there are both limited and contradictory results 
concerning the fate of DaNs in the OB of PD patients. Whereas even elevated numbers of 
DaNs in the GL were reported as a result of potential compensatory mechanisms (Mundinano 
et al. 2011), no differences could be detected by other groups when comparing PD patients 
and healthy individuals (Huisman, Uylings, and Hoogland 2008; Cave et al. 2016). Hence, 
there are currently no data revealing a mechanistic explanation for PD-related hyposmia or the 
contribution of OB DaNs to this pathology. Furthermore, it is not known whether DaNs in the 
OB are as vulnerable to mitochondrial dysfunction as their midbrain counterparts. 
1.2.4 Depression 
Depression is a common non-motor symptom associated with PD, arising with a prevalence 
of 15-50% (Obeso et al. 2017). It can occur at any time during the course of PD, whereas 
development in the early phase is associated with an increased risk for more severe motor 
deficits (Pfeiffer 2016). While being a complex interplay of psychological and neurobiological 
factors, depression frequently correlates with anxiety, which can be expressed by generalized 
anxiety disorder, panic attacks and social phobia (Berg et al. 2015). Besides its contribution to 
resting tremor and L-DOPA-induced dyskinesias (Doder et al. 2003; Rylander et al. 2010; 
Politis et al. 2014), impairment of serotonergic signalling is the main cause of depressive 
behavior. Hence, additional antidepressant therapy, including serotonin reuptake inhibitors, is 
quite common in PD (Richard et al. 2012). 
Brainstem raphe nuclei (RN) are highly enriched in serotonin-expressing neurons, which 
project to the basal ganglia, amygdala, hippocampus, and diverse cortical areas (Parent et al. 
2011; Wallman, Gagnon, and Parent 2011). While presenting Lewy pathology in the early 
course of PD (Braak et al. 2003), post mortem investigations further revealed severe 
degeneration of serotonergic neurons in the RN (Halliday et al. 1990) correlating with 
diagnosed depression in these patients (Paulus and Jellinger 1991). Commensurately, 
reduced serotonin levels have been found in RN projection areas, including the basal ganglia, 
hypothalamus, hippocampus and prefrontal cortex (Fahn, Libsch, and Cutler 1971; Shannak 
et al. 1994). However, in vivo imaging studies mainly using the positron emission tomography 
(PET) technique did not show consistent results. Striatal serotonin transporter (SERT) density 
was found to be reduced in PD patients (Kerenyi et al. 2003), but binding features of SERT 





al. 2007). In contrast, another study detected increased SERT availability in the RN and the 
limbic cortex of depressive PD patients, which were referred to compensatory enhanced 
serotonin binding upon the progressive loss of the serotonergic system (Politis et al. 2010). 
Intriguingly, investigation of DA and noradrenaline transporters revealed lower binding capacity 
in the locus coeruleus and areas of the limbic system, such as the ventral striatum, when 
comparing depressed and non-depressed PD patients (Remy et al. 2005). This suggests that 
besides serotonergic denervation, PD-related depression is further caused by the depletion of 
DA in the ventral striatum. Indeed, depressive behavior can be reproduced in primates and 
rodents when the dopaminergic mesolimbic pathway, including projections originating from the 
VTA to the nucleus accumbens (NAcc), is impaired (Brown et al. 2012; Furlanetti, Coenen, 
and Dobrossy 2016; Nobili et al. 2017). 
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2 Aim of the Thesis 
The contribution of mitochondrial dysfunction to the loss of SNc DaNs in PD is undisputed. 
However, it is still unsolved why particularly this dopaminergic subpopulation degenerates 
upon mitochondrial damage. In contrast to the less affected VTA (Alberico, Cassell, and 
Narayanan 2015), pacemaker activity in SNc DaNs is associated with Ca2+ oscillations (Chan 
et al. 2007), which are causing oxidative stress (Guzman et al. 2010) and are thought to render 
these highly energy demanding neurons (Pacelli et al. 2015) more vulnerable to 
neurodegeneration through the metabolic challenge upon increased Ca2+ levels (Surmeier et 
al. 2012; Duda, Potschke, and Liss 2016). The potential consequences of impaired intracellular 
Ca2+ homeostasis in SNc DaNs are further underscored by the severe loss of calbindin-
negative cells in the ventrolateral SNc of PD patients (Damier et al. 1999). However, a 
mechanistic link between mitochondrial dysfunction and intracellular Ca2+ handling in PD is still 
missing. Thus, the first manuscript of the thesis focused on studying the impact of neuronal 
Ca2+ handling on the selective vulnerability of SNc DaNs upon mitochondrial dysfunction by 
using the MitoPark mouse model. 
In the second manuscript, the same mouse model was used to investigate the influence of 
mitochondrial dysfunction on DaNs that are located in the OB as well as the olfactory-related 
behavior. Despite hyposmia being an important PD-related prodromal non-motor symptom 
(Beach et al. 2010; Obeso et al. 2017), little is known about the vulnerability of this 
dopaminergic subpopulation in PD and there are contradictory results regarding the number 
of OB DaNs in patients (Huisman, Uylings, and Hoogland 2008; Mundinano et al. 2011; Cave 
et al. 2016). 
In the MitoPark model, DaN-specific TFAM depletion leads to the rapid loss of mtDNA encoded 
transcripts. However, rather than progressively losing mtDNA, SNc DaNs have been reported 
to accumulate mtDNA deletions with increasing age and even more abundantly in PD (Bender 
et al. 2006; Kraytsberg et al. 2006; Reeve et al. 2008; Elstner et al. 2011; Dolle et al. 2016). In 
our lab, we make use of mice expressing a mutated, dominant-negative variant of the 
mitochondrial helicase Twinkle (K320E mutation) in a cell-specific manner, in order to study 
the impact of accumulating mtDNA deletions on the function of various tissues (Baris et al. 
2015; Weiland et al. 2018; Holzer et al. 2019). We consequently generated mice in which 
K320E is exclusively expressed in DaNs. Accordingly, the third manuscript of this thesis 
includes the outcome of impaired mtDNA replication on survival as well as mitochondrial 
function of DaNs in these animals. 
The content of the manuscripts was kept in its original form. However, integration of figures 
and corresponding figure legends into the text, consecutive labeling of figures as well as 
uniform font style were applied in order to improve readability of the thesis. The aim of was to 
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present the three manuscripts and eventually discuss their findings in a coherent manner. This 
led to the following key questions of this thesis: 
1. How are distinct subpopulations of DaNs differently affected upon the loss of TFAM 
followed by mitochondrial dysfunction? 
2. What are the differences between the early-onset MitoPark and the delayed-onset 
K320E-TwinkleDaN mouse model regarding loss of mitochondrial function, DaN survival, 
striatal innervation and behavioral phenotype? 
3. Which clinical relevance do these mouse models have? 
 
2.1 Manuscript Declaration 
The manuscripts included in this thesis report about degeneration of DaNs following 
mitochondrial dysfunction in mice induced by differential genetic impairment of mtDNA 
maintenance. The first two manuscripts deal with the well-established MitoPark mouse model, 
which is characterized by the DaN-specific loss of TFAM and mimics the course of PD within 
weeks. The one published in the Journal of Neuroscience reveals that upon mitochondrial 
dysfunction, high Ca2+ loads lead to an imbalance in the antioxidant system of vulnerable SNc 
DaNs right before the onset of neurodegeneration, in contrast to their VTA counterparts. The 
second, published in Molecular Neurobiology, contrasts the impact of mitochondrial defects in 
midbrain DaNs to DaNs located in the OB and further presents the consequence for olfactory-
related behavior in MitoPark mice. The third manuscript, which is in preparation for submission, 
includes the newly generated K320E-TwinkleDaN mouse model. In contrast to the MitoPark 
mouse model, K320E-TwinkleDaN animals reveal a delayed, non-selective degeneration of 
midbrain DaNs following mitochondrial dysfunction, induced by the expression of a mutated 
form of the mitochondrial replicative helicase Twinkle (K320E). However, dopaminergic striatal 
projections are differentially affected, causing a depressive-like behavior but normal motor 
performance in these mice. Hence, the three manuscript provide insights into vulnerability but 
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Mitochondrial dysfunction is critically involved in Parkinson's disease, characterized by loss of 
dopaminergic neurons (DaNs) in the Substantia nigra (SNc), while DaNs in the neighboring 
ventral tegmental area (VTA) are much less affected. In contrast to VTA, SNc DaNs engage 
calcium channels to generate action potentials, which leads to oxidant stress by yet unknown 
pathways. To determine the molecular mechanisms linking calcium load with selective cell 
death in the presence of mitochondrial deficiency, we analyzed the mitochondrial redox state 
and the mitochondrial membrane potential in mice of both sexes with genetically induced, 
severe mitochondrial dysfunction in DaNs (MitoPark mice), at the same time expressing a 
redox-sensitive GFP targeted to the mitochondrial matrix. Despite mitochondrial insufficiency 
in all DaNs, exclusively SNc neurons showed an oxidized RedOx-system, i.e. a low 
GSH/GSSG ratio. This was mimicked by cyanide, but not by rotenone or antimycin A, making 
the involvement of reactive oxygen species (ROS) rather unlikely. Surprisingly, a high 
mitochondrial inner membrane potential was maintained in MitoPark SNc DaNs. Antagonizing 
calcium influx into the cell and into mitochondria, respectively, rescued the disturbed RedOx-
ratio and induced further hyperpolarization of the inner mitochondrial membrane. Our data 
therefore show that the constant calcium load in SNc DaNs is counterbalanced by a high 
mitochondrial inner membrane potential, even under conditions of severe mitochondrial 
dysfunction, but triggers a detrimental imbalance in the mitochondrial redox system, which will 
lead to neuron death. Our findings thus reveal a new mechanism, redox imbalance, which 
underlies the differential vulnerability of DaNs to mitochondrial defects. 
 
Key words: Parkinson’s disease, mitochondrial dysfunction, selective neuron loss, redox 
imbalance, mitochondrial membrane potential 
 
Significance Statement  
Parkinson’s disease (PD) is characterized by the preferential degeneration of dopaminergic 
neurons (DaNs) of the substantia nigra pars compacta (SNc), resulting in the characteristic 
hypokinesia in patients. Ubiquitous pathological triggers cannot be responsible for the selective 
neuron loss. Here we show that mitochondrial impairment together with elevated calcium 
burden destabilize the mitochondrial defense only in SNc DaNs, and thus promote the 
increased vulnerability of this neuron population. 
  
 




The motor symptoms of Parkinson’s disease (PD) are caused by the selective degeneration 
of dopaminergic neurons (DaNs) in the substantia nigra pars compacta (SNc) (Dauer and 
Przedborski, 2003; Sulzer, 2007; Obeso et al., 2017). Mitochondrial dysfunction is a central 
feature of idiopathic PD, but also a large percentage of genetic forms is due to mutations of 
proteins involved in quality control of the mitochondrial pool (Pickrell and Youle, 2015). 
The probability to develop idiopathic PD strongly increases with age (De Lau and Breteler, 
2006). At the same time, dopaminergic midbrain regions are hot spots for the accumulation of 
mitochondrial DNA (mtDNA) deletions (Cortopassi et al., 1992; Meissner et al., 2008), which 
reach detrimental levels in single DaNs with increasing age (Bender et al., 2006; Kraytsberg 
et al., 2006; Dölle et al., 2016). Thus, it is tempting to speculate that these two aging-related 
phenomena are causally connected. We have shown that it is catecholamine metabolism 
which drives the enhanced generation of mtDNA deletions (Neuhaus et al., 2014; Neuhaus et 
al., 2017), and leads to mitochondrial dysfunction (Burbulla et al., 2017), explaining why cells 
producing dopamine are mostly affected by these mtDNA alterations. 
While there is a general aging-related decline of neurons in the SNc, surprisingly the DaNs in 
the neighboring ventral tegmental area (VTA) are more or less spared (Reeve et al., 2014), 
although we have clearly shown that they also accumulate mtDNA deletions (Neuhaus et al., 
2014). This specific decline can be further observed in PD patients (Hirsch et al., 1988; Damier 
et al., 1999), as well as in rodents, where the same specific neuron loss is induced by 
mitochondrial toxins like MPTP (German et al., 1992) or rotenone (Betarbet et al., 2000). 
Several reasons have been proposed to explain this puzzling differential vulnerability. One 
hypothesis is that DaNs of the SNc are unusually large neurons with an extremely branched 
axonal network which connects to a very high number of other nerve cells. These axonal 
branches are even unmyelinated (Braak et al., 2004), thus the energy demand to maintain ion 
homeostasis for action potential propagation and to supply synaptic processes is extremely 
high (Bolam and Pissadaki, 2012; Pacelli et al., 2015). Roeper and Liss, on the other hand, 
have shown that this metabolic "stress" triggers activity of K-ATP channels and NMDA 
receptors, promoting action potential bursting in vivo and propelling excitotoxicity, but only in 
SNc DaNs (Schiemann et al., 2012; Duda et al., 2016), since in VTA DaNs, mitochondria are 
mildly uncoupled, potentially preventing K-ATP channel-mediated vulnerability (Liss et al., 
2005). Last but probably most attractive, the differential vulnerability of VTA and SNc neurons 
has been linked to their different modes of pacemaking: While SNc DaNs use L-type calcium 
channels as well as sodium channels (Chan et al., 2007; Philippart et al., 2016; Ortner et al., 
2017), VTA neurons exclusively use sodium channels (Betarbet et al., 2000). Therefore, the 
maintenance of steep calcium concentration gradients across membranes may again place a 
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much higher energy demand on SNc DaNs. Moreover, their well-known low intrinsic calcium 
buffering capacity (German et al., 1992; Damier et al., 1999; Schiemann et al., 2012), together 
with α-synuclein- and L-type calcium channel-dependent increase in cytosolic calcium 
(Lieberman et al., 2017) causes “oxidant stress” in mitochondria of vulnerable SNc DaNs, 
promoting their specific death (Guzman et al., 2010; Dryanovski et al., 2013). 
In order to further explain why two closely related neuron subtypes respond so differently to 
mitochondrial dysfunction, we investigated the changes in their mitochondrial redox state and 
inner membrane potential, respectively, in vivo. To achieve this, we targeted a redox-sensitive 
GFP to the matrix (mito-roGFP) (Guzman et al., 2010) in MitoPark mice. MitoPark mice display 
COX-deficiency in DaNs (12 weeks) followed by degeneration of the dopaminergic system and 
motor impairment, which becomes more pronounced with increasing age (from 13 to 20 weeks) 
(Ekstrand et al., 2007). The mito-roGFP probe is sensitive to the ratio of reduced/oxidized 
glutathione (GSH/GSSG) (Dooley et al., 2004) in the mitochondrial matrix, which in turn 
depends on the NAD(P)H/NAD(P) + ratio (Nelson and Cox, 2005), which again is closely linked 
to respiratory chain activity. 
Materials and methods 
Experimental model 
Experiments were performed in agreement with European and German guidelines and 
approved (LANUV NRW, Recklinghausen, Germany; 84-02.04.2013-A141). All experiments 
were carried out with male or female mice of the strain C57/BL6N. TfamloxP/loxP and Dat-cre 
mice were provided by Nils-Göran Larsson (Max-Planck-Institute for Biology of Ageing, Köln, 
Germany). MitoPark mice (TfamloxP/loxP +/Dat-cre) were bred as described previously 
(Ekstrand et al., 2007) and TfamloxP/WT or TfamloxP/loxP mice were used as controls. Mito-
roGFP mice were provided by James D. Surmeier (Northwestern University Feinberg School 
of Medicine, Chicago IL 60611, USA). MitoPark x mito-roGFP mice were generated by crossing 
TfamloxP/WT +/Dat-cre mito-roGFP males with TfamloxP/loxP females. 
Genotyping 
All genetic lines were identified by qualitative PCR-approaches using genomic DNA either from 
tail tip or ear punch biopsies. Tissue lysis was done in 75 µL lysis buffer (10 mM NaOH, 0.2 
mM EDTA) at 96 °C for 45 min. After adding 75 µL of neutralization buffer (40 mM Tris-HCl, 
pH 7.6), lysates were centrifuged (1 min, 3000 rpm) and stored at -20 °C. Cycling conditions 
and primer sequences for the genetic lines are available upon request. Agarose gels 
containing 1.2 or 1.5% agarose (Tfam PCR: 1.5%, DatCre and mito-roGFP PCR: 1.2%) and 
0.8 µg/mL ethidium bromide in TAE buffer (40 mM Tris base, 20 mM Acetic acid, 1mM EDTA, 
pH 8) were used to illustrate PCR products under UV-light. 
 




All immunohistochemical approaches were performed on 5 µm paraffin sections. Striatal 
tyrosine hydroxylase (TH) immunoreactivity was done using a TH antibody (polyclonal rabbit, 
Abcam, #ab112, 1:750) and a biotinylated secondary antibody (donkey anti-rabbit, dianova, 
#111-065-006, 1:500). Fluorescence stainings of midbrain sections were performed with 
primary antibodies against TH (polyclonal rabbit, Abcam, #ab112, 1:1500), mitochondrial 
complex IV SU1 (COX I, monoclonal mouse, Abcam, #ab14705, 1:1000) or calbindin-D28k 
(Cb-D28k, monoclonal mouse, Swant, #300, 1:150) and fluorochrome-conjugated secondary 
antibodies (Goat anti-rabbit TRITC-conjugated, AffiniPure, #111-025-144, 1:2000, Goat anti-
mouse DyLight488-conjugated, Jackson-ImmunoResearch, #115-485-003, 1:400). 
Visualization of Cytochrome c Oxidase (COX) deficiency was performed by COX-SDH 
enzymatic activity staining at Bregma -3.08 mm similar to Lotter et al., 2017, but incubation 
with SDH solution was performed for 180 min. 
Bright-field microscopy was done with a slidescanner (SCN400, Leica) equipped with a 40x 
objective. TH-positive striatal fiber density was determined by optical density analysis using 
ImageJ-software with 2 sections/mouse at Bregma +0.74 mm. Fluorescence images were 
obtained with an inverse confocal microscope (TCS SP8 gSTED, Leica) with a 10x objective 
(Cb-D28k) or a 40x oil objective (COX) at Bregma -3.08 mm. COX-signal intensity was 
measured in the perikarya of TH-positive neurons and normalized to the COX-signal of a TH-
negative area. Cb-D28k and TH double stainings were done on 2 midbrain sections/mouse, 
followed by identification of double-positive and TH-positive neurons similar to (Liang et al., 
1996). 
Two-photon laser scanning microscopy 
Two-photon laser scanning microscopy (2PLSM) recordings were performed in 300 µm thick 
coronal midbrain sections. 10 to 12 week-old mice were anaesthetized with isoflurane and 
afterwards decapitated. The brain was quickly removed and brain sections were prepared with 
a vibratome (Leica VT1000 S or Thermo Scientific HM 650 V) in ice-cold, carbonated artificial 
cerebrospinal fluid (ACSF, 125 mM NaCl, 2.5 mM KCl, 25 mM NaHCO3, 1.25 mM NaH2PO4 
x H2O, 25 mM Glucose, 2 mM MgCl2, 2 mM CaCl2 x 2 H2O). 
2PLSM analysis was adapted from (Guzman et al., 2010). Ex vivo 2PLSM measurements in 
midbrain sections were conducted using a two-photon excitation microscope (TCS SP8 MP-
OPO, IR APO L25x/0.95 objective, Leica). Before recordings, sections were incubated for at 
least 20 min at room temperature. Sections were transferred into the recording chamber of the 
imaging setup containing ~ 0.5 mL ACSF (37°C) and continuously perfused with carbonated 
ACSF. Solutions were applied at a flow rate of 4 to 5 mL per minute. Analysis of the 
mitochondrial RedOx-ratio in intact cells is enabled by the use of a redox-sensitive variant of 
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the green fluorescent protein (roGFP; (Vevea et al., 2013)). In the analyzed mouse line, 
expression of mito-roGFP is driven by the TH promoter (Guzman et al., 2010; Dryanovski et 
al., 2013), restricting the origin of any mito-roGFP signal to dopaminergic neurons. SNc and 
VTA DaNs were identified according to their location in the slice. Mito-roGFP excitation was 
done with 920 nm wavelength (Chameleon Vision II) and fluorescence detection between 500 
to 550 nm. Fluorescence intensity in perikarya of single cells was measured using ImageJ-
software. The fluorescence intensity from a GFP negative region was subtracted from each 
DaN signal, to remove mito-roGFP unspecific noise. Previous 2PLSM analysis of mito-roGFP 
mice (Guzman et al., 2010; Dryanovski et al., 2013) was presented as levels of “relative 
oxidation” and the mito-roGFP signal was detected on a single focus level, excluding a 
considerable fraction of the mitochondrial network. Here we analyzed the fluorescence of the 
entire mitochondrial network in perikarya by stacking approximately 45 focus planes (z-stacks, 
Figure 3-4, 3-4-1 and 3-4-2). Z-stacks covered a tissue depth of 45 µm. Neurons which were 
located at the surface of the slice were excluded from analysis. Discrete mito-roGFP recordings 
were performed with the multiphoton laser being activated at 4 time points: 1) At the beginning 
of the recording (0 minutes), 2) at 20 minutes to define the baseline, 3) after application of DTT 
at 30 minutes and 4) after application of ALD at 40 minutes. The fluorescence intensity after 
DTT application was interpreted as the mito-roGFP response at minimal oxidation or maximal 
reduction (RedOx-ratio = 0). The signal intensity after application of ALD was taken as 
response at maximal oxidation (RedOx-ratio = 1). The mitochondrial RedOx-ratio of DaNs was 
calculated using the following formula: RedOx-ratio = (roGFP-F ACSF, 20 min - roGFP-F DTT, 
30 min)/ (roGFP-F ALD, 40 min - roGFP-F DTT, 30 min). 
Conditions for TMRM 2PLSM recordings for the analysis of the DaN mitochondrial membrane 
potential were identical to mito-roGFP experiments. Sections were incubated with 100 nM 
TMRM for 30 min (37°C). TMRM recordings were conducted with TMRM-free ACSF. TMRM 
excitation was performed at 830 nm with laser intensities between 0.1 to 0.4% and 
fluorescence detected at 565 to 605 nm. DaNs were identified by their mito roGFP signal 
elicited with 920 nm. TMRM fluorescence was analyzed sequentially in perikarya of neurons 
in a fixed focus level and was detected at the beginning of each session. Only neurons with 
stable fluorescence traces were considered for TMRM signal quantification. At the end of each 
recording, sections were perfused with 5 mM KCN for 20 min and the difference between 
TMRM fluorescence before and after KCN was calculated (ΔTMRM-FKCN = TMRM-FACSF, 
20 min - TMRM-FKCN, 40 min). Thus, low TMRM signal intensities induced by KCN are 
reflected by high ΔTMRM-FKCN values. A high ΔTMRM-FKCN value, in turn, represents a 
high mitochondrial membrane potential. Background signal was detected by analogous 
recordings of brain slices without TMRM and subtracted from the TMRM signal emitted by 
DaNs. 
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Spherical GFP aggregates were observed in MitoPark mito-roGFP midbrain sections. It was 
previously reported that these aggregates are mitochondria with a severely disturbed 
morphology (Sterky et al., 2011). The GFP aggregates in our MitoPark mice were primarily, 
yet not exclusively, observed in the SNc and those neurons were excluded from the analysis 
to eliminate their potential impact on 2PLSM readouts. 
For blockade of calcium channels, sections were incubated with 300 nM isradipine or 20 µM 
Ru360 for at least 30 minutes. 
COX-SDH staining 
Visualization of Cytochrome c Oxidase (COX) deficiency was performed by COX-SDH 
enzymatic activity staining (Sciacco and Bonilla, 1996). COX is a respiratory chain (RC) 
complex which is partially encoded by mtDNA, while succinate dehydrogenase (SDH), another 
RC enzyme, is entirely encoded by nuclear DNA. Impaired integrity of mtDNA results in COX-
deficiency, but sustained SDH-activity. Cells with decreased COX-activity will stain blue, while 
cells with normal COX-activity will appear brown. Mice were killed by cervical dislocation. 
Following dissection, brains were embedded (O.C.T. Tissue-Tek), frozen on dry ice and stored 
at -80 °C. Cryostat (Leica CM3050 S) sections of 7 µm were stored at -80 °C. Coronal midbrain 
cryosections at Bregma -3.08 mm were air dried and treated with COX incubation solution (100 
µM Cytochrome C, 4 mM diaminobenzidine, 4400 U catalase in 0.1 M phosphate buffer) for 
40 min at 37 °C. Afterwards, sections were washed in ddH2O (3 x 30 sec) and treated with 
SDH incubation solution (1.5 mM Nitroblue tetrazolium, 130 mM sodium succinate, 200 µM 
phenazine methosulfate, 1 mM sodium azide) for 180 min at 37 °C. Sections were washed 
again in ddH2O (3 x 30 sec), dehydrated in 95% (2 x 2 min) and 100% ethanol (10 min), air 
dried and mounted with glycerol-gelatine. 
Immunohistochemistry 
Anaesthetized mice (ketamine/xylazine: 100/10 mg/kg body weight, intraperitoneally) were 
intracardially perfused with PBS (GIBCO; 140 mM NaCl, 10 mM sodium phosphate, 2.68 mM 
KCl, pH 7.4) for 3 min and 4% PFA in PBS for 15 min. Brains were dissected and immersion-
fixed in 4% PFA in PBS overnight. Afterwards tissues were dehydrated in a series of ethanol 
solutions (ethanol percentages are given): 70%, 90%, 2x 100% (15 min each), 100% (30 min) 
and 100% (45 min, Leica ASP300, CMMC Tissue Embedding Facility) and embedded in 
paraffin (Leica EG1150 H, CMMC Tissue Embedding Facility). Coronal 5 µm striatal sections 
were cut with a microtome (Leica RM2125 RTS). Sections were deparaffinized in xylene (2 x 
5 min), washed in a series of ethanol solutions (100%, 95%, 70% and 50%, 1 min each) and 
afterwards washed in ddH2O (5 min). For epitope retrieval, sections were heated in citrate 
buffer (10 mM citric acid monohydrate, pH 6) using a microwave oven.  
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Brightfield microscopy: Sections were washed in TBS (10 mM Tris base, 150 mM NaCl, pH 
7.6, 3 x 5 min), quenched with 0.3% H2O2/TBS solution and washed again in TBS (3 x 5 min). 
Subsequently, sections were blocked in 10% normal goat serum in TBS (45 min, RT) and 
afterwards incubated with the tyrosine hydroxylase (TH) antibody (polyclonal rabbit, Abcam, 
#ab112, 1:750 in 3% skim milk powder/TBS, overnight, 4°C). After another TBS washing step 
(3 x 5 min), sections were incubated with the secondary biotinylated antibody (donkey anti-
rabbit, dianova, #111-065-006, 1:500 in 3% skim milk powder/TBS, 30 min, RT), followed by 
avidin/biotin Vectastain Elite ABC HRP Kit (Vector Laboratories). Visualization was performed 
using DAB solution (0.46 mM 3,3’-Diaminobenzidine tetrahydrochloride, 7.3 mM Imidazole, 
15.2 mM Ammonium nickel (II) sulfate hexahydrate, 0.015% H2O2 in TBS, pH 7.1, 6 min). 
Following a short washing in ddH2O (1 sec), sections were dehydrated in 50%, 70% (1 sec 
each), 95% and 100% ethanol (1 min each), cleared in xylene (2 x 10 min) and mounted with 
Entellan.  
Fluorescence stainings: Sections were rinsed in 0.2% Triton-X 100 in TBS (3 x 5 min) after the 
epitope retrieval and incubated with the primary antibodies (TH polyclonal rabbit, Abcam, 
#ab112, 1:1500, mitochondrial complex IV SU1 (COX I) monoclonal mouse, Abcam, 
#ab14705, 1:1000 or calbindin-D28k (Cb-D28k) monoclonal mouse, Swant, #300, 1:150 in 
Dako antibody diluent, overnight, 4°C). Sections were washed in 0.2% Triton-X 100 in TBS (3 
x 5 min) and incubated with fluorochrome-conjugated secondary antibodies (Goat anti-rabbit 
TRITC-conjugated, AffiniPure, #111-025-144, 1:2000, Goat anti-mouse DyLight488-
conjugated, Jackson-ImmunoResearch, #115-485-003, 1:400, overnight, 4°C). Following 
another washing step in 0.2% Triton-X 100 in TBS (3 x 5 min), midbrain sections were 
counterstained with DAPI (1 µg/mL in ddH2O, 1 min), washed again in 0.2% Triton-X 100 in 
TBS (3 x 5 min) and mounted with Fluoromount. 
Stereological quantification of dopaminergic neurons 
For the counting of DaNs, tyrosine hydroxylase stainings of serial coronal paraffin midbrain 
sections were performed similar to stainings in the striatum. Sections were incubated with DAB 
solution (0.46 mM 3,3’-Diaminobenzidine tetrahydrochloride, 7.3 mM Imidazole, 15.2 mM 
Ammonium nickel (II) sulfate hexahydrate, 0.015% H2O2 in TBS, pH 7.1) for 14 min and 
counterstained with nuclear fast red (NFR, 0.1% in 5% aluminium dissolved 1:5 in ddH2O). 
Stereological quantification of DaNs was conducted with the physical fractionator approach, 
which is typically used for the quantification of large neuron numbers in brain nuclei using thin, 
paired tissue sections (Gundersen et al., 1988; Ma et al., 2003; Glaser et al., 2007). The region 
of interest was confined either to the SNc or to the VTA using the mouse brain atlas (Paxinos 
and Franklin, 2001) on sections between Bregma -2.54 mm and -3.88 mm. Neurons Q were 
only counted, if their TH- and NFR-positive profiles appeared in the reference section but not 
in the lookup section. In addition, neurons had to be located either within the counting frame, 
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or touching the open frame, but not touching the forbidden frame. The height sampling fraction 
hsf (section thickness/dissection height = 5 µm/5 µm = 1) and the area sampling fraction asf 
(area of counting frame/area of sampling grid = 42.9 µm²/191.82 µm² = 0.223647) were given 
as constants. The section sampling fraction ssf was set by the number of sections between 
the analyzed section pairs (typically 21 sections). Total dopaminergic neuron numbers N were 
calculated by means of the following formula (Dorph-Petersen et al., 2001; Howard and Reed, 
2005): N = Q x 1/hsf x 1/asf x 1/ssf. 
Spontaneous motor activity 
Beam break experiments were performed to examine the spontaneous horizontal and vertical 
movement (rearing behaviour) of mice. The activity measurements were done in home-made 
beam break detector cages. Before the experiments, cages were cleaned with ethanol. 
Horizontal movement and vertical activity were detected by infrared beams. Interruptions on 
the horizontal and vertical level were recorded during a tracking period of 60 minutes. The total 
counts after 60 minutes are presented as percentages of control animals. All experiments were 
conducted between 12:00 and 17:00 p.m. 
Oxygen consumption measurements 
Polarographic measurements were performed in 300 µm thick coronal brain sections. 10 to 
20 week-old mice were killed by cervical dislocation and the brain was quickly removed. 
Sections were prepared with a vibratome (Leica VT1000 S) in ice-cold, carbonated artificial 
cerebrospinal fluid (ACSF: 125 mM NaCl, 2.5 mM KCl, 25 mM NaHCO3, 1.25 mM NaH2PO4 x 
H2O, 25 mM Glucose, 2 mM MgCl2, 2 mM CaCl2 x 2 H2O). Tested compounds were dissolved 
freshly or prepared from stock solutions (stored at -80 °C) on the day of the experiment. 
Oxygen consumption of midbrain sections was measured at 37 °C using a Clark-type oxygen 
electrode (Hansatech oxyview system) in a closed glass chamber containing 1 mL 
uncarbonated recording ACSF. An initial zero calibration with sodium dithionite was performed 
before the measurement. Mitochondrial respiratory chain inhibitors were applied to midbrain 
sections with a micro syringe. Mitochondrial oxygen consumption was stopped by adding 5 
mM potassium cyanide at the end of the recordings. Relative values of oxygen content given 
by the measurement were converted into absolute values using reference oxygen values of 
electrolyte solutions at defined conditions (http://water.usgs.gov/software/DOTABLES/, 37.5 
°C solution temperature, 760 mmHg barometric pressure and 12‰ salinity). Mean oxygen 
consumption was determined over a period of 5 to 10 minutes. Oxygen consumption during 
application of potassium cyanide was averaged over a period of 2 minutes in order to measure 
non-mitochondrial oxygen consumption. After oxygen consumption measurements, midbrain 
sections were snap frozen in liquid nitrogen and stored at -20 °C. Brain material was thawed 
on ice and lysed in TOTEX (20 mM Hepes, 400 mM NaCl, 20% Glycerol, 1% NP-40, 1 mM 
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MgCl2, 0.5 mM EDTA, 0.1 mM EGTA, 10 mM α-glycerophosphat, 5 mM DTT, 10% Roche 
complete Protease Inhibitor, pH 7.9) buffer with fourfold volume of the sample volume. Lysates 
were frozen at -80 °C to rupture membranes. For the measurement of the protein content, 
lysates were thawed on ice again, centrifuged (15 min, 4 °C, 14,000 rpm) and supernatants 
were carefully removed. Protein concentrations of the supernatants were determined using 
Bradford assay with a BSA standard. Oxygen consumption values of midbrain sections were 
normalized to their protein content and presented as percentages of control measurements. 
Values of sample size (n) represent the number of investigated brain sections.  
Experimental Design and Statistical Analysis 
Statistical analysis was done with GraphPad Prism 4. Quantified Data is presented as mean + 
SEM. Values of sample size (n) refer to mouse numbers or, in COX-immunohistochemistry 
and in 2PLSM experiments, to neuron numbers. Unpaired t tests, one-way or two-way ANOVA 
with post hoc comparisons (Kruskal-Wallis with Dunn`s or Bonferroni post hoc test) were used 
to determine differences between groups. A significance level of 0.05 was accepted for all 
statistical tests. Asterisks mark P-values of 0.05 (*), 0.01 (**), 0.001 (***) or 0.0001 (****). 
Results 
MitoPark mice recapitulate the differential vulnerability of the dopaminergic system 
following mitochondrial impairment 
In PD patients, degeneration of dopaminergic projections is primarily observed in the caudate 
putamen region (CPu) of the striatum (Miller et al., 1997), which is innervated by SNc DaNs 
(Liss and Roeper, 2008). In contrast, the nucleus accumbens (NAc), which is a major projection 
area for VTA DaNs, is more or less spared (Miller et al., 1997). A similar pattern of differential 
fiber loss was also observed in the striatum of MitoPark mice (Figure 3-1A). There was no 
reduction of dopaminergic projections in the nucleus accumbens of 12 and 14 week-old 
MitoPark mice (Figure 3-1B, 12 week-old MitoPark mice 105% ± 2% TH-positive fiber density 
compared to controls, P=0.9656, n.s., 14 week-old MitoPark mice 104% ± 3%, P>0.9999, n.s.), 
and only a minor reduction in 20 week-old MitoPark mice (85% ± 3%; P=0.0226). However, 
there was rapid degeneration of dopaminergic projections in the caudate putamen: A severe 
loss of fibers was observed already at 14 weeks (Figure 3-1C, fibers remaining: 53% ± 9%, 
P<0.0001) and even more at 20 weeks (16% ± 3%; P<0.0001) in MitoPark mice, underlining 
also in this genetic PD model the striking differential vulnerability of dopaminergic projections 
to mitochondrial dysfunction. 
This differential vulnerability was also clearly observed when counting neurons in the midbrain. 
In aging MitoPark mice, SNc DaNs die earlier than VTA DaNs (Figure 3-1D, 20-week-old 
MitoPark mice: VTA 81% ± 5%, SNc 32% ± 3%, P=0.0001) and neurodegeneration starts at 
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12 weeks and becomes pronounced at 20 weeks (20 weeks: control SNc 100% ±9%, MitoPark 
Fig. 3-1 Degeneration of the nigro-striatal system in MitoPark mice. A) Tyrosine hydroxylase (TH) 
immunohistochemistry in the striatum (CPu and NAc, marked by the dashed line) of 12-, 14- and 20-week-old 
MitoPark and age-matched control mice. Scale bar, 1 mm. B) Quantification of the striatal TH signal revealed minor 
degeneration of dopaminergic projections with increasing age in the NAc of MitoPark mice (black dots on white 
bars). C) In contrast, there was a dramatic loss of the dopaminergic projections in the CPu of aging MitoPark mice 
(Control mice: n = 5-7, MitoPark mice: n = 5-6, # indicates significances between CPu and NAc of MitoPark mice). 
D) Immunohistochemical staining of TH-positive neurons in the VTA and SNc in 12- and 20-week-old MitoPark and 
control mice (VTA and SNc delimitated by dashed lines). Scale bar, 500 µm. DaN numbers (TH+ neurons) in both 
midbrain regions of MitoPark (black dots on white bars, n = 4-6) and control mice (white dots on black bars, n = 4) 
were estimated by stereological quantification. E) Beam break events are presented on the horizontal and vertical 
levels to show the spontaneous motoric activity of MitoPark mice (black dots on white bars, n = 8-13) in comparison 
to control mice (white dots on black bars, n = 9-11). Data are represented as mean ± SEM; * p < 0.05, ** p < 0.01, 
*** p < 0.001, **** p < 0.0001, ### p < 0.0001. 
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12 weeks and becomes pronounced at 20 weeks (20 weeks: control SNc 100% ±9%, MitoPark 
SNc 32% ± 3%, P<0.0001). Nigro-striatal degeneration causes impairment of spontaneous 
movement, starting at 14 weeks (Figure 3-1E, horizontal 55% ± 5%, P=0.0040). Reflecting the 
progressive development of the PD phenotype, motor behaviour of MitoPark mice was further 
decreased over time (horizontal 15 weeks 60% ± 4%, P=0.0067, 20 weeks ± 53% 4%, 
P=0.0002, vertical 20 weeks 14% ± 6%, P=0.0036). Next, we asked if the selective vulnerability 
P=0.0002, vertical 20 weeks 14% ± 6%, P=0.0036). Next, we asked if the selective vulnerability 
observed in MitoPark mice is due to a different time course in the loss of the respiratory chain 
(RC), which is represented by the mtDNA-encoded subunit I of cytochrome c oxidase (COX), 
essential for activity as well as assembly (Figure 3-2A and B). Interestingly, somata of DaNs 
of control mice exhibited a higher COX-signal compared to the surrounding tissue (VTA: 134% 
± 15%, SNc: 129% ± 8%). The COX-signal was clearly reduced, however to a similar extent in 
Fig. 3-2 Mitochondrial respiratory chain integrity is lost in dopaminergic neurons of MitoPark mice. A) The 
signal of the COX immunostaining (green) was analyzed in TH-positive (red) neurons in the VTA and SNc of 12 
week-old control and MitoPark mice. Scale bars, 10 µm. B) The fluorescence intensity of the COX-staining (norm. 
COX-FI) was dramatically decreased in both, VTA and SNc DaNs of MitoPark mice (control mice: white dots on 
black bars, n = 21-32 neurons, 4 mice, MitoPark mice: black dots on white bars, n = 45-47 neurons, 6 mice). C) 
Neurons with reduced activity of COX in the VTA and the SNc in 12-week-old MitoPark mice were unraveled by 
COX-SDH staining (dashed lines delimitate the dopamine midbrain regions in the overview with 500 µm scale bars 
and single neurons in the close-ups with 10 µm scale bars). Data are represented as mean ± SEM; **** p < 0.0001. 
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both, VTA and SNc of MitoPark mice at 12 weeks, at the onset of neurodegeneration (VTA: 
72% ± 2%, P<0.0001, SNc: 66% ± 2%, P<0.0001). In addition, a severe deficiency of 
enzymatic COX-activity was detected by histochemistry in DaNs in the SNc, but, importantly, 
again similarly in the VTA of MitoPark mice (Figure 3-2C). Therefore, both dopaminergic 
midbrain regions displayed comparable and severe mitochondrial dysfunction, implying that 
other SNc DaN specific characteristics must be responsible for their enhanced vulnerability. 
Calbindin-D28k expression increases the probability for survival of dopaminergic 
neurons in MitoPark mice  
The higher vulnerability of SNc DaNs to mitochondrial dysfunction might be linked to differential 
expression of calcium-binding proteins, since mitochondria are importantly involved in calcium 
handling: Indeed, in post mortem PD patient samples those midbrain regions which are prone 
to neurodegeneration contain fewer calbindin-expressing neurons than areas with low 
susceptibility (Yamada et al., 1990). Therefore, the presence of calbindin was investigated in 
the surviving fraction of DaNs in MitoPark mice (Figure 3-3A). In the VTA, the proportion of 
calbindin-positive neurons did not differ between control and MitoPark mice (Figure 3-3B, 12 
weeks: control 25% ± 1%, MitoPark 39% ± 5%, P=0.1600, n.s.; 14 weeks: control 26% ± 5%, 
MitoPark 39% ± 9%, P=0.3068, n.s.; 20 weeks: control 21% ± 2%, MitoPark 40% ± 7%; 
P=0.0671, n.s.). In addition, in the VTA the amount of calbindin-positive neurons of control and 
MitoPark mice did not significantly change over time. However, in the SNc, we observed a 
higher fraction of remaining, calbindin-positive DaNs in 20 week-old MitoPark mice compared 
to controls (control 9% ± 3%, MitoPark 29% ± 9%, P=0.0262), strongly suggesting that the 
presence of this protein is protective in the context of severe general neuron loss (Figure 3-1D). 
The inhibition of mitochondrial complex IV increases the RedOx-ratio of SNc DaNs 
TH-mito-roGFP mice (here referred to as mito-roGFP) express a redox-sensitive GFP variant 
in the mitochondrial matrix of DaNs, and thus can be used to assess changes of the redox 
system, more specifically the GSH/GSSG ratio, in situ. Surmeier and colleagues used this 
fluorescence sensor to estimate “oxidant stress” of the mitochondrial matrix in DaNs (Guzman 
et al., 2010). The reducing compound dithiotreitol (DTT) and the oxidizing compound aldrithiol 
(ALD) were sequentially applied during 2PLSM experiments in order to calibrate the redox-
sensitive GFP signal (Guzman et al., 2010; Dryanovski et al., 2013). In order to optimize our 
RedOx calibration protocol, in a first experiment, DTT and ALD were applied to midbrain 
sections for 10 minutes whilst the 2PLSM laser was inactive (Figure 3-4-1). DTT induced a 
strong increase (VTA: +0.34 ± 0.06-fold change, SNc: +0.32 ± 0.04-fold change) and ALD a 
strong decrease of the fluorescence intensity (VTA: -0.35 ± 0.02-fold change, SNc: -0.42 ±  
 




Fig. 3-3 Colocalization of TH and calbindin-D28k (Cb-D28k) in the midbrain of 12-, 14-, and 20-week-old 
MitoPark mice. A) Merged TH (red, 1st column) and Cb-D28k (green, 2nd column) fluorescence immunostainings 
depict Cb-D28k-expressing DaNs (yellow, marked by asterisks). Scale bar, 50 µm. B) There were significantly more 
Cb-D28k positive DaNs in the SNc of 20-week-old MitoPark mice compared with control mice. Data are represented 
as mean ± SEM (Control mice: white dots on black bars, n = 4-6, MitoPark mice: black dots on white bars, n = 4-5; 
* p < 0.05). 
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0.04-fold change) measured after this time. Also, application of H2O2 resulted in a pronounced 
decrease of the fluorescence intensity in both, VTA (-0.66 ± 0.04-fold change) and SNc DaNs 
(-0.65 ± 0.03-fold change). In addition, a kinetic analysis was performed in 2PLSM experiments 
with a continuously active laser (Figure 3-4-2). The normalized mito-roGFP fluorescence 
(F/Fo) displayed a constant loss of intensity over time (Figure 3-4-3A). Application of DTT 
(Figure 3-4-2B) induced a pronounced increase of the fluorescence intensity which reached a 
plateau after 10 minutes of application (127% ± 5%; P<0.001). The mito-roGFP signal reached 
the initial level (99% ± 4%) after 10 further minutes of DTT application. A rapid loss of the 
fluorescence intensity (46% ± 2%; P<0.01) was observed when application of DTT was 
followed by ALD (Figure 3-4-2C). Thus, the mito-roGFP signal can be maximally increased by 
a 10-minute application of DTT and maximally decreased by a consecutive 10-minute 
application of ALD. These application intervals were used in follow-up experiments to gain 
reference values for signal intensity. Since we observed a permanent signal loss in the 
continuous recording mode, we evaluated the signal in “discrete” experiments, with the laser 
being inactive for most of the time. The laser was active at the beginning of the recording (0 
minutes), at 20 minutes, after application of DTT at 30 minutes and after application of ALD at 
40 minutes (Figure 3-4-2D). The signal loss after 20 minutes during this protocol was 
considerably lower compared to continuous recordings (Figure 3-4-2E). Few neurons which 
displayed a rundown by more than 40% after 20 minutes were excluded from analysis. In 
remaining neurons, DTT and ALD caused prominent changes of the fluorescence intensity 
(Figure 3-4-2D). 
After optimizing the recording conditions, selective RC inhibitors were applied to acute 
midbrain sections of Th-mito-roGFP wild type mice in order to investigate how defects of the 
RC change the RedOx-ratio of the glutathione system. In order to prove their efficiency, we 
confirmed that Rotenone, antimycin A and potassium cyanide (KCN) significantly reduced 
oxygen consumption of similarly isolated midbrain sections at the same concentrations used 
in 2PLSM (Figure 3-4-3, rotenone: 36% ± 3% of control measurements, P=0.0019, antimycin 
A: 23% ± 3%, P=0.0016, KCN: 6% ± 2%, P<0.0001). Rotenone was used at its maximal 
solubility and a higher concentration of antimycin A (200 µM) did not further reduce oxygen 
consumption (data not shown). Oligomycin at maximal concentration, probably due to its high 
lipophilicity and the myelin rich brain slice, displayed extremely slow wash in kinetics and did 
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not significantly reduce oxygen consumption (59% ± 8%, P>0.9999, n.s.). Also, the inner 
membrane uncoupler CCCP did not increase oxygen consumption (91% ± 6%, P>0.9999, 
n.s.), because mitochondria in mouse brain seem to utilize oxygen at maximal rate which 
cannot be further increased by uncouplers, as shown recently also by others (Dias et al., 2018). 
Surprisingly, only KCN increased the RedOx-ratio of SNc DaNs (Figure 3-4A, RedOx-ratio 
rotenone control: 0.37 ± 0.09, rotenone: 0.43 ± 0.08; antimycin A control: 0.50 ± 0.07, antimycin 
A: 0.45 ± 0.04; KCN control: 0.54 ± 0.05, KCN: 0.90 ± 0.09, P=0.0004), indicating that the level 
of GSH in the matrix is decreased by the inhibition of COX. Importantly, inhibition of complex I 
and III by rotenone and antimycin A, respectively, which is established to result in pronounced 
production of reactive oxygen species (ROS) (Murphy, 2009), did not change this ratio. 
Fig. 3-4 The mitochondrial RedOx-ratio of SNc DaNs is reduced by application of isradipine or Ru360 in 
MitoPark mice. A) Only application of 5 mM potassium cyanide (KCN) induced an increase of the mitochondrial 
RedOx-ratio. B) Incubation of midbrain mito-roGFP sections with 300 nM isradipine (similar to Dragicevic et al., 
2014; Ortner et al., 2017) for at least 30 min induced a reduction of the RedOx-ratio in SNc DaNs of control mice, 
but not in VTA DaNs. Treatment with 20 µM Ru360 only induced a small decrease of the RedOx-ratio in control 
SNc neurons. On the contrary, the RedOx-ratio was elevated in SNc, but not in VTA neurons of 10 – 12-week-old 
MitoPark mice. This SNc-specific high RedOx-ratio in MitoPark mice was diminished by isradipine and Ru360. Data 
are represented as mean ± SEM (A: Rotenone control: n = 12, rotenone: n = 23, antimycin A control: n =2 2, 
antimycin A: n = 16, KCN control: n = 23, KCN: n = 22, 3-5 mice per condition; B: control VTA n = 21, control SNc 
n = 22, control VTA + isradipine n = 36, control SNc + isradipine n=25, control VTA + Ru360 n = 23, control SNc + 
Ru360 n = 37, MitoPark VTA n=19, MitoPark SNc n = 35, MitoPark VTA + isradipine n = 34, MitoPark SNc + 
isradipine n=26, MitoPark VTA + Ru360 n = 25, MitoPark SNc + Ru360 n = 23, 3-5 mice per condition, # indicates 
significance between SNc DaNs of MitoPark and control mice); ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
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Calcium influx is responsible for the high RedOx-ratio of vulnerable SNc DaNs 
2PLSM experiments showed that, in control mice, both VTA and SNc DaNs display almost 
identical mitochondrial RedOx-ratios (Figure 3-4B, VTA: 0.54 ± 0.05, SNc: 0.50 ± 0.07, 
P>0.9999, n.s.). Neither blockade of plasma membrane calcium channels by the selective 
inhibitor isradipine, nor inhibition of the mitochondrial calcium uniporter (MCU) with Ru360 
induced changes in SNc and VTA DaNs of control animals (SNc + 300 nM isradipine 
0.26 ± 0.04, P>0.9999, n.s., VTA + 300 nM isradipine 0.62 ± 0.04, P>0.9999, n.s.; SNc 20 µM 
Ru360 0.42 ± 0.05, P>0.9999, n.s., VTA 20 µM Ru360 0.57 ± 0.07, P>0.9999, n.s.). 
Importantly, there was a much higher RedOx-ratio in MitoPark SNc DaNs (Figure 3-4B, 0.90 ± 
0.08) at the age of 12 weeks, i.e. at the onset of neurodegeneration, compared to MitoPark 
VTA DaNs (0.49 ± 0.06, P=0.0009), but also compared to control SNc DaNs (P=0.0004). This 
high RedOx-ratio was robustly decreased in MitoPark SNc when treating sections with 
isradipine (0.45 ± 0.05, P<0.0001), but no effect was seen in MitoPark VTA DaNs (0.44 ± 0.05, 
P>0.9999, n.s.). Also, when MitoPark midbrain sections were incubated with Ru360, the 
RedOx-ratio of SNc DaNs was again significantly lowered (0.42 ± 0.05, P=0.0010). 
In conclusion, an elevated RedOx-ratio, indicating a low GSH/GSSG ratio in the mitochondrial 
matrix, was found to be a hallmark of SNc, but not VTA DaNs in MitoPark mice, preceding the 
onset of severe neurodegeneration. This high RedOx-ratio could be rescued by reducing 
neuronal as well as mitochondrial calcium influx. 
Mitochondrial membrane potential is hyperpolarized in MitoPark SNc DaNs and is 
further elevated when calcium influx is blocked 
The electrochemical potential of the inner mitochondrial membrane was assessed in midbrain 
sections loaded with TMRM, in order to better understand how mitochondrial dysfunction 
affects the RedOx-ratio. Initial experiments showed that, quite surprisingly, the TMRM signal 
was lower in the somata of midbrain neurons compared to the surrounding tissue 
(Figure 3-5A), in contrast to the higher signal for COXI protein (Figure 3-2A), indicating that 
mitochondria in the somata have a lower inner membrane potential than those in other cell 
types and neurites. The mitochondrial network was clearly visualized by TMRM as shown in 
mouse fibroblasts (Figure 3-5B). As expected, the TMRM signal of identified DaNs, but also of 
mitochondria in surrounding neurites, was dramatically reduced by KCN (Figure 3-5C). TMRE, 
another fluorescent dye sensitive to the inner membrane potential displayed a signal similar to 
TMRM and its intensity was likewise decreased by KCN (Figure 3-5-1). It was not possible to 
decrease these signals by the uncoupler CCCP, as usually used as a control, again probably 
due to its high lipophilicity and the myelin rich brain sections. Therefore, we decided to use the 
deflection of the TMRM signal upon maximal RC inhibition by KCN as a convenient readout  
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the somata have a lower inner membrane potential than those in other cell types and neurites. 
Fig. 3-5 KCN induces an increase of ΔTMRM-FKCN in MitoPark SNc DaNs. A) Quantitative data presenting a high 
fluorescent TMRM signal in the surrounding of cell somata and midbrain DaNs, compared to DaNs from sections 
that were not loaded with TMRM and ACSF containing TMRM without tissue, respectively. B) TMRM visualizes the 
mitochondrial network in mouse fibroblasts. Pictures were taken by using both conventional fluorescent microscope 
and 2PLSM. Scale bar, 10 µm. C) TMRM signal of a mito-roGFP expressing midbrain DaN before and after 
application of KCN. Scale bar, 10 µm. KCN (5 mM) induced a significant reduction of the TMRM signal in the soma 
of DaNs. D) Reduction of the TMRM signal after KCN application was used to calculate the difference between 
TMRM fluorescence before and after KCN (ΔTMRM-FKCN = TMRM-FACSF, 20 min - TMRM-FKCN, 40 min). Low TMRM signal 
intensities induced by KCN are reflected by high ΔTMRM-FKCN values. A high ΔTMRM-FKCN value, in turn, represents 
a high mitochondrial membrane potential. ΔTMRM-FKCN did not differ between VTA and SNc DaNs in control animals. 
However, in MitoPark mice, SNc DaNs showed a significantly higher ΔTMRM-FKCN deflection compared to MitoPark 
VTA and control SNc DaNs. Administration of KCN to midbrain sections preincubated with 300 nM isradipine led to 
a significant elevation of ΔTMRM-FKCN in control and MitoPark SNc DaNs. In contrast, the use of isradipine did not 
alter the TMRM signal in both control and MitoPark VTA DaNs. Data are represented as mean ± SEM (control VTA 
n = 23 neurons, MitoPark VTA n = 31 neurons, control VTA + 300 nM isradipine n = 20 neurons, MitoPark VTA + 
300 nM isradipine n = 26 neurons, control SNc n = 28 neurons, control SNc + 300 nM isradipine n = 21 neurons, 
MitoPark SNc n = 28 neurons, MitoPark SNc + 300 nM isradipine n = 26 neurons, 3-6 mice per group); * p < 0.05, ** 
p < 0.01, *** p < 0.001, # p < 0.05. 
 
Ricke, Paß et al. 2020, J Neurosci 
 
46 
for the actual inner mitochondrial membrane potential present in situ, before addition of KCN. 
VTA and SNc DaNs of control mice revealed a similar ΔTMRM-FKCN value (Figure 3-5D, SNc: 
40.7 ± 5.1, VTA: 45.1 ± 3.9, P>0.9999, n.s.), indicating that the inner mitochondrial membrane 
potential is similar in these DaN populations. In addition, there was no difference in ΔTMRM-
FKCN between control (45.1 ± 3.9) and MitoPark VTA DaNs (39.7 ± 4.2, P=0.3670, n.s.), 
indicating that the mitochondrial membrane potential remained similar in the latter neurons, 
even in the presence of severe mitochondrial dysfunction. Interestingly, inhibition of complex 
IV by KCN led to an increase of ΔTMRM-FKCN in MitoPark SNc DaNs (53.0 ± 2.5) compared to 
MitoPark VTA (39.7 ± 4.2, P=0.0278) and control SNc DaNs (40.7 ± 5.1, P=0.0352). This quite 
unexpectedly indicates that a high mitochondrial inner membrane potential was present in SNc 
DaNs of MitoPark mice in situ. 
Last, L-type plasma membrane calcium channels were blocked by isradipine to investigate if 
and how the elevated mitochondrial membrane potential of MitoPark SNc DaNs is affected by 
calcium fluxes. Isradipine induced a significant increase of ΔTMRM-FKCN in control as well as 
in MitoPark SNc DaNs (Figure 3-5D, control + 300 nM isradipine: 61.5 ± 2.9, P=0.0052, 
MitoPark + 300 nM isradipine: 66.4 ± 2.3, P=0.0392), but not in VTA DaNs, showing that the 
mitochondrial membrane potential in SNc DaNs of both control and MitoPark mice is further 
elevated when cytosolic calcium influx is inhibited. This suggests that a high mitochondrial 
membrane potential is established in SNc DaNs of control, but surprisingly also in MitoPark 
mice, in order to electrogenically remove and thus buffer cytosolic calcium, even when RC 
function is severely impaired, and consequently reaches an even higher maximal value when 
calcium influx is blocked. 
Discussion 
In order to answer the question how mitochondrial impairment leads to the selective 
degeneration of SNc DaNs, the mitochondrial RedOx-ratio and the inner membrane potential 
was analyzed in MitoPark mice with preferential degeneration of the nigrostriatal system, 
similar to patients (Hirsch et al., 1988; Miller et al., 1997; Damier et al., 1999) (Figure 3-1A and 
Figure 3-1D). COXI-expression was reduced to the same degree in VTA and SNc, and neurons 
with low COX activity were detected in both midbrain regions of MitoPark mice (Figure 3-2), 
showing that the respiratory chain was affected to a similar extent. Substantial loss of COX did 
not lead to significant neuron death at 12 weeks (compare Figure 3-1D and Figure 3-2), 
implying that other factors than simply energy-deprivation are involved.  
Calcium-binding proteins buffer excessive cytosolic calcium, shape calcium transients and 
contribute to calcium homeostasis (Baimbridge et al., 1992). In PD patients, SNc with few Cb-
D28k-expressing DaNs suffers more from neuron loss than the Cb-D28k-enriched VTA 
(Yamada et al., 1990; German et al., 1992; Reyes et al., 2012). Supporting these results, 
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colocalization experiments of TH and Cb-D28k in MPTP-treated mice revealed predominant 
survival of calbindin-positive DaNs, suggesting that the presence of calbindin confers 
protection (Liang et al., 1996). Indeed, also our experiments revealed more calbindin-
expressing DaNs remaining in both regions in 12- and 14-week-old MitoPark mice, and 
significantly more in SNc of 20 week-old MitoPark mice (Figure 3-3B). Interestingly, the 
calbindin mRNA content in pooled single substantia nigra DaNs from PD patients was found 
to be six fold higher compared to healthy individuals (Schiemann et al., 2012), potentially 
indicating a response to mitochondrial defects. In summary, our colocalization experiments 
show that calbindin may render midbrain DaNs more resistant against neurodegeneration 
induced by mitochondrial dysfunction.  
The substantia nigra of PD patients contains high levels of oxidized and damaged molecules 
(Dexter et al., 1994; Alam et al., 1997a; Alam et al., 1997b), correlating with low concentrations 
of the ROS-scavenging GSH molecule (Sian et al., 1994). Thus, mtDNA deletions leading to 
mitochondrial dysfunction, a high calcium load and oxidative stress due to changes in the 
antioxidant defense system might be causally linked and ultimately lead to SNc DaN death. 
Inhibitors were applied to midbrain sections to investigate if and how impaired activity of the 
different RC complexes results in changes of the RedOx-ratio (Figure 3-4A). Despite reducing 
oxygen consumption, as expected (Figure 3-4-3), neither antimycin A nor rotenone altered the 
mitochondrial RedOx-ratio of DaNs. Superoxide (O2•-) is increased by the complex III inhibitor 
antimycin A (Zhang et al., 1998) or the complex I inhibitor rotenone (Kushnareva et al., 2002), 
summarized in (Murphy, 2009), in SNc DaNs at even lower concentrations than used by us 
(Freestone et al., 2009). Therefore, the mito-roGFP signal is not sensitive to increased ROS-
production from RC complexes and our data make ROS rather unlikely as the cause of neuron 
death. 
In contrast, KCN considerably increased the RedOx-ratio (Figure 3-4A). KCN results in 
increased autofluorescence in substantia nigra DaNs (Tucker et al., 2016), which is generally 
used as a readout for enhanced levels of reduced NAD(P)H. Elevated NAD(P)H should 
increase the GSH/GSSG ratio (Nelson and Cox, 2005), which should lower the RedOx-ratio 
(Dooley et al., 2004). However, our high RedOx-ratio after KCN implies that inhibition of 
complex IV decreases levels of GSH in DaNs. We postulate that the pool of NAD(P)H in 
mitochondria is slowly consumed upon inhibition, without being further replenished by the 
Krebs cycle dehydrogenases.  
After having established these relations, the RedOx-ratio was analyzed in MitoPark DaNs 
(Figure 3-4B) at the age of 12 weeks, before wide-spread neuron death, but with severe COX 
deficiency (compare Figure 3-1D and Figure 3-2). SNc DaNs, but not VTA DaNs of MitoPark 
mice presented with an increased RedOx-ratio, similar to KCN treatment, showing that 
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additional, SNc-specific factors must account for this outcome. Since isradipine rescued the 
elevated RedOx-ratio in MitoPark SNc DaNs (Figure 3-4B), we postulate that calcium influx 
through Cav1.3 channels (Chan et al., 2007; Guzman et al., 2009; Ortner et al., 2017) is 
responsible for mitochondrial “relative oxidation” in mitochondrially impaired SNc DaNs. 
Isradipine did not decrease the RedOx-ratio in VTA neurons, since their pacemaking activity 
is predominantly driven by sodium channels (Khaliq and Bean, 2010). 
Although isradipine at 300 nM, as we used, has been shown to completely block pacemaking 
by ablating Cav1.3-mediated calcium influx in SNc DaNs (Ortner et al., 2017), it remains a 
matter of debate to which extent the magnitude of intracellular calcium is altered by this 
inhibitor, as indicated by fluorescent calcium probes: Isradipine at lower concentrations 
(30 nM) did not alter somatic calcium fluctuations (Ortner et al., 2017), while higher levels of 
isradipine (5 µM) were sufficient to minimize dendritic calcium oscillations in SNc DaNs 
(Guzman et al., 2009). Blockade of calcium-driven pacemaking may significantly lower the 
energy demand of neurons, which may have caused the observed changes in mito-roGFP 
fluorescence. However, Ru360, the inhibitor of the mitochondrial calcium uniporter MCU, also 
reduced the RedOx-ratio in MitoPark SNc DaNs (Figure 3-4B), which was also observed in 
dendrites of SNc DaNs in control mice (Guzman et al., 2010), but not in their somata. Thus, in 
our hands, reduction of mitochondrial calcium uptake by Ru360 is not sufficient to reduce the 
RedOx-ratio in functional mitochondria, while it does so in DaNs with a defective respiratory 
chain. 
Elevated mitochondrial calcium leads to an increased rate of production of NADH by enhancing 
the activity of dehydrogenases and thus Krebs cycle flux (Denton, 2009), which should result 
in elevated GSH/GSSG. However, in SNc DaNs of MitoPark mice, reduction of mitochondrial 
calcium influx resulted in a decrease of the RedOx-ratio and thus high levels of mitochondrial 
GSH.  
In addition, and counterintuitively, although complex IV was reduced in both DaN types before 
the onset of neuron death (Figure 3-2), MitoPark SNc DaNs had maintained a high 
mitochondrial inner membrane potential (Figure 3-5D), even higher than SNc DaNs in controls. 
We postulate that this is achieved by bringing in a net negative charge by importing ATP4-, 
produced by glycolysis, from the cytosol via the adenine nucleotide transporter. ATP is 
hydrolyzed by ATP synthase operating in reverse mode, followed by export of ATP2- + Pi-. 
This mechanism of generating an inner membrane potential is well established in cell lines 
lacking mtDNA and thus a functioning respiratory chain (Buchet and Godinot, 1998; Appleby 
et al., 2001), however has not yet been shown in vivo to our knowledge. RC deficient SNc 
DaNs in MitoPark mice might maintain a high inner membrane potential - even at the expense 
of precious glycolytic ATP - in order to be able to pump calcium from the cytosol into the 
negative matrix via MCU. This is substantiated by our finding that inhibiting calcium influx 
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through plasma membrane channels by isradipine further hyperpolarizes the inner membrane 
potential, both in control as well as in MitoPark mice (Figure 3-5D), since, under this condition, 
the depolarizing cation influx into the matrix is blocked. In conclusion, even under conditions 
of a severe respiratory chain dysfunction, SNc DaNs in MitoPark mice maintain a high inner 
membrane potential in order to preserve calcium homeostasis. 
The question remains how a high inner membrane potential, driving a constant calcium influx 
into the matrix, relates to the redox system changes we observed. The drop of the RedOx-ratio 
after isradipine or Ru360 (Figure 3-4B) shows that calcium influx contributed to the reduced 
GSH levels in SNc DaNs of MitoPark mice. Mammalian mitochondria contain two isocitrate 
dehydrogenase (IDH) isoforms, specific for NAD+ (IDH3) and NADP+ (IDH2), respectively, 
which catalyze the conversion of isocitrate to α-ketoglutarate (α-KG) (Denton, 2009). 
Importantly, calcium is known to increase the activity of only IDH3, by lowering its Km for 
isocitrate (Denton et al., 1978; Rutter and Denton, 1988; Rutter and Denton, 1989; Denton, 
2009; Llorente-Folch et al., 2015). Therefore, mitochondrial calcium influx would enhance 
IDH3, but not IDH2 activity, with a resultant decrease in NADPH generation. We therefore 
hypothesize that the blockage of mitochondrial calcium influx by isradipine and Ru360 in our 
studies has decreased the activity of IDH3, thereby enhancing NADPH generation by IDH2, 
resulting in a normalization of the RedOx-ratio. Alternatively, the teams of Mosharov and 
Sulzer have shown in primary mouse DaNs that the mitochondrial toxin MPP+ activates a 
cascade of increased cytosolic dopamine and calcium, followed by an elevation of 
mitochondrial calcium and activation of mitochondrial nitric oxide synthase, so generation of 
NO may also contribute to the disturbed mitochondrial redox system (Lieberman et al., 2017). 
In summary, we hypothesize that mitochondrial dysfunction in SNc DaNs, in combination with 
their high mitochondrial calcium load, in contrast to the VTA, impairs the mitochondrial 
antioxidant defense system, which finally promotes their preferential degeneration. 
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Fig. 3-4-1 Reducing and oxidizing agents alter the mito-roGFP fluorescence intensity during 2PLSM 
experiments. A) Mito-roGFP expressing DaNs were either selected in the ventral tegmental area (VTA) or in the 
substantia nigra pars compacta (SNc, dashed lines enframe Da regions, 500 µm scale bar). B) Application of 2 mM 
DTT for 10 minutes led to a strong increase and 1 mM ALD to a strong decrease of the mito-roGFP fluorescence 
intensity. C) Application of 10 mM H2O2 also induced a strong decrease of the mito-roGFP fluorescence intensity. 
Data are represented as mean ± SEM (dashed lines delimitate single DaNs, 10 µm scale bars, VTA: turquoise bars, 
n = 17-18, SNc: green bars, n = 13-19, 3 mice per condition). 
 








Fig. 3-4-2 RedOx-ratio imaging protocol during 2PLSM experiments. A) There was a constant decrease of the 
normalized mito-roGFP fluorescence intensity (F/F0) during continuous 2PLSM recordings. B) 2 mM DTT induced 
a strong increase of the mito-roGFP fluorescence intensity, reaching a plateau after roughly 10 minutes of 
application. C) The mito-roGFP signal decreased dramatically, when application of 2 mM DTT was followed by 1 
mM ALD. Data are represented as mean ± SEM (green traces represent mean fluorescence intensities, grey dashed 
lines indicate mean values of prior experiment: grey line in B) = mean of A), grey line in C) = mean of B) n = 13-20, 
3 mice per condition). D) Application of 2 mM DTT from 20 to 30 minutes resulted in a strong increase and application 
of 1 mM ALD from 30 to 40 minutes induced a strong decrease of the mito-roGFP fluorescence intensity in DaNs 
during discrete recordings (DaNs marked by dashed line, 20 µm scale bar, fluorescence intensities of a single 
neuron plotted as green dots). E) Continuous recordings (dark green bar, n = 20) with a permanent activated 2PLSM 
laser displayed a higher loss of mito-roGFP fluorescence intensity than discrete recordings (light green bar, n=21, 
3 mice per condition). The loss of fluorescence intensity was calculated after 20 minutes. Data are represented as 
mean ± SEM; ** p < 0.01. F) RedOx-ratio values of the mitochondrial network in Da-Ns (values of the same neuron 
as in D) plotted as green dots) were calculated using the following formula: RedOx-ratio = (F20 min – FDTT, 30 min)/(FALD, 
40 min – FDTT, 30 min). Quantification of RedOx-ratios was performed with values obtained at 20 minutes (marked by 
dashed red square). 
 










Fig. 3-4-3 Oxygen consumption of midbrain sections. A) Polarographic measurements with fresh brain sections 
revealed that oxygen consumption of midbrain sections was, as expected, significantly reduced by 20 µM rotenone 
in comparison to DMSO control experiments (DMSO: striped blue bar, n=3, rotenone: blue bar, n=3). B) 
Mitochondrial oxygen consumption was, as expected, significantly reduced by 20 µM antimycin A and 5 mM KCN, 
but not by 10 µM oligomycin or 5 µM CCCP. Higher concentrations of rotenone were not possible due to limited 
solubility, higher concentrations of antimycin A did not further decrease oxygen consumption (data not shown). Data 
are represented as mean ± SEM (control: n = 10, antimycin A: n = 8, KCN: n = 10, oligomycin: n = 2, CCCP: n = 2); 
* p < 0.05, ** p < 0.01, **** p < 0.0001. 
Fig. 3-5-1 TMRE fluorescent signal is similarly responding to KCN. A) KCN reduced the signal intensity of 
TMRE, another inner membrane potential probe. B) Quantification of KCN-induced TMRE signal reduction is 
demonstrated in the representative DaN from A (asterisk, 50 µm scale bar). 
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Understanding non-motor symptoms of Parkinson’s disease is important in order to unravel 
the underlying molecular mechanisms of the disease. Olfactory dysfunction is an early stage, 
non-motor symptom which occurs in 95% of Parkinson’s disease patients. Mitochondrial 
dysfunction is a key feature in Parkinson’s disease and importantly contributes to the selective 
loss of dopaminergic neurons the substantia nigra pars compacta. The olfactory bulb, the first 
olfactory processing station, also contains dopaminergic neurons, which modulate odor 
information and thereby enable odor detection as well as odor discrimination. MitoPark mice 
are a genetic model for Parkinson’s disease with severe mitochondrial dysfunction, 
reproducing the differential vulnerability of dopaminergic neurons in the midbrain. These 
animals were used to investigate the impact of mitochondrial dysfunction on olfactory-related 
behavior and olfactory bulb dopaminergic neuron survival. Odor detection was severely 
impaired in MitoPark mice. Interestingly, only the small anaxonic dopaminergic subpopulation, 
which is continuously replenished by neurogenesis, was moderately reduced in number, much 
less compared to dopaminergic neurons in the midbrain. As a potential compensatory 
response, an enhanced mobilization of progenitor cells was found in the subventricular zone. 
These results reveal a high robustness of dopaminergic neurons located in the olfactory bulb 
towards mitochondrial impairment, in striking contrast to their midbrain counterparts. 
 
Key words: Parkinson’s disease, mitochondrial dysfunction, olfactory bulb, neurogenesis 
  
 




Parkinson’s disease (PD) is the most common movement disorder affecting 1% of the 
population above 60 years [1] characterized by the initial loss of midbrain dopaminergic 
neurons (DaNs) in the substantia nigra pars compacta (SNc). The depletion of striatal 
dopamine leads to progressive and irreversible motor impairment [2]. Besides the cardinal 
symptoms of PD, non-motor dysfunctions including depression, sleep disturbance and 
hyposmia have been described. Olfactory dysfunction is found in more than 95% of PD patients 
and can precede motor symptoms by up to ten years [3–5]. 
The olfactory bulb (OB) is the first station of sensory processing in the olfactory system. 
Besides the midbrain, DaNs are also present in the OB and make up 5% of the neuronal 
population [6]. They function as interneurons and are necessary for odor discrimination rather 
than for odor detection [7, 8]. They are primarily located in the glomerular layer (GL), where 
they modulate the activity of both olfactory sensory fibers [9, 10] and mitral cells by D2 
receptor-mediated inhibition [11, 12] as well as via contacts with external tufted cells [13]. 
Despite of multiple as well as contradictory statements regarding their categorization, OB 
DaNs can be clearly divided into small (5 10 µm), anaxonic (SCs) and large (10 15 µm 
diameter), axonic cells (LACs) [14]. In contrast to LACs, SCs can be continuously generated 
throughout life by neurogenesis, in mice as well as in humans [15–19]. Progenitor cells are 
formed in the dorsolateral region of the subventricular zone (SVZ) [20] and are characterized 
by the expression of the transcription factor PAX6, required for development into the DaN 
phenotype [21–23]. The majority of progenitor cells in the OB differentiate into interneurons in 
the granule cell layer, while only 5% of the 20,000-30,000 new-born cells generated daily 
migrate to the GL [24, 25]. 
In PD, there are contradictory results according to the fate of DaNs in the OB. Luquin and 
colleagues reported elevated numbers of periglomerular DaNs, potentially displaying a 
compensatory mechanism induced by the early degeneration of other neurotransmitter 
systems and resulting in the olfactory dysfunction of patients [26]. In contrast, no difference in 
OB DaN numbers were found between PD patients and healthy individuals, implying that PD-
related hyposmia is not due to alterations in the quantity of OB DaNs [27, 28]. 
Mitochondrial dysfunction is a central feature of PD, both in the common idiopathic as well as 
in the rare familiar forms caused by mutations, e.g. in the Parkin, Pink1, LRRK2 or DJ 1 genes. 
During normal aging, SNc DaNs accumulate high loads of deletions in mitochondrial DNA 
(mtDNA), present in thousands of copies in neurons. Interestingly, this is accompanied by an 
upregulation of mtDNA copy numbers in healthy humans, while this compensatory mechanism 
is disrupted in PD patients [29]. This indicates that a defective mtDNA maintenance system 
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and subsequent severe mitochondrial impairment is an important factor for the degeneration 
of SNc DaNs in PD. 
The mitochondrial transcription factor A (TFAM) is crucial for mtDNA transcription and 
maintenance [30, 31]. Depletion of TFAM consequently leads to the loss of mtDNA encoded 
transcripts followed by a respiratory chain defect. MitoPark mice are lacking TFAM exclusively 
in DaNs, which culminates in progressive neuronal death and corresponding motor impairment 
starting from 14 weeks of age [32, 33]. The progression of PD is recapitulated in terms of both 
anatomical and behavioral malfunctions. However, the impact of mitochondrial dysfunction on 
OB DaNs has not been investigated so far. Therefore, olfactory-related behavior was explored 
in MitoPark mice. Furthermore, mice were used to study the impact of mitochondrial defects 
on OB DaN survival as well as adult neurogenesis. 
Materials and Methods 
Experimental model 
All experiments were conducted in agreement with European and German guidelines and 
approved by local authorities (LANUV NRW; 81-02.04.2018-A210) (for breeding details, see 
supplementary methods). Experiments were carried out with male or female mice of the strain 
C57/BL6N. For the generation of MitoPark mice, DAT cre mice (Cre-gene inserted upstream 
of the translation start codon in exon 2 of the DAT gene) and animals with a loxP-flanked Tfam 
allele were crossed as described in detail previously [32]. MitoPark mice (genotype 
TfamloxP/loxP, +/DAT cre) show homozygous disruption of Tfam in dopaminergic neurons. 
TfamloxP/loxP and Dat-cre mice were provided by Nils-Göran Larsson (Max-Planck-Institute 
for Biology of Ageing, Köln, Germany). TfamloxP/WT or TfamloxP/loxP mice were used as 
controls. 
COX-SDH staining 
Visualization of Cytochrome c Oxidase (COX) deficiency was performed by COX-SDH 
enzymatic activity staining [34]. COX is a respiratory chain (RC) complex which is partially 
encoded by mtDNA, while succinate dehydrogenase (SDH), another respiratory chain enzyme, 
is entirely encoded by nuclear DNA. Impaired integrity of mtDNA results in COX-deficiency, 
but sustained SDH-activity. Cells with decreased COX-activity will stain blue, while cells with 
normal COX-activity will appear brown (for details, see supplementary methods). 
Quantification of COX-deficient cells was performed at Bregma +4.30 mm and +3.00 mm. Four 
images (33 x 50 µm) were taken from dorsal, ventral and lateral OB regions per slice each. 
Number of COX-deficient cells was defined per slice. 
 
 




Brain sections were stained for tyrosine hydroxylase to visualize DaNs and their projections 
(for details, see supplementary methods).  
Soma size quantification of OB DaN subpopulations: Soma sizes of DaNs stained for tyrosine 
hydroxylase were analyzed by using FIJI-software (https://imagej.net/Fiji/Downloads). Cells 
were selected and automatically measured by the Wand-Auto-Tool based on the black-white-
contrast of the cells compared to background. The outline of the cell soma was detected and 
the area within the shape was automatically calculated. Two subpopulations of DaNs with 
distinct morphological characteristics have been described [35]. DaN somata in the GL were 
differentiated into areas of 20-80 µm2 for SCs and 80-180 µm2 for LACs. Two consecutive 
brain sections per mouse were analyzed at Bregma +4.3, +3.75 and +3.21. Images were taken 
from both dorsal and ventral OB regions (for details, see supplementary methods). 
Analysis of immunohistochemical stainings 
Automated bright-field microscopy was done with a slidescanner (SCN400, Leica) equipped 
with a 40x objective. High resolution images from the OB and striatum were generated by the 
Leica SlidePath Gateway and the Microsoft Image Composite Editor software. TH-positive 
striatal fiber density was determined by optical density (OD) analysis using FIJI-software (area 
fraction, https://imagej.net/Fiji/Downloads) with two consecutive sections per mouse at Bregma 
+0.74 mm. Non-specific background signal of the corpus callosum was subtracted from the 
striatal OD values. Fluorescence images were obtained by utilizing an inverse confocal 
microscope (TCS SP8 gSTED, Leica) with a 40x oil objective and the Leica Application Suite 
(LAS) 3 software. OB fluorescence microscopy was performed at Bregma +4.30 mm, +3.30 
mm and +2.30 mm. TH- as well as PAX6-expressing cells were detected independently before 
merging the channels and quantifying the number of colocalizing cells, respectively. PAX6 
expression in the SVZ was performed at Bregma +1.10 mm, +0.70 mm and +0.30 mm. 
Sections immunostained for EYFP/TH were imaged using with an inverted Zeiss AxioObserver 
Z1 microscope equipped with an ApoTome. Fluorescence images were acquired with Zeiss 
AxioCam MRm 1388 x 1040 pixels (Carl Zeiss). At 10X (EC PlnN 10x/0.3, Carl Zeiss) tile 
images were acquired with conventional epifluorescence. At 20X (EC PlnN 20x/0.5, Carl Zeiss) 
tile images were acquired using the ApoTome function. 
Odor discrimination test 
Odor discrimination ability was examined to analyze DaN functionality in the OB. In addition, 
the odor discrimination test provides an opportunity to investigate odor detection rather 
independently from motor activity (for details of the test, see supplementary methods).  
 
 




Statistical analysis was done with GraphPad Prism 4 for Windows. Quantified data in the 
figures and in the text is presented as mean + SEM. Relative data is shown as percentage of 
control experiments. Values of sample size (n) refer to mouse numbers. Unpaired t tests, one-
way or two-way ANOVA with post hoc comparisons (Bonferroni post hoc test) were used to 
determine differences between groups. A significance level of 0.05 was accepted for all 
statistical tests. Asterisks mark P-values of 0.05 (*), 0.01 (**), 0.001 (***) or 0.0001 (****). 
Results 
Time course of TFAM loss in different DaN populations 
To determine the onset of Cre-mediated recombination, and thus TFAM knockout, in DaNs in 
the DatCre mouse line, we crossed DatCre/+ mice with a reporter mouse line expressing 
enhanced yellow fluorescent protein (EYFP) (Rosa26loxP-stop-loxP-EYFP) [36]. In the 
midbrain, YFP expression starts in laterally located tyrosine hydroxylase-positive (TH-positive) 
DaNs at E13.5 and spreads to medial DaN populations by E15.5 (Fig. 3-6) [37]. In the OB, we 
could not detect any YFP-expression in TH-positive DaNs at E15.5 (Fig. 3-6) or P0 (not 
shown), although some TH-positive neurons were present. Only at 4 weeks of age, TH-positive 
DaNs expressed YFP, indicating that recombination in OB DaNs only occurs postnatally in 
DatCre mice. Consistent with this, RNA in situ hybridization data from the Allen Brain Atlas 
show that Dat is not expressed in the OB at P4 [38] while by P14, weak expression of DAT is 
detected in the OB and this is maintained into adulthood. These data suggest that inactivation 
of TFAM in the MitoPark model occurs at least two weeks later in OB DaNs than in midbrain 
DaNs. 
MitoPark mice show dopaminergic nigro-striatal degeneration 
TFAM depletion causes progressive motor impairment evoked by the loss of midbrain SNc 
DaNs and corresponding striatal fibres in the caudate putamen (CPu) starting from 14 weeks 
of age [32, 33]. Since Tfam inactivation in OB DaNs occurs later, 20- and 30-week-old MitoPark 
mice were used in this study. The severe degeneration of the nigro-striatal and the mesolimbic 
pathway was confirmed in 30-week-old MitoPark mice. In particular, the reduction of TH-
positive cells in the SNc and ventral tegmental area (VTA) (Fig. 3-7A-B) as well as TH staining 
in the corresponding striatal projection areas is dramatic (Fig. 3-7C-D). In addition, the olfactory 
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tubercle (OT), located in the ventral striatum and innervated by VTA DaNs, shows lowered TH- 
TH-staining. 
Respiratory chain defects in OB DaNs of MitoPark mice 
Loss of TFAM is accompanied by loss of mtDNA encoded transcripts [32]. Consequently, 
respiratory chain defects become apparent in midbrain DaNs of 12-week-old MitoPark mice 
even before the onset of neurodegeneration [39]. In order to verify mitochondrial impairment 
in OB DaNs, a histochemical staining procedure for COX/SDH activity was performed 
(Fig. 3-7E). Sporadically, COX-deficient cells were found in the GL of the OB in MitoPark mice, 
however, no COX-deficient cells were observed in any of the control animals. These data 
reveal that COX-deficiency also occurs in OB DaNs of MitoPark mice after inactivating the 
Tfam gene driven by Dat-Cre recombination. 
Fig. 3-6 Colocalisation of TH and YFP is delayed in OB DaNs. In the midbrain, TH-positive cells are co-expressing 
YFP at both E15.5 and 4 weeks of age (yellow in merged panel). In contrast, colocalisation of TH and YFP in the OB 
becomes apparent only at the age of 4 weeks. Scale bars: 100 µm. 
 
Paß et al. 2020, Mol Neurobiol  
 
65 
MitoPark mice exhibit impaired odor detection 
To assess OB functionality in MitoPark mice, the olfactory behavior of control and Mito Park 
mice was investigated at different stages. In the buried pellet test, the latency to locate a food 
pellet, either hidden underneath the bedding or visible on the surface, respectively, was tested 
(for details of this widely used test, see supplementary methods). There was no significant 
difference in the latency time to detect the buried food pellet between MitoPark and control 
mice in any of the investigated ages (Fig. 3-8-1A). However, at the age of 30 weeks, MitoPark 
mice took significantly longer to find the visible pellet (control 15.14 ± 5.21 s, MitoPark 134.65 ±  
Fig. 3-7 Degeneration of midbrain DaNs and striatal projections in 30-week-old MitoPark mice. A, B) Tyrosine 
hydroxylase (TH) immunohistochemistry in the midbrain of MitoPark and age-matched control mice showing severe 
neuronal loss in the ventral tegmental area (VTA) and the substantia nigra pars compacta (SNc). C, D) Striatal 
staining presenting the reduction in TH-positive projection area in the nucleus accumbens (NAc), caudate putamen 
(CPu) as well as the olfactory tubercle (OT). Three control and four MitoPark mice were analyzed. E) COX-deficient 
DaNs in the OB of 30-week-old MitoPark mice. Neurons with reduced activity of cytochrome c oxidase (COX; brown) 
were unmasked by COX-SDH double staining (blue). In the midbrain, first COX-deficient cells become apparent at 
12 weeks of age. Conversely, COX-deficient cells were found in the OB only after 30 weeks. F) COX-deficient cells 
in the OB of 30-week-old MitoPark mice. Quantitative analysis revealed a significantly higher number of blue cells 
in the OB of MitoPark mice when compared to control animals. Control mice: black bar n=5; MitoPark mice: red bar 
n=4. Scale bars: 500 µm (A, B), 1 mm (C, D), midbrain 500 µm, enlarged 50 µm; olfactory bulb 100 µm, enlarged 
50 µm (E). 
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48.14 s, two-way ANOVA, P<0.05), indicating that the severe motor impairment of 30-week-
old MitoPark mice may influence the result rather than showing exclusively an affected ability 
for odor detection. 
In order to analyze odor discrimination as well as odor detection more independent from motor 
performance, the odor discrimination test was carried out in 20- and 30-week-old MitoPark and 
control mice. Both non-social and social odors were presented consecutively three times each. 
Control animals revealed typical olfactory memory and discrimination. They presented 
habituation behavior to identical odors characterized by decreasing sniffing times as well as 
dishabituation to new odors with increasing sniffing times (Fig. 3-8A-D). For MitoPark mice, 
the time spent at the odors was dramatically reduced and they were not able to detect any of 
the presented odors. The time spent sniffing at the odor was significantly decreased in 20-
week-old MitoPark mice for all odor types (Fig. 3-8C-D, water-1: two-way ANOVA, P<0.001, 
almond-1: P<0.01, banana-1: P<0.01, social 1-1: P<0.001). Furthermore, 30-week-old 
MitoPark mice spent no time at any of the presented odors (Fig. 3-8C-D). These results 
indicate that odor detection is fundamentally impaired in MitoPark mice. 
 
 
Fig. 3-8 Impaired odor detection in MitoPark mice. A-D) Time spent sniffing at the odor by 20 (A-B) and 30-
week-old (C-D) MitoPark (red squares) and control mice (black squares). 20 weeks: (9-10 mice); 30 weeks: (5-6 
mice). 
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Reduction of dopaminergic SCs in the OB of MitoPark mice 
Soma size-based quantification was performed to examine the number of DaNs in the two 
main subpopulations (Fig. 3-9A-B). The number of SCs was higher compared to LACs in this 
area, in line with previously reported observations in wt mice [40]. The number of LACs and 
SCs did not differ between both groups at the age of 20 weeks, however, comparison of control 
and MitoPark mice showed a decreased number of SCs in 30-week old MitoPark (Fig. 3-9C, 
control: 351.25 ± 26.06, MitoPark: 228.67 ± 22.50, unpaired t-test, P<0.01). These results 
suggest that TFAM depletion in OB DaNs preferentially affects SC survival and that this may 
lead to the observed odor detection impairment. Alternatively, the continuous generation of 
progenitor cells could be affected and be the reason for the decreased SC number in MitoPark 
mice. 
 
Fig. 3-9 Reduced proportion of SCs in the OB of MitoPark mice. A) Tyrosine hydroxylase (TH) 
immunohistochemistry of the OB and the enlarged glomerular layer. B) TH staining in MitoPark and age-matched 
control mice. C) Quantification of DaN subpopulations showed an increase in the proportion of LACs and a reduction 
in SCs in the OB of 30-week-old MitoPark mice. The fraction of SCs was higher compared to LACs (20 weeks, 
control 92.14 ± 1.32 % SCs vs. 7.86 ± 1.32 % LACs, one-way ANOVA, P<0.0001; MitoPark 89.69 ± 2.92 SCs vs. 
10.31 ± 2.92 % LACs, P<0.0001; 30 weeks, control 93.92 ± 2.59 % SCs vs. 6.08 ± 2.59 % LACs, P<0.0001; 
MitoPark 80.37 ± 2.43 % SCs vs. 19.63 ± 2.43 % LACs, P<0.0001). Values are illustrated as percentage from total 
DaN number. Control mice: black bars, 20 weeks n=4, 30 weeks n=4; MitoPark mice: red bars, 20 weeks n=5, 30 
weeks n=6. Scale bars: 200 µm and 50 µm (A), 10 µm (B). 
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Number of PAX6+ DaNs is not altered in the OB of MitoPark mice 
In contrast to LACs, SCs can be newly generated even postnatally. To investigate if the 
reduced number of SCs in MitoPark mice is caused by an alteration in progenitor cell 
differentiation, PAX6 immunohistochemistry was performed in the OB (Fig. 3-10A). The 
transcription factor PAX6 is postnatally expressed in progenitor cells of the subventricular zone 
to mediate their dopaminergic fate [21–23, 41–43] and remains expressed in DaN progenitors 
after arriving in the OB [44–46]. In addition, PAX6 has recently been used by Höglinger and 
colleagues as a marker for neurogenic progenitors within the rostral migratory stream, which 
gives rise to DaNs in the OB [47]. In contrast, PAX6 expression in cells already established 
during development decreased over time with no colocalization in neurons [48]. This makes 
PAX6 an ideal marker for adult-born DaNs in the mouse OB. The amount of TH-positive 
neurons also expressing PAX6 did not differ between MitoPark and control mice (Fig. 3-10B, 
20 weeks: control 65.66 ± 1.79 %, MitoPark 66.55 ± 3.76 %; 30 weeks; control 75.30 ± 1.17 
%, MitoPark 72.54 ± 1.59 %, one-way ANOVA, n.s.). These data reveal that DaN progenitor 
cell differentiation in the OB is not impaired in MitoPark mice. 
MitoPark mice show increased progenitor cell mobilization in the SVZ 
To further assess whether OB progenitor cell proliferation is affected earlier in the lineage of 
these neurons, PAX6 expression in the dorsal SVZ was studied (Fig. 3-10C). At 20 weeks of 
age, there was no difference between MitoPark and control animals (Fig. 3-10D, control 37.69 
± 10.00 %, MitoPark 38.48 ± 3.71 %). However, 30-week-old MitoPark mice revealed a 
significantly increased number of PAX6-expressing cells when compared to 20-week-old 
MitoPark mice and age-matched control animals (MitoPark: 20 weeks 38.48 ± 3.71 %, 30 
weeks 80.80 ± 16.63 %, one-way ANOVA, P<0.05; 30 weeks: control 24.02 ± 3.65 %, one-
way ANOVA, P<0.01). These results indicate an enhanced mobilization of progenitor cells in 
the dorsal SVZ, probably induced by the decline of SCs in the OB. 
Discussion 
In contrast to the midbrain, OB DaNs reveal no Dat-Cre expression during embryonic 
development (Fig. 3-6). Moreover, RNA in situ hybridization data [38] suggest that the Dat 
gene only starts to be expressed in OB DaNs in the second postnatal week. Subsequently, 
cells with respiratory chain deficits become apparent in OB DaNs only in 30-week-old MitoPark 
mice (Fig. 3-7E), i.e. 28 weeks after TFAM inactivation at around P14, whereas midbrain DaNs 
uniformly present COX deficiency already after 12 weeks of age [39], i.e. 13 weeks after TFAM 
inactivation at around E15.5. This reveals a surprisingly different response of different DaN 
populations to inactivation of mitochondrial gene expression. 
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To inspect MitoPark mice for OB functionality, olfactory behavior was investigated. The widely 
Fig. 3-10 No change in the amount of PAX6-expressing DaNs in the OB but in the amount of progenitor cells 
in the SVZ of MitoPark mice. A) Merged tyrosine hydroxylase and PAX6 immunofluorescent staining presents 
newborn OB DaNs in 20- and 30-week-old MitoPark and age-matched control mice. B) Quantitative analysis of 
PAX6-expressing DaN number revealed no difference between MitoPark and control animals. Control mice: black 
bars, 20 weeks n=5, 30 weeks n=5; MitoPark mice: red bars, 20 weeks n=5, 30 weeks n=5. Increase of PAX6-
expressing progenitor cells in the SVZ of MitoPark mice. C) Combined nuclear (DAPI) and immunofluorescent PAX6 
staining depicts the distribution of progenitor cells in MitoPark and age-matched control mice in the SVZ. D) 
Quantitative analysis showed an enhanced number of progenitor cells in 30-week-old MitoPark mice. Control mice: 
black bars, 20 weeks n=4, 30 weeks n=5; MitoPark mice: red bars, 20 weeks n=5, 30 weeks n=5. Scale bars: 50 µm 
(A), 25 µm (B). 
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To inspect MitoPark mice for OB functionality, olfactory behavior was investigated. The widely 
used buried pellet test did not reveal olfactory dysfunction in MitoPark mice (Fig. 3-8-1A-B), 
but this may rather be a consequence of the motor impairment at 30 weeks of age. It further 
has to be noted, that the outcome of the buried food pellet test does not exclusively depend 
on the detection of odors. As a consequence of the bradykinesia, MitoPark mice have to be 
supplied with moistened food pellets on the surface of the bedding from an age of 15 weeks 
onward. MitoPark mice are thereby trained to seek for food at the surface by housing 
conditions. Furthermore, the animals were not food deprived, since this would be ethically not 
permitted with MitoPark mice. In fact, these animals could even suffer from an enhanced desire 
for food, since they start losing weight at 20 weeks of age [49]. Thereby, the buried food pellet 
test might not be an appropriate test to analyze odor detection impairment in MitoPark mice. 
It has further been shown that OB DaNs are involved in olfactory discrimination [7, 50, 51]. In 
order to analyze discrimination as wells as detection more independently from motor 
performance and food seeking, the odor discrimination test was performed (Fig. 3-8A D). 
Already 20-week-old MitoPark mice show sharply reduced times spent at all presented odors. 
After 30 weeks of age, no sniffing time is observed at all, indicating a severe impairment in 
fundamental odor detection. Noteworthy, the ability of MitoPark mice to move was still sufficient 
to localize the presented odors (video sequences, not shown). 
In order to investigate the number of DaNs in the GL, soma size based quantification was 
performed. Intriguingly, only a reduced number of SCs is found in 30-week-old MitoPark mice, 
whereas LACs were unaffected (Fig. 3-9C). In the midbrain of MitoPark mice, both SNc and 
VTA DaNs present mitochondrial dysfunction at 12 weeks of age, followed by progressive 
neurodegeneration, with SNc neurons being more affected [32]. This selective vulnerability is 
one hallmark for PD in patients [52] and raises the question which cell type-specific factors 
render SNc DaNs vulnerable to mitochondrial dysfunction. Much research has been conducted 
characterizing neuroanatomical as well as electrophysiological properties of midbrain and OB 
DaNs. On the one hand, complex axonal morphology might play an essential role regarding 
the time course of degeneration. SNc DaNs show an extremely large arborization with an 
estimated number of 100.000 – 250.000 synapses per neuron [53], compared to both VTA and 
OB DaNs, with the SCs even being anaxonic [14]. The extended branching results in an 
extreme bioenergetic demand, leaving SNc DaNs working on a tight energy budget [54], 
especially when facing additional stressors, such as mitochondrial dysfunction. On the other 
hand, all three DaN populations are characterized as autonomous pacemakers [40, 55, 56]. 
The pacemaking machinery of VTA and OB DaNs is mainly driven by a persistent sodium 
current [40, 57, 58]. Conversely, SNc pacemaker activity is associated with Ca2+ influx through 
plasma membrane Cav1.3 channels, postulated to cause oxidant stress in the mitochondrial 
compartment [59, 60]. Combined with low intrinsic calcium buffering capacities, mitochondrial 
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dysfunction leads to an oxidized RedOx-system and hyperpolarized membrane potential in 
mitochondria of SNc DaNs, which thereby causes neuron death [39]. 
SCs and LACs differ in various aspects, including morphology, functionality and neurogenic 
potential. SCs are anaxonic and thereby generate somatic action potentials with a low firing 
rate. In contrast, the wide-branching LACs do have an axon and a high firing frequency [19]. 
SCs are typically type 1 periglomerular cells [61–65]. They receive olfactory nerve and 
dendrodendritic synapses, which in turn lead to the inhibition of mitral cells [66], the principal 
output neurons of the OB. A reduced number or functional changes of SCs in MitoPark mice 
could thereby cause temporal shifts in mitral cell activity, previously shown to impair olfactory-
related behaviors [67]. 
In addition, anaxonic SCs are even continuously formed via adult neurogenesis, whereas 
LACs are exclusively established during embryonic development [15–19]. Consequently, 
affected neuronal replenishment of SCs could be the explanation for the reduced number of 
SCs. OB progenitor cells are created in the SVZ of the lateral ventricles and tangentially 
migrate along the rostral migratory stream, before they enter the OB [68]. Those progenitor 
cells are characterized by the expression of PAX6. Interestingly, MitoPark mice reveal an 
increased mobilization of PAX6-expressing cells in the SVZ at 30 weeks of age (Fig. 3-10C-D), 
indicating a potential compensatory upregulation of progenitor cells. However, the amount of 
PAX6 expressing DaNs in the OB is stable (Fig. 3-10A-B). This gives reason to suppose that 
either the death rate of SCs is so high that the number of replenished neurons in the OB cannot 
compensate for this, or that the upregulation of progenitor cells in the SVZ is not a direct cause 
of the reduced SC number. In addition, even though the time line of RMS migration is very well 
established, there is no evidence to when DAT expression is initiated in OB progenitor cells. 
Potentially, new but not fully matured neurons are more vulnerable to the TFAM knockout due 
to early DAT expression and die even before reaching the OB. 
Besides the reduced number of SCs it is likely that the severe olfactory dysfunction is caused 
by other factors. So far no direct link between the midbrain and the OB could be demonstrated 
[69, 70]. However, a recent study discovered the existence of axonal projections from SNc 
DaNs to the OB and the ablation of this connectivity resulted in impaired olfactory perception 
[71]. At 30 weeks of age, MitoPark mice reveal a severe degeneration of SNc DaNs (Fig. 3-7B). 
Therefore, the absence of these nigro-bulbar connections could contribute to the olfactory 
dysfunction in MitoPark mice. More precisely, the loss of SNc-OB projections might lead to 
Ca2+-induced hyperactivity of mitral cells caused by the missing dopaminergic inhibition, as 
recently demonstrated in a 6 OHDA induced PD mouse model [72]. However, Zhang et al. did 
not show any data concerning the dopaminergic projection area in the striatum after partial 
depletion of SNc DaNs, though striatal denervation is likewise affecting olfactory behavior [73]. 
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Since MitoPark mice reveal the degeneration of SNc DaNs as well as corresponding striatal 
fibres, we postulate that, besides the decreased number of SCs, olfactory dysfunction might 
be caused by the degeneration of the complete nigro-striatal system. Moreover, the loss of the 
nigro-striatal system might be the reason for the increased mobilization of progenitor cells in 
the SVZ observed in 30-week-old MitoPark mice, as shown likewise after 6-OHDA lesioning 
[74]. Noteworthy, DaNs from the VTA innervate the SVZ and are involved in proliferation of 
progenitor cells [75]. Increased progenitor cell mobilization may thereby also have its reason 
in a compensatory upregulation due to the loss of VTA DaNs. More importantly, the SNc, the 
VTA as well as the striatum further possess dopaminergic projections to higher olfactory brain 
regions, such as the piriform cortex and the olfactory tubercle [76–78]. Therefore, a prospective 
disconnection between the nigro-striatal system as well as the VTA and higher olfactory 
centers might importantly contribute to the impaired olfactory-related behavior in MitoPark 
mice. 
Apart from the dopaminergic system, serotonin could also play a role in the olfactory 
dysfunction of MitoPark mice. Serotonergic neurons from the raphe nuclei are innervating all 
layers of the OB [79–81] and deafferentiation of corresponding fibres causes anosmia and OB 
atrophy [82]. Furthermore, mice that are deficient for PTEN-induced kinase 1 (PINK1), 
mutations of which make up 1-2% of the familiar forms of PD, possess a decreased 
serotonergic innervation in the GL, leading to an impaired olfactory behavior [83]. Besides the 
SNc, the raphe nuclei are also affected in PD patients, with a loss of serotonergic neurons and 
its projections [84, 85]. However, altered serotonin transporter activities in PD patients failed 
to correlate with olfactory dysfunction [86], leaving the role of serotonergic neurons in PD-
related anosmia unclear.  
Our data provide new insights into olfactory dysfunction and adaptations of adult neurogenesis 
in response to genetic depletion of the dopaminergic system. Furthermore, we show that 
dopaminergic neurons located in the olfactory bulb reveal a high robustness towards 
mitochondrial impairment, in striking contrast to their midbrain counterparts. 
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Video 1: Odor Discrimination Test of a 30-week-old MitoPark mouse. Movement and 
sniffing behavior of the test mouse are shown during the presentation of a new odor via a 
cotton swab in an open cage. While the MitoPark mouse’s ability to move was sufficient to 
discover the cotton swab, the sniffing behavior appeared undirected. The mouse did not locate 
the swab at any time in the presented video sequence. 
Video 2: Odor Discrimination Test of a 30-week-old control mouse. Movement and sniffing 
behavior of the test mouse are shown while a new odor is presented via a cotton swab in an 
open cage. The control mouse shows a normal olfactory behavior. In particular, a targeted 
sniffing behavior is seen, followed by the rapid detection of the odor’s source. 
 














Fig. 3-8-1 No significant difference in buried food pellet detection between MitoPark and control mice. A) 
Latency time of MitoPark (red bars) and age-matched control mice (black bars) to the buried and B) unburied food 
pellet (n = 5-23 mice). 
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Mitochondrial dysfunction in midbrain dopaminergic neurons (DaNs) is a central feature of 
Parkinson’s disease (PD), including the common idiopathic as well as those rare familial forms 
induced by mutations in the Parkin, Pink1, LRRK2 or DJ-1 genes. Mitochondrial dysfunction is 
probably caused by the accumulation of mitochondrial DNA (mtDNA) deletions, as shown post-
mortem in elderly humans as well as in PD patients. Motor symptoms are caused by DaN loss, 
especially in the substantia nigra pars compacta (SNc), while those in the neighboring ventral 
tegmental area (VTA) are largely spared. In order to accelerate the accumulation of mtDNA 
deletions, we generated mice in which the DaNs express a mutated, dominant-negative variant 
of the mitochondrial helicase Twinkle (K320E), leading to mtDNA deletions in patients. K320E-
TwinkleDaN mice show no motor decline even at the age of 20 months, although DaN number 
in both SNc and VTA was severely reduced. Surprisingly, the corresponding striatal projection 
areas, the caudate putamen (CPu) and the nucleus accumbens (NAcc), were differentially 
affected. In stark contrast to other genetically and chemically induced mitochondrial PD models 
described in the literature, fibres in the NAcc innervated by the VTA were dramatically reduced, 
causing a depressive-like behavior in these animals. Despite the severe neurodegeneration, 
the SNc-innervated CPu of homozygous K320E-TwinkleDaN mice still possessed ~80% of 
dopaminergic projections, which was sufficient to maintain voluntary movement control. Our 
data reveal that, although both surviving VTA and SNc DaNs show normal expression levels 
of complex IV, only SNc DaNs were able to compensate for neurodegeneration by preserved 
striatal innervation when facing slow and progressive impairment of mtDNA replication. 








Parkinson’s disease (PD) is characterized by the progressive loss of midbrain dopaminergic 
neuron (DaNs) in the substantia nigra pars compacta (SNc), while the neighboring ventral 
tegmental area (VTA) is largely spared. The depletion of dopamine in the dorsal striatum leads 
to the cardinal motor symptoms of PD, including tremor, rigidity, bradykinesia and postural 
instability (Michel et al. 2016). Besides the movement disorder, non-motor symptoms, such as 
gastrointestinal dysfunction, loss of smell, sleep disturbances, anxiety and depression, are 
frequently reported to precede and accompany the neurodegenerative disease (Reijnders et 
al. 2008; Kurtis et al. 2013; Simuni and Fernandez 2013; Fasano et al. 2015). While being 
important for diagnosis, motor symptoms only arise after 30-50% of SNc DaNs and up to 80% 
of striatal dopamine are already gone (Obeso et al. 2017). Up to now, available drugs and 
treatments can then only dampen the symptoms for a foreseeable time. Therefore, 
medications which both stop the ongoing loss of DaNs and promote striatal innervation of the 
surviving DaNs are urgently needed. 
Mitochondrial dysfunction in DaNs is a central feature of PD, including the common idiopathic 
as well as those rare familial forms caused by mutations in the Parkin, Pink1, LRRK2 or DJ-1 
genes (Park et al. 2018; Chen et al. 2019). With increasing age, DaNs accumulate 
mitochondrial DNA (mtDNA) deletions, which are even further elevated in PD and thought to 
be a key process in the pathogenesis of the neuronal loss (Bender et al. 2006; Kraytsberg et 
al. 2006; Meissner et al. 2008; Elstner et al. 2011; Dölle et al. 2016). We could already show 
that the enhanced accumulation of mtDNA deletions is driven by the metabolism of 
catecholamines (Neuhaus et al. 2014; Neuhaus et al. 2017), explaining why dopamine-
producing cells are hot spots for such alterations in the mtDNA. 
In order to investigate the impact of mtDNA deletions on the function of various tissues, we 
generated mice in which a mutated, dominant-negative variant of the mitochondrial helicase 
Twinkle (K320E mutation) is expressed in a cell-specific manner. The equivalent mutation of 
twinkle is found in patients with the sensory ataxic neuropathy with dysarthria and 
ophtalmoparesis (SANDO) syndrome (Hanisch et al. 2015), leading to progressive external 
ophthalmoplegia (PEO) and is accompanied by the accumulation of multiple mtDNA deletions 
in skeletal muscle (Hudson et al. 2005). In addition, the brain has been reported to reveal high 
amounts of mutated mtDNA as well in a patient with PEO (Suomalainen et al. 1992). Our lab 
already reported the mitochondrial defects in various tissues upon the expression of K320E 
(Baris et al. 2015; Weiland et al. 2018; Holzer et al. 2019). In order to investigate the impact of 
the increased accumulation of mtDNA deletions in DaNs on neuronal survival, mitochondrial 
function and motor behavior, we generated mice in which K320E is expressed in DaNs. 
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Materials and Methods 
Experimental model 
All experiments were conducted in agreement with European and German guidelines and 
approved by local authorities (LANUV NRW, Recklinghausen, Germany; 84-02.04.2013-A141, 
81-02.04.2018-A210). Experiments were carried out with male or female mice of the strain 
C57/BL6N. For depressive state only group-housed animals were used to avoid possible 
effects induced by social deprivation. Heterozygous (K320E/WtDaN) and homozygous 
(K320E/K320EDaN) K320E-TwinkleDaN mice were generated by crossing DAT cre mice (Cre-
gene inserted upstream of the translation start codon in exon 2 of the DAT gene, (Ekstrand et 
al. 2007)) with R26-K320E-TwinkleloxP/+ mice. DAT cre mice had been kindly provided by 
Nils-Göran Larsson (Karolinska Institutet, Sweden). Generation of R26-K320E-TwinkleloxP/+ 
mice has been described previously (Baris et al. 2015). Mice were genotyped by PCR using 
genomic DNA isolated from ear punches. Primer sequences and PCR conditions are available 
upon request. 
Histology 
All immunohistochemical approaches were performed on 5 µm paraffin sections. Striatal 
tyrosine hydroxylase (TH) immunoreactivity was assayed using a TH antibody (polyclonal 
rabbit, Abcam, #ab112, 1:750) and a biotinylated secondary antibody (donkey anti-rabbit, 
dianova, #111-065-006, 1:500). Fluorescence stainings of midbrain sections were performed 
with primary antibodies against TH (polyclonal rabbit, Abcam, #ab112, 1:1500) and 
mitochondrial complex IV subunit 1 (mtCOI, monoclonal mouse, Abcam, #ab14705, 1:1000) 
and fluorochrome-conjugated secondary antibodies (Goat anti-rabbit TRITC-conjugated, 
AffiniPure, #111-025-144, 1:2000, Goat anti-mouse DyLight488-conjugated, Jackson-
ImmunoResearch, #115-485-003, 1:400). Visualization of Cytochrome c Oxidase (COX) 
deficiency was performed by COX-SDH enzymatic activity staining at Bregma -3.08 mm similar 
to (Aradjanski et al. 2017), but incubation with SDH solution was performed for 180 min. 
For densitometric analysis of striatal sections, bright-field microscopy was used (Slide 
Scanner, SCN400, Leica) equipped with a 40x objective. High resolution images from striatal 
sections at Bregma +0.74 mm were generated by the Leica SlidePath Gateway and the 
Microsoft Image Composite Editor software. TH-positive striatal fibre density was determined 
by optical density analysis using ImageJ-software with two sections per mouse. Non-specific 
background signal of the corpus callosum was subtracted from the striatal optical density 
values. Fluorescence images were obtained with an inverse confocal microscope (TCS SP8 
gSTED, Leica) with a 40x oil objective at Bregma -3.08 mm. mtCOI-signal intensity was 
measured in the somata of TH-positive neurons. Fluorescent intensity was normalized to the 
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mtCOI-signal of TH-positive cells from the same objective slide using a tissue slice which was 
not incubated with the primary antibody against mtCOI (negative control). 
 
Immunohistochemistry 
Anaesthetized mice (ketamine/xylazine: 100/10 mg/kg body weight, intraperitoneally) were 
intracardially perfused with PBS (GIBCO; 140 mM NaCl, 10 mM sodium phosphate, 2.68 mM 
KCl, pH 7.4) for 3 min and 4% PFA in PBS for 15 min. Brains were dissected and immersion-
fixed in 4% PFA in PBS overnight. Afterwards tissues were dehydrated in a series of ethanol 
solutions (ethanol percentages are given): 70%, 90%, 2x 100% (15 min each), 100% (30 min) 
and 100% (45 min, Leica ASP300, CMMC Tissue Embedding Facility) and embedded in 
paraffin (Leica EG1150 H, CMMC Tissue Embedding Facility). Coronal 5 µm striatal sections 
were cut with a microtome (Leica RM2125 RTS). Sections were deparaffinized in xylene 
(2x5 min), washed in a series of ethanol solutions (100%, 95%, 70% and 50%, 1 min each) 
and afterwards washed in ddH2O (5 min). For epitope retrieval, sections were heated in citrate 
buffer (10 mM citric acid monohydrate, pH 6) using a microwave oven.  
Brightfield microscopy: Sections were washed in TBS (10 mM Tris base, 150 mM NaCl, pH 
7.6, 3x5 min), quenched with 0.3% H2O2/TBS solution and washed again in TBS (3x5 min). 
Subsequently, sections were blocked in 10% normal goat serum in TBS (45 min, RT) and 
afterwards incubated with the tyrosine hydroxylase (TH) antibody (polyclonal rabbit, Abcam, 
#ab112, 1:750 in 3% skim milk powder/TBS, overnight, 4°C). After another TBS washing step 
(3x5 min), sections were incubated with the secondary biotinylated antibody (donkey 
anti-rabbit, dianova, #111-065-006, 1:500 in 3% skim milk powder/TBS, 30 min, RT), followed 
by avidin/biotin Vectastain Elite ABC HRP Kit (Vector Laboratories). Visualization was 
performed by using DAB solution (0.46 mM 3,3’-Diaminobenzidine tetrahydrochloride, 7.3 mM 
Imidazole, 15.2 mM Ammonium nickel (II) sulfate hexahydrate, 0.015% H2O2 in TBS, pH 7.1, 
6 min). Following a short washing in ddH2O (1 sec), sections were dehydrated in 50%, 70% (1 
sec each), 95% and 100% ethanol (1 min each), cleared in xylene (2x10 min) and mounted 
with Entellan.  
Fluorescence stainings 
Sections were rinsed in 0.5% Tween20 in TBS (3x5 min) after the epitope retrieval and 
incubated with the primary antibodies (TH polyclonal rabbit, Abcam, #ab112, 1:750, 
mitochondrial complex IV subunit 1 (mtCOI) monoclonal mouse, Abcam, #ab14705, 1:1000 in 
Dako antibody diluent, overnight, 4°C). Sections were washed in 0.5% Tween20 in TBS 
(3x5 min) and incubated with fluorochrome-conjugated secondary antibodies (Goat anti-rabbit 
TRITC-conjugated, AffiniPure, #111-025-144, 1:1000, Goat anti-mouse DyLight488-
conjugated, Jackson-ImmunoResearch, #115-485-003, 1:400, overnight, 4°C). Following 
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another washing step in 0.5% Tween20 in TBS (3x5 min), midbrain sections were 
counterstained with DAPI (1 µg/mL in ddH2O, 1 min), washed again in 0.5% Tween20 in TBS 
(3x5 min) and mounted with Fluoromount. At each time point, immunofluorescent stainings 
were performed with all sections at the same time.  
Stereological quantification of dopaminergic neurons 
For the counting of DaNs, tyrosine hydroxylase stainings of serial coronal paraffin midbrain 
sections were performed similar to stainings in the striatum. Sections were incubated with DAB 
solution (0.46 mM 3,3’-Diaminobenzidine tetrahydrochloride, 7.3 mM Imidazole, 15.2 mM 
Ammonium nickel (II) sulfate hexahydrate, 0.015% H2O2 in TBS, pH 7.1) for 14 min and 
counterstained with nuclear fast red (NFR, 0.1% in 5% aluminium sulfate dissolved 1:5 in 
ddH2O). Stereological quantification of DaNs was conducted with the physical fractionator 
approach, which is typically used for the quantification of large neuron numbers in brain nuclei 
using thin, paired tissue sections (Gundersen et al., 1988; Ma et al., 2003; Glaser et al., 2007). 
The region of interest was confined either to the SNc or to the VTA using the mouse brain atlas 
(Paxinos and Franklin, 2001) on sections between Bregma -2.54 mm and -3.88 mm. Neurons 
Q were only counted, if their TH- and NFR-positive profiles appeared in the reference section 
but not in the lookup section. In addition, neurons had to be located either within the counting 
frame, or touching the open frame, but not touching the forbidden frame. The height sampling 
fraction hsf (section thickness/dissection height = 5 µm/5 µm = 1) and the area sampling 
fraction asf (area of counting frame/area of sampling grid = 42.9 µm²/191.82 µm² = 0.223647) 
were given as constants. The section sampling fraction ssf was set by the number of sections 
between the analyzed section pairs (typically 27 sections). Total dopaminergic neuron 
numbers N were calculated by means of the following formula (Dorph-Petersen et al., 2001; 
Howard and Reed, 2005): N = Q x 1/hsf x 1/asf x 1/ssf. 
COX-SDH staining 
Visualization of Cytochrome c Oxidase (COX) deficiency was performed by COX-SDH 
enzymatic activity staining (Sciacco and Bonilla 1996). COX is respiratory chain (RC) complex 
IV which is partially encoded by mtDNA, while succinate dehydrogenase (SDH), complex II, is 
entirely encoded by nuclear DNA. Impaired integrity of mtDNA results in COX-deficiency, but 
sustained SDH-activity. Cells with decreased COX-activity will stain blue for SDH, while cells 
with normal COX-activity will appear brown. Following dissection, brains were embedded 
(O.C.T. Tissue-Tek), frozen on dry ice and stored at -80 °C. Cryostat (Leica CM3050 S) 
sections of 7 µm were stored at -80 °C. Coronal midbrain cryosections at Bregma -3.08 mm 
were air dried and treated with COX incubation solution (100 µM Cytochrome C, 4 mM 
diaminobenzidine, 4400 U catalase in 0.1 M phosphate buffer) for 40 min at 37 °C. Afterwards, 
sections were washed in ddH2O (3x30 sec) and treated with SDH incubation solution (1.5 mM 
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Nitroblue tetrazolium, 130 mM sodium succinate, 200 µM phenazine methosulfate, 1 mM 
sodium azide) for 180 min at 37 °C. Sections were washed again in ddH2O (3x30 sec), 
dehydrated in 95% (2x2 min) and 100% ethanol (10 min), air dried and mounted with glycerol-
gelatine. 
Behavioral Tests 
Beam Break Experiment 
Spontaneous horizontal as well as vertical movement of mice was tested by performing the 
open field test. The activity measurements were done in home-made beam break detector 
cages. Before individual mice were transferred, the experimental cages were cleaned with 
ethanol. Horizontal and vertical movement were detected by infrared beams. Interruptions on 
the horizontal and vertical level were recorded during a tracking period of 60 minutes. The total 
counts after 60 minutes are presented as percentages of control animals. All experiments were 
conducted between 12:00 and 17:00 p.m. 
Tail Suspension Test 
The tail suspension test was used to inspect K320E-TwinkleDaN mice for depressive-like 
behavior. The test was performed in accordance with (Can et al. 2012) with minor 
modifications. Before testing, mice were kept individually in a new cage for 30 min in the 
experimental room. Mice were suspended for 6 min by using laboratory tape (1.91 cm width, 
Roti®-Tape-marking tapes, Carl Roth). Each trial was performed with one mouse only. In order 
to prevent animals from climbing their tails, clear hollow home-made cylinders were placed 
around their tails. Each session was recorded by a video camera. The time of immobility was 
calculated for each video by measuring the time of active movement and its subtraction from 
the total recording time. Active movement has been defined as the condition when at least 
three paws are in motion. Immobility time was presented in relation to the body weight at the 
time of the behavioral testing. Values were normalized to relative data from control animals. 
The observer was blinded concerning the genotype of the animals. 
Sugar Preference 
Another test to assess depression-related behavior in rodents is the sugar preference test. 
Together with their littermates, animals were transferred into a new cage for 24 h. During this 
time, mice are offered two bottles with 200 ml, one with 5% sucrose solution and the other with 
tap water. After the habituation phase, the littermates were transferred back to the regular 
cages and the experimental mice were kept single-housed for another 24 h. The amount of 
consumed water and sucrose solution was measured and presented in relation to the body 
weight at the time of the behavioral testing. Values were normalized to relative data from 
control animals. To avoid influences that might occur by the preference of a bottle’s position, 
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the order of the bottles had been changed randomly after the habituation phase. Mice were 
not deprived of food or water prior to the test. All experiments were conducted on the weekend, 
ensuring a quiet environment for the tested animals. For normalization of behavioral data, the 
body weight of K320E-TwinkleDaN and control mice was determined. 
Statistics 
Statistical analysis was done with GraphPad Prism 8 for Windows. Quantified data in the 
figures and in the text is presented as mean + SEM. Relative data is shown as percentage of 
control experiments. Values of sample size (n) refer to mouse numbers. Unpaired t tests, one-
way or two-way ANOVA with post hoc comparisons (Bonferroni post hoc test) were used to 
determine differences between groups. A significance level of 0.05 was accepted for all 
statistical tests. Asterisks mark P-values of 0.05 (*), 0.01 (**), 0.001 (***) or 0.0001 (****). 
Hashtags were analogously used in order to visualize P-values of 0.05 (#), 0.01 (##), 0.001 
(###) or 0.0001 (####) between groups of different time points. 
Results 
Motor activity is not impaired in K320E-TwinkleDaN mice 
In order to investigate the impact of the mutated TWINKLE helicase on DaN functionality and 
motor behavior, motor function was assayed in a bream break setup in 10- and 20-month-old 
K320E-TwinkleDaN and control mice (Fig. 3-11A). There was no significant difference in the 
activity, neither at the horizontal nor vertical level, between K320E-TwinkleDaN and control 
animals at both ages (Fig. 3-11B, 10 months: horizontal control 100.00 ± 11.54 %, 
K320E/WtDaN 105.69 ± 11.08 %, K320E/K320EDaN 118.30 ± 9.29 %, vertical control 100.00 ± 
18.97 %, K320E/WtDaN 77.15 ± 11.15 %, K320E/K320EDaN 102.96 ± 15.94 %; 20 months: 
horizontal control 100.00 ± 6.30 %, K320E/WtDaN 116.87 ± 11.48 %, K320E/K320EDaN 114.65 
± 19.42 %, vertical control 100.00 ± 10.74 %, K320E/WtDaN 120.54 ± 21.32 %, 
K320E/K320EDaN 92.75 ± 26.33 %; one-way ANOVA, n.s.). 
Severe loss of midbrain DaNs 
The absent motor phenotype in K320E-TwinkleDaN mice indicates that midbrain DaNs are not 
affected by the impairment of the mtDNA replication machinery. To verify the survival of DaNs 
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despite the presence of the mutated TWINKLE, stereological cell quantification of midbrain 
sections was performed (Fig 3-12A). At the age of 5 months, no difference in the number of 
TH-positive cells was found between K320E-TwinkleDaN and control mice (Fig. 3-12B, control 
100.00 ± 4.33 %, K320E/WtDaN 108.03 ± 5.67 %, K320E/K320EDaN 96.35 ± 8.67 %, one-way 
ANOVA, n.s.). However, 10-month-old hetero- and homozygous K320E-TwinkleDaN mice both 
showed decreased DaN amounts when compared to control animals (control 100.00 ± 8.43 %, 
K320E/WtDaN 66.83 ± 6.12 %, one-way ANOVA, P=0.0039; K320E/K320EDaN 42.85 ± 3.19 %, 
one-way ANOVA, P<0.0001), with the homozygous expressers being more affected than the 
heterozygous ones (one-way ANOVA, P=0.0473). In addition, when compared to 5-month-old 
individuals, the relative number of TH-positive cells was significantly reduced in hetero- and 
homozygous K320E-TwinkleDaN mice of 10 months of age (K320E/WtDaN, unpaired t-test, 
Fig. 3-11 No differences in spontaneous motor activity between K320E-TwinkleDaN and control mice. A) 
Beam break cage with connected motor activity reading device. B) Beam break events are shown on the horizontal 
and vertical level. Quantitative data revealed no difference between K320E-TwinkleDaN and control animals at 10 
as well as 20 months of age (control mice n = 7-9, K320E/WtDaN mice n = 7-11, K320E/K320EDaN mice n = 4-11). 
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p=0.0014, K320E/K320EDaN, unpaired t-test, P=0.0022). At the age of 20 months, the relative 
DaN number was further decreased in both hetero- and homozygous K320E-TwinkleDaN mice 
compared to control animals (control 100.00 ± 8.42 %, K320E/WtDaN 58.62 ± 0.95 %, one-way 
ANOVA, P=0.0019; K320E/K320EDaN 23.05 ± 3.24 %, one-way ANOVA, P<0.0001). Again, 
homozygous K320E-TwinkleDaN mice revealed a lower number of TH-positive cells than 
heterozygous animals (one-way ANOVA, P=0.0077). Moreover, the relative DaN number of 
Fig. 3-12 K320E-TwinkleDaN mice show loss of TH-positive cells in both VTA and SNc. A) 
Immunohistochemical staining of Tyrosine hydroxylase (TH)-positive neurons in the ventral tegmental area (VTA) 
and the substantia nigra pars compacta (SNc) in 20-month-old hetero- and homozygous K320E-TwinkleDaN mice 
as well as age-matched control animals. Scale bar, 500 µm. B) Stereological quantification of TH-positive neurons 
in the midbrain revealed unaltered cell numbers between K320E-TwinkleDaN and control mice at the age of 5 
months. After 10-month-old K320E-TwinkleDaN mice showed decreased numbers of TH-positive cells with the 
homozygous expressers being more affected. The number of TH-positive cells was further reduced in 20-month-
old homozygous K320E-TwinkleDaN mice after 20 months of age (control mice n = 4-5, K320E/WtDaN mice n = 3-5, 
K320E/K320EDaN mice n = 4-5). C) Region-specific differentiation of TH-positive neurons revealed VTA and SNc 
being similarly affected in K320E-TwinkleDaN animals. However, homozygous expressers showed less TH-positive 
cells in the VTA than the SNc after 20 months of age. # indicates significance compared to individuals of prior time 
point. Data are represented as mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ## p < 0.01, ### 
p < 0.001.  
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homozygous K320E-TwinkleDaN mice was further decreased compared to 10-month-old 
animals (10 months 42.85 ± 3.19 %, 20 months 23.05 ± 3.24 %, unpaired t-test, P=0.0028).  
Reduced DaN number in both VTA and SNc 
The selective cell death in PD patients as well as the differential vulnerability upon 
mitochondrial damage of SNc DaNs is highly conserved (Obeso et al. 2017). In order to 
investigate if the slow impairment of mtDNA replication in DaNs leads to region-specific loss, 
midbrain DaN numbers were further divided into the SNc and the VTA (Fig. 3-12C). In 5-month-
old animals, no changes in the number of TH-positive cells were found between K320E-
TwinkleDaN and control mice as well as between SNc and VTA (control SNc 100.00 ± 5.19 % 
VTA 100.00 ± 5.35 %, K320E/WtDaN SNc 108.87 ± 5.67 % VTA 106.97 ± 6.10 %, 
K320E/K320EDaN SNc 91.57 ± 10.33 % VTA 102.33 ± 6.97 %; two-way ANOVA, n.s.). 
Region-specific quantification of DaNs in hetero- and homozygous K320E-TwinkleDaN mice 
at the age of 10 months revealed that neurodegeneration was similarly present in both SNc 
and VTA (K320E/WtDaN SNc 59.43 ± 4.01 % VTA 76.15 ± 9.47 %, K320E/K320EDaN SNc 
41.16 ± 4.62 % VTA 44.99 ± 1.93 %; two-way ANOVA, n.s.). After 20 months, TH-positive cells 
were lost to a similar extent in the SNc and the VTA of heterozygous K320E-TwinkleDaN mice 
(K320E/WtDaN SNc 60.50 ± 1.82 % VTA 56.68 ± 0.60 %, two-way ANOVA, n.s.). However, 
homozygous K320E-TwinkleDaN mice revealed an even stronger degeneration of DaNs in the 
VTA compared to the SNc (K320E/K320EDaN SNc 29.64 ± 4.18 % VTA 16.25 ± 2.76 %, two-
way ANOVA, P=0.0027). In addition, the VTA DaN number of 20-month-old homozygous 
K320E-TwinkleDaN mice was further decreased when compared to 10-month-old individuals 
(10 months 44.99 ± 1.93 %, 20 months 16.25 ± 2.76 %, unpaired t test, P=0.0001), whereas 
the amount of SNc DaNs did not significantly change (10 months 41.16 ± 4.62 %, 20 months 
29.64 ± 4.18 %, unpaired t test, n.s.). 
Decrease of mitochondrially deficient DaNs with age 
To confirm that neurodegeneration is linked to mitochondrial dysfunction, enzymatic 
cytochrome c oxidase (COX) activity was analyzed by histochemistry in midbrain sections of 
K320E-TwinkleDaN mice. 10-month-old hetero- and homozygous K320E-TwinkleDaN mice 
revealed blue, COX-deficient cells in both the SNc and the VTA (Fig. 3-13A, representative 
images). Interestingly, almost no blue cells could be detected after 20 months of age 
(Fig. 3-13B, representative images). For quantitative analysis, we further investigated the 
expression level of the mtDNA-encoded subunit I of COX (mtCOI), which is essential for COX 
activity and assembly, in the somata of DaNs in K320E-TwinkleDaN and control mice by 
immunofluorescent stainings (Fig. 3-14A). At the age of 5 months, fluorescent intensity of 
mtCOI was decreased in the somata of DaNs in the VTA of both hetero- and homozygous 
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K320E-TwinkleDaN mice when compared to control animals (Fig. 3-14B, control 388.67 ± 
16.63 %, K320E/WtDaN 275.46 ± 16.36 %, one-way ANOVA, P=0.0001; K320E/K320EDaN 
311.16 ± 21.03 %, one-way ANOVA, P=0.0062). The same was true for DaNs in the SNc 
(control 468.30 ± 23.20 %, K320E/WtDaN 266.32 ± 17.36 %, one-way ANOVA, P<0.0001; 
K320E/K320EDaN 329.92 ± 24.20 %, one-way ANOVA, P<0.0001). Interestingly, mtCOI 
expression was higher in VTA than in SNc DaNs for control animals (two-way ANOVA, 
P=0.0051), whereas there was no difference between the midbrain regions in the mutants. 
However, after 10 months, fluorescence intensity of mtCOI was only reduced in the VTA of 
homozygous K320E-TwinkleDaN mice (control 308.94 ± 12.22 %, K320E/WtDaN 268.40 ± 
23.04 %, one-way ANOVA, n.s.; K320E/K320EDaN 223.84 ± 14.06 %, one-way ANOVA, 
P=0.0033). No reduction in mtCOI expression became apparent for the SNc in any of the 
K320E-TwinkleDaN mice (control 276.91 ± 9.47 %, K320E/WtDaN 242.57 ± 15.64 %, one-way 
ANOVA, n.s.; K320E/K320EDaN 249.50 ± 21.06 %, one-way ANOVA, n.s.). Finally, hetero- and 
homozygous 20-month-old K320E-TwinkleDaN mice revealed similar mtCOI fluorescent 
intensities in DaNs of both VTA and SNc (VTA: control 309.43 ± 10.06 %, K320E/WtDaN 307.55 
± 17.30 %, one-way ANOVA, n.s.; K320E/K320EDaN 305.78 ± 19.17 %, one-way ANOVA, n.s.; 
SNc: control 295.90 ± 9.26 %, K320E/WtDaN 273.37 ± 16.99 %, one-way ANOVA, n.s.; 
K320E/K320EDaN 283.98 ± 15.09 %, one-way ANOVA, n.s.). 
Fig. 3-13 COX-deficient cells in the midbrain of 10-month-old K320E-TwinkleDaN. A) Cells with reduced COX 
activity (blue, highlighted by red arrowheads) were unmasked by COX-SDH staining in the midbrain of 10-months-
old hetero- and homozygous K320E-TwinkleDaN mice. B) After 20 months, almost no blue cells could be detected in 
mutant mice. Scale bars, 500 µm, single neuron presentation with 10 µm. 
 
 




Fig. 3-14 Higher proportion of DaNs with normal complex IV expression in K320E-TwinkleDaN mice with 
increasing age. A) The immunofluorescent signal of subunit I of complex IV (mtCOI; green) was analyzed in the 
cell bodies of TH-positive (red) neurons in the ventral tegmental area (VTA) and the substantia nigra pars compacta 
(SNc) of 5-, 10- and 20-month-old control, hetero- and homozygous K320E-TwinkleDaN mice. Scale bars, 50 µm. 
B) The normalized fluorescence intensity of the mtCOI-staining (norm. mtCOI FI) was reduced in both the VTA 
and the SNc of 5-month-old hetero- and homozygous K320E-TwinkleDaN mice (n = 57-96 cells of 5 mice each). At 
10 months of age, no difference could be found in the SNc. In contrast, TH-positive neurons in the VTA of 
homozygous K320E-TwinkleDaN animals showed decreased mtCOI fluorescent intensity (n = 67-84 cells of 3-5 
mice). After 20 months, the mtCOI signal was similar in both the SNc and the VTA of hetero- and homozygous 
K320E-TwinkleDaN mice when compared to control animals (n = 58-100 cells of 4-5 mice). Data are represented 
as mean ± SEM; ** p < 0.01, *** p < 0.001. 
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Dopaminergic SNc projections are less affected than VTA projections in K320E-
TwinkleDaN mice 
Despite the severe loss of midbrain DaNs, and especially those which are located in the SNc, 
the motor activity of K320E-TwinkleDaN mice was not impaired. Apparently, sufficient levels 
of dopamine are still released by dopaminergic projections in the dorsal striatum in order to 
maintain directed movement. To test this hypothesis, we performed TH-based 
immunohistochemical analyses of striatal sections in K320E-TwinkleDaN and control mice 
(Fig. 3-15A). The striatum was further divided into the dorsal caudate putamen (CPu), where 
most of the SNc DaNs are projecting to (Liss and Roeper 2008), and the nucleus accumbens 
(NAcc), which is mostly innervated by VTA DaNs (Miller et al. 1997; Watabe-Uchida et al. 
2012). Although DaN numbers were unaltered at this age, 5-month-old homozygous K320E-
TwinkleDaN mice revealed a slight decrease of the TH-positive fibre density in the CPu 
compared to control animals (Fig. 3-15B, control 100.00 ± 1.38 %, K320E/K320EDaN 82.66 ± 
5.71 %, one-way ANOVA, P=0.0240). In contrast, dopaminergic projections in the NAcc were 
not affected (control 100.00 ± 7.90 %, K320E/K320EDaN 95.35 ± 1.59 %, one-way ANOVA, 
n.s.). Due to the mild decrease of TH-positive fibres in the CPu, whole striatum quantification 
of fibre density was significantly reduced as well (control 100.00 ± 1.93 %, K320E/K320EDaN 
86.80 ± 4.13 %, one-way ANOVA, P=0.0430). There were no differences between 
heterozygous K320E-TwinkleDaN and control mice for any of the projection areas (Striatum 
Fig. 3-15 Severe loss of TH-positive fibre density in the NAcc of K320E-TwinkleDaN mice. A) 
Immunohistochemical staining of TH-positive fibres in the striatum of 5-, 10- and 20-month-old hetero- and 
homozygous K320E-TwinkleDaN and control mice. The striatum is divided into the dorsal caudate putamen (CPu) 
with dopaminergic projections originating from the SNc, and the ventral nucleus accumbens (NAcc), which is 
innervated by fibres of VTA DaNs. Scale bar, 2000 µm. B) Quantification of the TH-positive fibre density revealed 
an age-dependent loss in the NAcc of K320E-TwinkleDaN mice. Whereas at 5 months of age, a reduction of fibre 
density was only present in the CPu of homozygous K320E-TwinkleDaN mice, 10-month-old animals showed a loss 
of fibre density in the NAcc, which was even stronger when compared to the CPu. At the age of 20 months, the 
selective loss of TH-positive fibres in the NAcc became apparent in both hetero- and homozygous K320E-
TwinkleDaN animals (control mice n = 4-8, K320E/WtDaN mice n = 3-5, K320E/K320EDaN mice n = 4-5). # indicates 
significance compared to individuals of the prior time point. Data are represented as mean ± SEM; * p < 0.05, ** p 
< 0.01, *** p < 0.001, **** p < 0.0001, # p < 0.05, ## p < 0.01. 
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93.14 ± 4.11 %, CPu 92.10 ± 3.96 %, NAcc 95.27 ± 5.14 %, one-way ANOVA, n.s.). After 10 
months of age, the density of TH-positive fibres were still slightly affected in the CPu (control 
100.00 ± 0.70 %, K320E/K320EDaN 90.94 ± 1.92 %, one-way ANOVA, P=0.0213) and 
striatum (control 100.00 ± 0.57 %, K320E/K320EDaN 82.30 ± 4.43 %, one-way ANOVA, 
P=0.0045) of homozygous K320E-TwinkleDaN compared to control animals, but did not show 
further reduction compared to 5-month-old individuals (CPu, unpaired t test, n.s.; striatum, 
unpaired t test, n.s.). Interestingly, dopaminergic innervation of the NAcc was significantly 
reduced (control 100.00 ± 0.74 %, K320E/K320EDaN 68.62 ± 7.21 %, one-way ANOVA, 
P=0.0067) and even more affected when compared to the CPu (two-way ANOVA, P=0.0330). 
The reduction in the NAcc was further enhanced compared to 5-month-old individuals 
(K320E/K320EDaN 5 months NAcc 95.27 ± 5.14 %, 10 months 68.62 ± 7.21 %, unpaired t-
test, P=0.0146). Again, no differences were found between heterozygous K320E-TwinkleDaN 
and control mice for any of the observed projection areas (striatum 92.54 ± 1.39 %, CPu 97.23 
± 1.03 %, NAcc 85.23 ± 4.93 %, one-way ANOVA, n.s.). At the age of 20 months, heterozygous 
K320E-TwinkleDaN mice showed a decreased fibre density in the NAcc (control 100.00 ± 1.80 
%, K320E/WtDaN 53.92 ± 4.95 %, one-way ANOVA, P<0.0001), but not in the CPu (control 
100.00 ± 1.51 %, K320E/WtDaN 94.02 ± 2.99 %, one-way ANOVA, n.s.) when compared to 
control animals. Due to the decrease of TH-positive fibres in the NAcc, whole striatum 
quantification of fibre density was significantly reduced as well (control 100.00 ± 1.52 %, 
K320E/WtDaN 84.07 ± 3.14 %, one-way ANOVA, P=0.0333). Homozygous K320E-
TwinkleDaN mice revealed a significant fibre loss in all three projection areas (striatum, control 
100.00 ± 1.52 %, K320E/K320EDaN 64.36 ± 8.90 %, one-way ANOVA, P<0.0001, CPu control 
100.00 ± 1.51 %, K320E/K320EDaN 77.23 ± 6.92 %, one-way ANOVA, P=0.0017, NAcc 
control 100.00 ± 1.80 %, K320E/K320EDaN 33.34 ± 7.84 %, one-way ANOVA, P<0.0001). 
However, the NAcc showed a stronger decrease in TH-positive fibres than the CPu for both 
hetero- and homozygous K320E-TwinkleDaN mice (K320E/WtDaN two-way ANOVA, 
P=0.0006; K320E/K320EDaN two-way ANOVA, P=0.0175). Moreover, the loss of the 
dopaminergic projections in the NAcc of both mutants was stronger when compared to 10-
month-old individuals (K320E/WtDaN 10 months 85.23 ± 4.93 %, 20 months 53.92 ± 4.95 %, 
unpaired t test, P=0.0021; K320E/K320EDaN 10 months 68.62 ± 7.21 %, 20 months 33.34 ± 
7.84 %, unpaired t test, P=0.0131). 
K320E-TwinkleDaN mice show depressive-like behavior 
The loss of VTA DaNs as well as their projections to the NAcc may cause a depression-related 
phenotype (Brown et al. 2012; Furlanetti et al. 2016). In order to inspect our K320E-
TwinkleDaN mice for depressive-like behavior, the tail suspension test as well as the sugar 
preference test were carried out initially (Fig. 3-16A). No difference was found in the body 
weight between the genetic groups at 10 and 20 months of age (Fig. 3-16B, 10 months: control 
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29.70 ± 2.15 g, K320E/WtDaN 30.63 ± 1.62 g, K320E/K320EDaN 33.99 ± 1.89 g, one-way 
ANOVA, n.s.; 20 months: control 32.08 ± 1.56 g, K320E/WtDaN 30.45 ± 1.51 g, 
K320E/K320EDaN 32.49 ± 2.17 g, one-way ANOVA, n.s). Neither 10- nor 20-month-old 
K320E-TwinkleDaN mice showed an alteration in the relative immobility time when compared 
to control animals (10 months: control 100.00 ± 7.91 %, K320E/WtDaN 91.06 ± 8.09 %, 
K320E/K320EDaN 94.55 ± 5.00 %, one-way ANOVA, n.s.; 20 months: control 100.00 ± 6.29 
%, K320E/WtDaN 100.26 ± 9.26 %, K320E/K320EDaN 112.09 ± 8.71 %, one-way ANOVA, 
n.s.). 
The sugar preference test (Fig. 3-16C) revealed a significant preference for the 5% sucrose 
solution compared to normal tap water in all genetic groups at the age of 10 months 
(Fig. 3-16D, control: water 3.51 ± 0.27 mL, 5% sucrose 15.05 ± 1.57 mL, two-way ANOVA, 
P<0.0001; K320E/WtDaN: water 2.65 ± 0.22 mL, 5% sucrose 11.48 ± 1.21 mL, two-way 
Fig. 3-16 Decreased sugar consumption but unaltered immobility time of K320E-TwinkleDaN mice. A) 
Exemplary representation of a test mouse during the tail suspension test. B) Quantitative data showed no 
differences in the body weight of K320E-TwinkleDaN mice compared to control animals. However, the time to reach 
immobility did not significantly differ between K320E-TwinkleDaN and control mice for both ages (n = 10-15). C) 
Sugar preference test setup presenting an experimental, marked cage equipped with one bottle of tap water and 
one bottle of 5% sucrose solution. D) Quantitative data revealed sugar preference for all animals, but reduced 
sucrose consumption of both hetero- and homozygous 20-month-old K320E-TwinkleDaN mice compared to control 
animals. At the age of 10 months, homozygous K320E-TwinkleDaN mice already showed less sucrose consumption 
when compared to control animals (n = 10-15). Data are represented as mean ± SEM; * p < 0.05, ** p < 0.01, *** p 
< 0.001, **** p < 0.0001. 
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ANOVA, P<0.0001; K320E/K320EDaN: water 3.43 ± 0.27 mL, 5% sucrose 9.27 ± 1.13 mL, 
two-way ANOVA, P=0.0006). The same was true for 20-month-old animals (control: water 3.08 
± 0.38 mL, 5% sucrose 16.36 ± 2.15 mL, two-way ANOVA, P<0.0001; K320E/WtDaN: water 
3.72 ± 0.47 mL, 5% sucrose 11.07 ± 0.87 mL, two-way ANOVA, P<0.0001; K320E/K320EDaN: 
water 3.83 ± 0.51 mL, 5% sucrose 9.88 ± 0.80 mL, two-way ANOVA, P=0.0003). However, 
relative as well as normalized sucrose consumption was significantly reduced in 10-month-old 
homozygous K320E-TwinkleDaN mice when compared to control animals (control 100.00 ± 
11.18 %, K320E/K320EDaN 59.21 ± 9.33 %, one-way ANOVA, P=0.0302), in contrast to 
heterozygous mutants (K320E/WtDaN 81.33 ± 11.46 %, one-way ANOVA, n.s.). After 20 
months of age, both hetero- and homozygous K320E-TwinkleDaN animals showed a decrease 
in sucrose consumption compared to control mice (control 100.00 ± 13.23 %, K320E/WtDaN 
66.26 ± 6.57 %, one-way ANOVA, P=0.0430; K320E/K320EDaN 58.25 ± 5.61 %, one-way 
ANOVA, P=0.0040). 
Discussion 
In this study, the impact of the increased accumulation of mtDNA deletions in DaNs on 
neuronal survival, mitochondrial function and behavior was investigated by generating mice, 
which express a mutated variant of Twinkle (K320E) exclusively in DaNs. As a first step, the 
voluntary movement behavior of hetero- and homozygous K320E-TwinkleDaN mice was 
investigated, showing no differences compared to control animals even at the age of 20 months 
(Fig. 3-11B). However, stereological quantification of midbrain DaNs revealed a severe 
neurodegeneration in both mutant genotypes, whereas it was most pronounced in 
homozygous expressers (Fig. 3-12B). Region-specific differentiation further disclosed that 
neurodegeneration was not selective for the SNc (Fig. 3-12C). In PD, motor symptoms start to 
arise when ~30-50% of SNc DaNs are gone (Obeso et al. 2017). PD-related mouse models 
show impaired motor activity at a DaN loss rate of ~40-55% upon genetic interference 
(Wakamatsu et al. 2007; Lu et al. 2009; Chen et al. 2012; Rousseaux et al. 2012) and ~60% 
when pharmacologically induced, respectively (Crocker et al. 2003; Becker et al. 2018; Zeng 
et al. 2018). We have already shown that MitoPark mice, which are lacking the TFAM protein, 
essential for transcription and maintenance of the mtDNA, exclusively in DaNs, present a motor 
decline being visible at the age of 14 weeks and even more severe at 20 weeks, when ~68% 
of SNc DaNs are lost due to a detrimental imbalance in the mitochondrial redox system (Ricke 
et al. 2020). Homozygous K320E-TwinkleDaN mice, however, revealed normal motor function 
with only ~30% of neurons left. Golden et al. (2013) already reported about the compensatory 
capacity of SNc DaNs. After the early developmental destruction of DaNs, 10% of SNc DaNs 
were sufficient to ensure movement control, probably due to an enhanced sensitization of 
striatal dopamine receptors. Nevertheless, to our knowledge, homozygous K320E-
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TwinkleDaN mice are the first PD-related mouse model showing motor behavior compensation 
in aging mice despite the degeneration of SNc DaNs by ~70%. 
Next, we wanted to investigate if the loss of DaNs in K320E-TwinkleDaN mice has been 
induced by mitochondrial dysfunction upon impairment of the mtDNA replication machinery. 
Indeed, COX-deficient cells as well as reduced complex IV expression levels were found in 
both hetero- and homozygous animals at the age of 5 and 10 months (Fig. 3-13 and 3-14B). 
Interestingly, we observed a decline in the number of mitochondrial-deficient DaNs with 
increasing age. Eventually, at the age of 20 months, DaNs expressed normal complex IV levels 
in both SNc and VTA, indicating that the surviving DaN populations successfully adapted to 
the impaired mtDNA replication. One adaptation could be an extremely efficient mitochondrial 
quality control mechanism, which enables the surviving DaN populations to both detect and 
remove dysfunctional mitochondria and those which surpassed a certain threshold of mtDNA 
deletions, respectively. 
In PD as well as related animal models, the loss of SNc DaNs is accompanied by the reduced 
innervation of the dorsal striatum, the CPu, whereas the ventral NAcc is spared (Miller et al. 
1997; Ekstrand et al. 2007; Villalba et al. 2009; Boix et al. 2015). In fact, it has been shown 
that dopaminergic striatal nerve terminals degenerate even before their cell bodies (Chu et al. 
2012; Kordower et al. 2013). To examine to what extent striatal innervation is affected in 
K320E-TwinkleDaN mice, densitometric analysis of dopaminergic terminals was performed. 
Surprisingly, 77% of striatal fibres were still preserved in the CPu of homozygous mutants 
despite the severe neurodegeneration (Fig. 3-15B), which is sufficient to maintain voluntary 
movement control. This imbalance between the number of SNc DaNs and its projections points 
to compensatory axonal sprouting. Given the unique morphological architecture of these 
neurons, any additional spread of their axon terminals would be astonishing. The axon of a 
single SNc DaN is estimated to give rise to up to 245,000 synapses in rats and 2.4 million 
synapses in humans, respectively (Bolam and Pissadaki 2012). The massive arborization of 
concurrently unmyelinated axons (Braak et al. 2004) is accompanied by an extremely high 
energetic demand in order to maintain ion homeostasis for action potential propagation and 
synaptic processes (Pacelli et al. 2015). In our homozygous K320E-TwinkleDaN mice, the 
surviving ~30% of SNc DaNs consequently have to deal with even higher energetic demands 
and therefore rely on the increased supply of functioning mitochondria. Again, efficient 
mitochondrial quality control is of great importance in these neurons. Furthermore, the 
enhanced synaptic energy supply of dopaminergic terminals in homozygous K320E-
TwinkleDaN mice might be further counteracted by an increased mobilization of astrocytes, 
which feed synapses with energy substrates from blood vessels on demand (Tsacopoulos and 
Magistretti 1996; Simard et al. 2003; Stobart and Anderson 2013). 
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To further unravel compensatory adaptations on a cellular level as well as to confirm the 
presence of mtDNA deletions in the surviving population of SNc DaNs, transcriptomic analysis 
of isolated DaNs will be performed after DAT-specific fluorescent activated cell sorting. 
Increased axonal arborization will be analyzed in future experiments by fluorescent labeling of 
single SNc DaNs and subsequent morphological analysis using acute midbrain slices of 
20-month-old K320E-TwinkleDaN and control mice. At the same time, electrophysiological 
recordings will be performed to unmask potential adaptations of single SNc DaNs in order to 
preserve synaptic activity in the risen amount of axon terminals per cell. It is likely, that 
surviving neurons might disclose increased burst activities as observed in PD patients 
(Zaghloul et al. 2009). 
Noteworthy, VTA DaNs were additionally affected besides the SNc in K320E-TwinkleDaN mice 
(Fig. 3-12B). Interestingly, the number of VTA DaNs was even lower compared to the SNc in 
homozygous mutants at the age of 20 months. Administration of the ubiquitin proteasome 
system inhibitor lactacystin, which has been used to model nigrostriatal degeneration in rats, 
was reported to decrease the number of VTA DaNs by ~32%, whereas loss of SNc DaNs was 
~54% (Harrison et al. 2016). Interestingly, overexpression of the human amyloid precursor 
protein led to an age-dependent loss of VTA DaNs, whereas the SNc was spared (Nobili et al. 
(2016). Hence, to our knowledge, K320E-TwinkleDaN mice are the first PD-related model 
revealing a similar (heterozygous) and even enhanced (homozygous) loss rate of VTA DaNs. 
In contrast to projections from SNc DaNs, fibres originating from the VTA were severely 
reduced (Fig. 3-15B). It has been shown that both the loss of VTA DaNs and dopaminergic 
fibres in the NAcc lead to depressive behavior (Brown et al. 2012; Furlanetti et al. 2016; Nobili 
et al. 2017). We therefore verified, if this behavior is manifested in our K320E-TwinkleDaN 
mice in consequence of the loss of the mesolimbic pathway. No abnormalities became 
apparent in the tail suspension test (Fig. 3-16B), whereas the test’s outcome could be 
influenced by its dependence on the stress condition as well as motor performance, as even 
increased spontaneous motor activity was observed for several mutant mice. In addition, the 
loss of VTA DaNs might have modified the activity of the amygdala, which is innervated by the 
VTA and controlling anxiety behavior (Brinley-Reed and McDonald 1999; Bissière et al. 2003; 
Kröner et al. 2005). This could have led to decreased fear in K320E-TwinkleDaN mice which 
in turn might have distorted the measured immobility time. However, depressive-like behavior 
was detected by reduced sugar preference in K320E-TwinkleDaN mice (Fig. 3-16D). 
Furthermore, social behavior in K320E-TwinkleDaN mice could be altered, since optogenetic 
approaches have highlighted the importance of VTA DaNs projecting to the medial prefrontal 
cortex for social interaction in mice (Chaudhury et al. 2013; Friedman et al. 2014). Social 
behavior will therefore be assessed by performing the three chamber test. 
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Here, we present the first genetic animal model for depression that is induced by the loss of 
the dopaminergic mesolimbic pathway upon mitochondrial dysfunction. Moreover, our data 
showing preserved motor function and CPu innervation despite severe SNc DaN degeneration 
in homozygous K320E-TwinkleDaN mice could be of great importance. Understanding, how 
small amounts of surviving SNc DaNs can counteract mtDNA deletions as well as 
mitochondrial dysfunction with increasing age, and maintain synaptic processes in the dorsal 
striatum although facing an energetic mammoth task, might help to find new pathways to 
prevent the loss of SNc DaNs and motor symptoms in PD. 
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Here, the results presented in each of the three manuscripts will be discussed in a coherent 
manner, in accordance with the key questions of the thesis. In particular, the first chapter 
focuses on the differences between distinct dopaminergic populations upon the loss of TFAM 
and thereby compares the outcomes of the first (3.1, Ricke, Paß et al. 2020) and the second 
manuscript (3.2, Paß et al. 2020). The second chapter, in turn, contrasts the well-known 
MitoPark model with our newly generated K320E-TwinkleDaN model in consideration of the data 
presented in the first and the third manuscript (3.3, Paß et al. ready for submission). 
4.1 DaN Subpopulations Are Differently Affected Upon TFAM Depletion 
In the MitoPark mouse model, midbrain SNc DaNs are severely affected upon the loss of 
TFAM, characterized by striatal denervation as well as neurodegeneration starting at the age 
of 12 weeks (Fig. 3-1A-D), as initially shown (Ekstrand et al. 2007). Breakdown of the 
nigrostriatal pathway consequently leads to progressive decline in motor activity (Fig. 3-1E). 
Conversely, VTA DaNs are relatively spared from neurodegeneration with more or less 
preserved striatal projections (Fig. 3-1A-D). One may argue that the differential susceptibility 
results from an incomplete penetrance of DatCre-mediated recombination in VTA DaNs and 
that TFAM inactivation is consequently absent in the surviving DaN population. However, both 
SNc and VTA DaNs consistently reveal DatCre-mediated recombination at E15.5, represented 
by YFP expression (Fig. 3-6), and no TH-positive but YFP-negative cells are apparent. In 
addition, at 12 weeks of age, SNc and VTA DaNs equally disclose mitochondrial impairment 
shown by low COX activity as well as reduced COXI expression (Fig. 3-2). This underscores 
the significance of cell type-specific factors concerning the selective vulnerability of SNc DaNs 
towards mitochondrial dysfunction. 
In the OB of MitoPark mice, DaNs present low COX activity only at a relatively late age of 
30 weeks (Fig. 3-7E). In contrast to the midbrain, where TFAM KO takes place during 
embryonic development at E15.5, in OB DaNs this occurs only at around two weeks after birth 
(P14) (Fig. 3-6). However, OB DaNs show mitochondrial impairment as a consequence after 
approximately 28 weeks, whereas midbrain DaNs reveal respiratory chain deficits already 
13 weeks after the KO of TFAM. In addition, COX-deficient cells appear to be much less 
frequent in the OB when compared to midbrain. Thus, these distinct subpopulations of DaNs 
respond very differently to inactivation of mitochondrial gene expression. 
While mitochondrial impairment of midbrain DaNs is followed by severe neurodegeneration in 
the SNc after 20 weeks, quantification of DaNs in the OB of MitoPark mice only revealed a 
reduced number of SCs after 30 weeks of age, whereas the amount of LACs did not change 
at all (Fig. 3-9C). Investigation at more extended time points was not possible due to the severe 
motor symptoms of these animals. It has to be noted, that regarding the in situ analysis it is 
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unclear whether COX deficiency in OB neurons of MitoPark mice is restricted to SCs, thereby 
explaining the decreased numbers of only this dopaminergic subtype, or whether it occurs to 
the same extent in both OB DaN populations. 
OB as well as VTA DaNs differ from their vulnerable counterparts in the SNc regarding distinct 
cellular characteristics. Though each of these dopaminergic subtypes are reported to be 
pacemakers, VTA and OB DaNs mainly use sodium currents for autonomous oscillatory 
activity (Pignatelli et al. 2005; Khaliq and Bean 2010; Pignatelli and Belluzzi 2017). Conversely, 
pacemaking activity in SNc DaNs is associated with Ca2+ oscillations which are mainly 
provided by Cav1 (Chan et al. 2007), but also T-type (Guzman et al. 2018; Tabata et al. 2018) 
and R-Type (Benkert et al. 2019) Ca2+ channels, which was reported to be accompanied with 
enhanced oxidative stress (Guzman et al. 2010). Increased intrinsic Ca2+ levels are therefore 
thought to be a critical factor concerning the susceptibility of SNc DaNs to mitochondrial 
dysfunction (Surmeier, Guzman, and Sanchez-Padilla 2010; Surmeier et al. 2012; Duda, 
Potschke, and Liss 2016). In MitoPark mice, it has been shown that decreased Ih, which is 
associated with a rise in intracellular Ca2+ (Carbone et al. 2017), and upregulation of Cav1 
channel subunits are preceding the death of SNc DaNs (Branch et al. 2016), which might be 
compensatory mechanisms to preserve neuronal function. This suggest a vicious circle for 
SNc DaNs with Ca2+ playing a crucial role. We could show that the mitochondrial redox system 
of MitoPark SNc DaNs is disturbed just before the onset of neurodegeneration, in contrast to 
spared VTA DaNs. Intriguingly, reducing both cytosolic as well as mitochondrial Ca2+ influx, 
normalizes the redox status of SNc DaNs (Fig. 3-4B). Ca2+ influx into SNc DaNs is 
counterbalanced by a high mitochondrial inner membrane potential even in the presence of 
mitochondrial dysfunction (Fig. 3-5D), but this might consequently further contribute to the 
detrimental imbalance in the mitochondrial redox system, which in turn eventually leads to 
neuron death. In order to prevent this, the presence of intracellular buffering proteins appear 
to be of great importance. In accordance with recent data supporting the neuroprotective role 
of the Ca2+ binding protein calbindin in MPTP-treated monkeys (Inoue et al. 2019), we found 
an age-dependent increase of the percentage of calbindin-expressing neurons within the 
surviving SNc DaNs of MitoPark mice (Fig. 3-3B). However, the mechanism of how calbindin 
might protect DaNs from cell death upon mitochondrial impairment is not fully understood and 
its potential neuroprotective effect still has to be investigated more closely. 
Besides the electrophysiological differences, SNc DaNs further reveal a unique axon 
morphology. In contrast to VTA as well as OB DaNs, where SCs are even anaxonic (Pignatelli 
and Belluzzi 2017), DaNs originating from the SNc show an extremely large arborization 
including ~100,000-250,000 synapses in rats (Bolam and Pissadaki 2012), which implies an 
extremely high energetic demand already under physiological conditions (Pacelli et al. 2015). 
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Thus, SNc DaNs are particularly susceptible to additional stressors, especially when impairing 
energy supply, such as the loss of TFAM followed by mitochondrial dysfunction. 
However, a higher vulnerability because of enhanced energetic demands or a special 
electrophysiological equipment might not apply to SCs in the OB, which are slightly reduced in 
numbers in 30-week-old MitoPark mice. LACs, which are spared, have an axon and show an 
even higher firing rate than SCs (Galliano et al. 2018). Thus, it is more likely that the lower 
number of SCs is due to other factors. In contrast to LACs, SCs are continuously generated 
via adult neurogenesis, already pointing to an intrinsic and permanently high susceptibility to 
cell death (Kosaka et al. 1987; Vergano-Vera et al. 2006; Bovetti et al. 2009; Kosaka and 
Kosaka 2009; Galliano et al. 2018). Although mobilization of progenitor cells in the SVZ of 
30-week-old MitoPark mice is indeed increased (Fig. 3-10C-D), indicating a compensatory 
response due to increased death of SCs upon mitochondrial dysfunction, the amount of 
progenitor cells present in the OB is stable (Fig. 3-10A-B). Since it is not known when Dat 
expression is initiated during the development of OB progenitor cells, it is possible that new 
but not fully maturated neurons are more vulnerable to the TFAM KO and die during 
differentiation into a dopaminergic phenotype or even before reaching the OB along the RMS. 
Despite the relatively low impact of TFAM depletion on OB DaNs, the moderately reduced 
numbers of SCs are associated with a severely impaired olfactory behavior (Fig. 3-8A-D) of 
MitoPark mice at the age of 30 weeks. This may be due to temporal shifts in mitral cell activity 
(Rebello et al. 2014) caused by the lower number or functional changes in SCs. However, loss 
of olfaction in MitoPark mice might be also directly linked to the preceding loss of the 
nigrostriatal system as well as VTA neurons, which have been shown to possess direct 
projections to higher olfactory brain regions, such as the piriform cortex and the olfactory 
tubercle (Hoglinger et al. 2015; Xiong and Wesson 2016; Zhang, Liu, et al. 2017; Zhang, 
Zhang, et al. 2017). 
4.2 Comparison between MitoPark and K320E-TwinkleDaN Mice 
The MitoPark mouse presents a well-established model in order to investigate potential 
mechanisms contributing to the selective loss of SNc DaNs and motor impairment upon 
mitochondrial dysfunction in PD. Regarding the disease course in humans, however, these 
animals reveal a very rapid and early-onset recapitulation of the key pathology. In addition, 
progressive loss of TFAM is most likely not reflecting the initial cause of mitochondrial 
dysfunction in SNc DaNs of PD patients. Since the elevated accumulation of deleted mtDNA 
molecules in SNc DaNs with increasing age has been associated with mitochondrial 
dysfunction and PD development (Bender et al. 2006; Kraytsberg et al. 2006; Elstner et al. 
2011), K320E-TwinkleDaN mice were generated to investigate the impact of accumulating 
mtDNA deletions on DaN survival and its contribution to the development of a PD-like 
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phenotype. In the following, these two mouse models are compared concerning mitochondrial 
dysfunction, DaN survival, striatal innervation and motor impairment. 
4.2.1 Mitochondrial Dysfunction 
COX-deficient cells are consistently found in both the SNc and VTA of MitoPark mice at the 
early age of 12 weeks (Fig. 3-2C). In hetero- and homozygous K320E-TwinkleDaN mice, blue 
cells become visible in the SNc and VTA only after 10 months (Fig. 3-13A), but cells with low 
COX activity appear to be much less frequent than in the midbrain of MitoPark mice. TFAM is 
not only important for packaging, but also necessary for mtDNA transcription and is essential 
for the maintenance of mtDNA (Gustafsson, Falkenberg, and Larsson 2016). The disruption of 
Tfam in midbrain DaNs of MitoPark mice is accompanied with rapidly reduced mtDNA 
expression (Ekstrand et al. 2007) and causes the progressive loss of mtDNA encoded 
transcripts. Since the catalytic subunits of COX are encoded by mtDNA, COX deficiency is 
inevitable and observed in cells located in the SNc and VTA after 12 weeks of age. In contrast 
to the progressive depletion of mtDNA in the MitoPark model, various cell types have been 
shown to accumulate mtDNA deletions upon expression of Twinkle carrying the K320E 
mutation, also followed by COX deficiency (Baris et al. 2015; Weiland et al. 2018; Holzer et al. 
2019). It is therefore likely that midbrain DaNs of hetero- and homozygous K320E-TwinkleDaN 
mice reveal accumulations of mtDNA deletions over time as well, but analysis of isolated DaNs 
will be necessary to confirm this. Accumulating deleted molecules upon impaired mtDNA 
replication is a stochastic event. The time point, at which the threshold for tolerable amounts 
of mtDNA deletions, which is thought to be around 60% of deleted molecules (Picard, Vincent, 
and Turnbull 2016), is exceeded and leads to COX deficiency, consequently varies from cell 
to cell. This is in line with the smaller number of blue cells in the SNc and VTA of 10-month-old 
K320E-TwinkleDaN mice compared to MitoPark animals. The exact mechanism, how K320E 
impairs the function of TWINKLE and how this contributes to the formation of mtDNA deletions, 
is still not known. According to the equivalent mutation found in patients with SANDO syndrome 
causing PEO, the helicase activity might be impaired by K320E through a stalled replication 
process, thereby promoting large mtDNA deletions to accumulate (Zeviani et al. 1989; 
Suomalainen et al. 1992; Suomalainen et al. 1997). Correspondingly, it is likely that K320E 
also belongs to mutations of the primase-like domain, which are suggested to disrupt oligomer 
formation of TWINKLE (Peter et al. 2019). 
In accordance with the COX-SDH assay, DaNs located in the SNc and VTA present equally 
reduced complex IV expression in 12-week-old MitoPark mice (Fig. 3-2A-B), represented by 
COXI fluorescence intensity. In K320E-TwinkleDaN mice, however, the proportion of midbrain 
DaNs with reduced complex IV expression decreases with age (Fig. 3-14A-B). Whereas SNc 
as well as VTA DaNs show low COXI signal in both hetero- and homozygous 
K320E-TwinkleDaN mice at 5 months of age, reduced complex IV expression in 10-month-old 
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animals is only found in VTA DaNs of homozygous expressers. Eventually, after 20 months of 
age, normal levels of complex IV are present in both midbrain DaN populations. With regard 
to neurodegeneration being first detected in K320E-TwinkleDaN mice at 10 months of age 
(Fig. 3-12B-C), we hypothesize that DaNs showing decreased complex IV expression in 
5-month-old animals are already perished at later ages and that surviving DaNs successfully 
adapted to the impaired mtDNA replication upon K320E mutation expression, respectively. 
This is underscored by the nearly complete absence of COX-deficient cells in the midbrain of 
K320E-TwinkleDaN mice after 20 months of age (Fig. 3-13B). 
Thus, impairment of mtDNA replication allows DaNs to adapt, in contrast to rapid mtDNA as 
well as mtRNA depletion upon loss of TFAM, and therefore prevents mitochondrial dysfunction 
and eventually neuron death. One adaption of surviving DaNs might be an extremely efficient 
mitochondrial quality control. A fast detection and subsequent removal of defective 
mitochondria and those which surpass a certain threshold of deleted molecules, respectively, 
via mitophagy would be essential to maintain energy supply and thereby neuronal activity in 
these cells. Accordingly, a beneficial effect of mitophagy stimulation on reducing mtDNA 
deletion load has been reported in Drosophila melanogaster (Kandul et al. 2016). Conversely, 
reducing mitophagy favors the accumulation of mutant mtDNA molecules in C. elegans 
(Gitschlag et al. 2016). The importance of mitophagy for DaNs, especially in the SNc, is 
underscored by PINK1 and Parkin mutations causing early-onset PD with selective loss of SNc 
DaNs (Kilarski et al. 2012; Truban et al. 2017). In addition, DaN-specific autophagy-deficient 
mice reveal neurodegeneration exclusively in the SNc, accompanied with Lewy pathology and 
motor deficits (Sato et al. 2018). It might further be possible that surviving DaNs are able to 
detect the deletion load within mitochondria and rather selectively degrade deleted molecules 
via the formation of MDVs in order to prevent the loss of whole organelles. Keeping deleted 
mtDNA molecules at low levels might be assisted by increasing mtDNA copy number, as 
previously indicated (Trifunovic et al. 2004; Perier et al. 2013). Thereby, sufficient numbers of 
wild-type mtDNA could be maintained, as was reported in SNc DaNs of healthy individuals 
during aging (Dolle et al. 2016). 
4.2.2 Neurodegeneration 
The consistent mitochondrial dysfunction of midbrain DaNs in MitoPark mice is followed by the 
selective loss of SNc DaNs, according to the pathology in PD patients, at 20 weeks of age 
(Fig. 3-1D). There is no indication for neurodegeneration of DaNs in hetero- and homozygous 
K320E-TwinkleDaN mice of the same age (Fig. 3-12B-C). Intriguingly, 10-month-old K320E-
TwinkleDaN mice reveal DaN loss occurring to a similar extent in SNc and VTA, and 
homozygous expressers are more affected than heterozygous animals. At 20 months of age, 
homozygous K320E-TwinkleDaN mice show further degeneration of DaNs, with the number of 
DaNs in the VTA being even lower than in the SNc. Thus, there is no selective death of SNc 
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DaNs in the K320E-TwinkleDaN model. Like for the MitoPark model, one may argue that the 
surviving DaNs in the midbrain of K320E-TwinkleDaN mice do not express the K320E mutation 
as a result of incomplete DatCre-mediated recombination. However, this seems rather unlikely, 
since DatCre-mediated recombination represented by YFP expression is consistently present 
in both midbrain neuron populations during embryonic development (Fig. 3-6), and the same 
DatCre line was used for generating K320E-TwinkleDaN mice. 
Depending on the perspective, the similar degeneration of SNc and VTA DaNs in our K320E-
TwinkleDaN mice either point to enhanced VTA DaN vulnerability or decreased SNc DaN 
vulnerability. When comparing with the selective loss of SNc DaNs presented in MitoPark mice 
or in other numerous genetically as well as pharmacologically induced PD mouse models and 
with the well-established susceptibility of SNc DaNs to mitochondrial dysfunction, it is more 
likely that, in our model, SNc DaNs indeed successfully prevent death for a period of time by 
unknown compensatory mechanisms upon slow accumulation of mtDNA defects. 
4.2.3 Striatal Fibre Density 
In MitoPark mice, the progressive degeneration of SNc DaNs is accompanied by the loss of 
corresponding fibres projecting to the dorsal striatum (CPu, Fig. 3-1A). Moreover, striatal 
denervation of the CPu starts at about 12 weeks of age (Fig. 3-1C), indicating that axon 
terminals of SNc DaNs even die before their cell bodies. In line with this, reduced neuritic 
branching has been recently reported to precede neuron death of MitoPark SNc DaNs (Lynch 
et al. 2018). In fact, striatonigral dying-back of DaNs is believed to occur in PD patients as well 
(Cheng, Ulane, and Burke 2010; Chu et al. 2012; Kordower et al. 2013). Like in patients, fibres 
of VTA DaNs projecting to the NAcc are more or less preserved in the MitoPark model 
(Fig. 3-1B). Hetero- as well as homozygous K320E-TwinkleDaN mice show similarly severe 
degeneration of SNc and VTA DaNs. Intriguingly, striatal projections are differently affected 
(Fig. 3-15A-B). Whereas only ~33% (~54%) of dopaminergic fibres are left in the VTA-
innervated NAcc, ~77% (~94%) of projections that originate from the SNc are still preserved 
in homozygous (heterozygous) K320E-TwinkleDaN mice at the age of 20 months. The severe 
loss of VTA DaNs as well as corresponding projections in the ventral striatum is associated 
with depressive-like behavior in both mutant genotypes, presented by reduced sugar 
preference (Fig. 3-16D), and thereby supports the contribution of the impaired dopaminergic 
mesolimbic pathway to PD-related depression. 
Astoundingly, while only ~30% of SNc DaNs are left in 20-month-old homozygous K320E-
TwinkleDaN mice, ~77% of striatal fibres in the corresponding projection area are still preserved. 
This imbalance points to compensatory axonal sprouting, which would imply an enormous 
energetic task with regard to the massive axonal arborization and energetic needs these 
neurons already have (Bolam and Pissadaki 2012; Pacelli et al. 2015). Thus, the small 
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population of surviving SNc DaNs relies on a fast and proper axonal transport machinery, 
which is affected in MitoPark mice (Sterky et al. 2011), in order to ensure synaptic supply with 
a large number of functioning mitochondria. This further underscores the importance of 
efficient mitochondrial quality control. Correspondingly, generation of new mitochondria is of 
great importance as well. In fact, increased levels of prokineticin-2 are found in PD patients as 
well as MitoPark mice and prokineticin-2 has been shown to slow down DaN degeneration by 
promoting mitochondrial biogenesis (Gordon et al. 2016). Moreover, compensatory responses 
could arise in the dopaminergic environment, such as enhanced mobilization of astrocytes in 
the dorsal striatum, which feed presynaptic terminals of SNc DaNs with energy substrates from 
blood vessels (Tsacopoulos and Magistretti 1996; Simard et al. 2003; Stobart and Anderson 
2013) and consequently support the maintenance of neuronal activity. 
Besides energetic requirements, electrophysiological properties might change as well upon 
increased axonal arborization. Surviving SNc DaNs could thereby show increased burst 
activity, as it is also observed in PD patients (Zaghloul et al. 2009), in order to ensure action 
potential propagation throughout the more branched axon. It is likely that in this case, ion 
channel physiology is modified as well to enable increased neuronal activity. In MitoPark mice, 
for instance, decreased Ih and upregulation of Cav1 channel subunits are preceding the death 
of SNc DaNs (Branch et al. 2016). Enhanced bursting of the surviving SNc DaNs of K320E-
TwinkleDaN mice would imply even higher Ca2+ oscillations and would require further buffering 
of intracellular Ca2+ levels through Ca2+-binding proteins or mitochondria, assuming that 
pacemaker activity in the surviving SNc DaN population is still primarily dependent on Cav 
channels. Furthermore, K-ATP channel expression or channel sensitivity could be decreased 
in order to prevent breakdown of SNc DaN activity following the enhanced energetic demands, 
as previously shown (Liss et al. 2005). Additional investigations are necessary to confirm 
compensatory axonal sprouting as well as electrophysiological modifications of surviving SNc 
DaNs in order to preserve striatal DA supply in K320E-TwinkleDaN mice. 
4.2.4 Motor Impairment 
The progressive loss of the dopaminergic nigrostriatal pathway in MitoPark mice is 
accompanied with a continuous decline in motor activity, becoming first apparent at 14 weeks 
of age (Fig. 3-1E). Reduced motor performance is explained by the corresponding lack of 
striatal DA, as previously shown (Ekstrand et al. 2007), which is essential for voluntary 
movement control (Wichmann and DeLong 1996). Despite the severe loss of SNc DaNs, 
K320E-TwinkleDaN mice, however, still reveal normal motor behavior at the age of 20 months 
(Fig. 3-11B). In PD, motor symptoms start to occur when ~30-50% of SNc DaNs are perished 
(Obeso et al. 2017). PD-related mouse models reveal a comparable range, with impaired 
motor performance at a DaN loss rate of ~40-55% upon genetic interference (Wakamatsu et 
al. 2007; Lu et al. 2009; Chen et al. 2012; Rousseaux et al. 2012) and ~60% when 
 
Discussion   
 
111 
pharmacologically induced (Crocker et al. 2003; Becker et al. 2018; Zeng, Geng, and Jia 2018). 
Given that already ~70% of SNc DaNs are lost in homozygous K320E-TwinkleDaN mice, absent 
motor impairment is surprising. In contrast to other PD-related mouse models, however, SNc 
DaN projections of K320E-TwinkleDaN mice are only mildly affected. Thus, the relatively 
preserved innervation of the dorsal striatum by dopaminergic projections is likely to maintain 
sufficient DA levels to ensure motor activity in these animals. 
4.3 Clinical Relevance 
The MitoPark mouse model mimics pathophysiological key features of PD, including 
dopaminergic denervation of the dorsal striatum (Fig. 3-1C) preceding the progressive as well 
Fig. 4-1 Schematic summary of the presented manuscripts. In MitoPark mice, DaN-specific TFAM KO leads to 
mitochondrial dysfunction, followed by the selective loss of SNc DaNs in the midbrain, causing progressive motor 
decline. In contrast, VTA DaNs are more or less spared. In the OB, only SCs are mildly affected in numbers, which 
is associated with olfactory dysfunction. Impaired mitochondrial function (highlighted by blue mitochondria 
representing COX-deficiency according to COX/SDH histochemistry) is due to mtDNA depletion. In K320E-
TwinkleDaN mice, impaired mtDNA replication in DaNs results in severe degeneration of both SNc and VTA DaNs. 
Whereas loss of the dopaminergic mesolimbic pathway is linked to decreased motivation and depressive-like 
behavior, respectively, SNc DaN projections in the dorsal striatum are preserved, indicating compensatory axonal 
sprouting. Surviving midbrain DaNs reveal normal mitochondrial function. This implies cellular adaptation 
mechanisms, especially for highly energy consuming SNc DaNs, which might be able to maintain low levels of 
mtDNA deletions and high levels of wild-type mtDNA, respectively, in order to prevent mitochondrial impairment 
(Figure was generated by using Photoshop CS2 and appropriate templates from BioRender). 
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as selective loss of SNc DaNs (Fig. 3-1D) upon mitochondrial dysfunction (Fig. 3-2A-C), 
causing impaired motor behavior (Fig. 3-1E). Thus, this mouse model is suitable for preclinical 
testing of drugs that may have the potential to slow down the death of SNc DaNs, due to 
mitochondrial impairment, and to improve motor performance, respectively, as done by a 
variety of studies (Le Poul et al. 2012; Zhang et al. 2012; Smith et al. 2014; Gordon et al. 2016; 
Ay et al. 2017; Langley et al. 2017; Hsieh et al. 2020). MitoPark mice further respond to 
L-DOPA treatment (Galter et al. 2010) and present behavioral as well as biochemical 
characteristics of long-term L-DOPA treatment in PD patients (Gellhaar et al. 2015). 
Conversely, these animals can be used to confirm pathways that might exacerbate SNc DaN 
degeneration or the motor phenotype (Gellhaar et al. 2015; Langley et al. 2018), and which 
can in turn be blocked or downregulated. However, in contrast to patients suffering from 
idiopathic PD, MitoPark mice reveal early-onset and much faster neurodegeneration. In 
consequence, drugs that are used to treat MitoPark mice will only be able to slow down but 
may not stop the loss of SNc DaNs. In addition, the rapid disease progression in MitoPark mice 
might obscure the contribution of potential compensatory processes occurring in humans, 
which might eventually become part of disease pathology. Olfactory dysfunction occurs in the 
late disease stage of MitoPark mice (Fig. 3-8A-D) and thereby renders these animals an 
inappropriate tool to study hyposmia as a prodromal symptom that arises before motor deficits 
in PD patients. 
Reduced TFAM expression and decreasing copies of mtDNA have been reported in SNc DaNs 
of PD patients (Grunewald et al. 2016). However, TFAM inactivation in DaNs and the 
consequently ongoing depletion of mtDNA as well as mtRNA in MitoPark mice, do not reflect 
the pathophysiological mechanism in humans. In PD patients, mitochondrial dysfunction of 
SNc DaNs rather results from decreasing levels of wild-type mtDNA upon failed copy number 
elevation (Dolle et al. 2016) and the concurrently increased accumulation of mtDNA deletions 
over time (Bender et al. 2006; Kraytsberg et al. 2006; Elstner et al. 2011). Hence, K320E-
TwinkleDaN mice have been generated to study the impact of accumulating mtDNA deletions 
on survival as well mitochondrial function of DaNs. On the one hand, hetero- and homozygous 
mutants reveal neurodegeneration of both SNc and VTA DaNs to a similar extent (Fig. 3-12C) 
after 20 months of age, which disqualifies this model concerning the investigation of drug 
effects on the selective loss of SNc DaNs. In addition, the absent motor phenotype in these 
animals does not allow any treatment testing in order to improve motor symptoms. On the 
other hand, degeneration of the dopaminergic mesolimbic pathway causing depressive-like 
behavior of K320E-TwinkleDaN mice implies the potential of using anti-depressant agents as 
well as studying depressive states that are independent of serotonergic signalling. 
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More importantly, however, the K320E-TwinkleDaN model offers the chance to identify which 
cellular mechanisms are responsible for cell death prevention in SNc DaNs of high age despite 
impaired mtDNA replication. Furthermore, transcriptome as well as proteome analysis of 
surviving SNc DaNs could unravel pathways that enable axonal sprouting in order to preserve 
striatal innervation and thereby DA supply, and that consequently ensure compensation of lost 
DaNs and normal motor function. PD patients are mostly diagnosed when motor symptoms 
become apparent. At this point, up to ~50% of SNc DaNs are already irreversibly lost (Obeso 
et al. 2017). Until today, drugs, such as L-DOPA or MAOB inhibitors, and surgical treatments, 
including DBS of the STN, can only dampen the outcome of the disease for a certain period of 
time. However, the origin of motor symptoms, the loss of the nigrostriatal system, cannot be 
stopped. Thus, novel therapeutic interventions are highly needed. Deciphering the 
compensatory adaptations of the surviving population of SNc DaNs in K320E-TwinkleDaN mice 
could therefore provide novel targets to both slow down degeneration of SNc DaNs as well as 
preserve dopaminergic innervation of the dorsal striatum. One may still argue, that those SNc 
DaNs, which survived in our model, do not express the mutated variant of TWINKLE. Assuming 
that this is true, it is still astounding how few aged SNc DaNs are able to compensate the 
severe neuron loss and maintain normal motor function. In this context, pharmacological 
stimulation of the ongoing pathways in surviving SNc DaNs of K320E-TwinkleDaN mice might 
help to boost resilience in remaining neurons of PD patients, preserving striatal innervation 
and recovering motor performance. The K320E-TwinkleDaN model might therefore host the 
potential to rescue motor symptoms and DA supply in the dorsal striatum via cellular 
modification of remaining SNc DaNs, even when neurodegeneration is ongoing. 
  
 




A key role of mitochondrial dysfunction for the selective degeneration of SNc DaNs in PD is 
confirmed by complex I impairing toxins, high accumulation of mtDNA deletions as well as the 
variety of mitochondrial-related monogenic mutations in familial forms of PD.  However, we 
showed that distinct DaN populations respond differently to impaired mitochondrial function, 
underscoring the importance of additional cell-type specific factors for the selective 
vulnerability of SNc DaNs in PD, such as ion channel equipment, axonal architecture and 
energetic demands. In the OB, only SCs are mildly affected upon TFAM inactivation following 
mitochondrial dysfunction. The associated olfactory dysfunction suggests a putative role for 
OB DaN functionality in the development of PD-related hyposmia. In the midbrain, SNc DaNs 
selectively degenerate in a striatonigral manner upon the rapid depletion of mtDNA, 
accompanied by progressive motor decline. Neuron death of MitoPark mice is caused by a 
detrimental imbalance in the mitochondrial redox system which is triggered by elevated 
intracellular Ca2+ loads. In contrast, neighboring VTA DaNs and corresponding striatal 
projections are more or less spared. At the same time, the newly generated K320E-TwinkleDaN 
model demonstrates that SNc DaNs possess a great potential for adaptation to mtDNA 
defects, provided they only accumulate slowly over time. They can further compensate severe 
neurodegeneration through preserved striatal innervation, which is associated with normal 
motor behavior, whereas VTA DaNs do not. Thus, the small number of remaining SNc DaNs 
in PD patients might also be able to recover motor performance by axonal re-innervation of the 
dorsal striatum following stimulation of compensatory mechanisms that are ongoing in 
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